In the journal abstract, an AI-ECG model trained on more than 330,000 ECG–echocardiogram pairs detected the dilated-cardiomyopathy phenotype (AUROC 0.87–0.97) and predicted later disease (C-index 0.80–0.87). In familial cohorts, five-year negative predictive values were 95.5% in Antwerp and 91.5% in Maastricht; positive predictive values were 42.4% and 39.4%. These are diagnostic and risk-prediction findings, not demonstrated clinical benefit.
Technology: Explainable deep learning model applied to electrocardiography
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Validated in UK Biobank, Zhongshan Hospital and Antwerp cohorts, and in two familial cohorts (Antwerp n=166, Maastricht n=177), compared with traditional ECG features and echocardiographic traits.
- Still unknown: Review limited to the indexed abstract and publication metadata; full-paper methods and additional limitations were not assessed.
- AI role: Deep learning model trained to detect and predict the echocardiographic DCM phenotype from ECG; explainable AI-ECG outperformed traditional ECG parameters.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A%2210.1093%2Feurheartj%2Fehag917%22&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Google Research reported a wearable-based health-age model associated with subsequent hypertension, cardiovascular disease and type 2 diabetes in the All of Us cohort (22,748 participants). A companion world model simulated 12-week trajectories. In 490 blinded paired reviews, coaches preferred simulation-grounded plans in 71.4% of evaluations; physicians rated 97.6% of physiological claims accurate. This summary is limited to the November 11, 2026 institutional blog. The authors state all evaluations were offline and retrospective; clinical effectiveness and durable habit change require prospective trials.
Technology: Coachable health-age model, SensorWM action-conditioned world model, feasibility-constrained optimizer with a language model agent, multimodal CKM deviation model
Publication: Preprint · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: retrospective or benchmark
- Tested: Retrospective clinical-risk modeling and blinded expert comparison of simulated coaching plans.
- Still unknown: Source checking does not establish independent confirmation. Review date: 2026-11-15.
- AI role: Built the health-age metric and multimodal CKM model from wearable and clinical markers, forecast physiological responses to habit changes with a world model, and filtered and converted simulated habit plans into coaching text with a language model agent.
Evidence sources: https://research.google/blog/using-wearables-to-enable-cardiovascular-kidney-metabolic-ckm-risk-profiling-for-personalized-coaching/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In the journal abstract, PREVIA used trauma narratives from 145 patients at two New York City trauma centers to predict PTSD assessed one month later. Reported AUROC was 78.49% ± 5.75%, with precision 46.76% ± 8.66%. On 30 randomly selected patients, its performance was comparable to one PTSD-specialist emergency clinician. The authors describe these as initial findings requiring larger independent-cohort validation; prospective collection does not establish prospective evaluation of a locked model.
Technology: PREVIA clinically informed large language model ensemble
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: One-month PTSD prediction in 145 trauma patients; comparison with a specialist emergency clinician on 30 selected patients.
- Still unknown: Abstract and metadata review only. Authors explicitly call for larger independent-cohort validation; full methods and timing of model selection relative to outcomes were not assessed.
- AI role: LLM ensemble extracts early post-traumatic stress symptoms, risk and protective factors from narratives and produces the risk forecast.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A%2210.1038%2Fs41467-026-78768-3%22&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A preprint reports external validation of an ECG-image ensemble for Takotsubo syndrome versus anterior STEMI in 95 participants: accuracy 0.914 and AUC 0.970. Among 70 readers, estimated diagnostic correctness rose from 0.632 unaided to 0.864 with AI. Only the fourth phase randomized assistance conditions; AI-assisted reader accuracy remained below model accuracy. This summary is limited to the abstract and version 3 preprint dated November 8, 2026; the first version was posted October 19.
Technology: Self-supervised deep learning ensemble with Grad-CAM explanations
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: ECG-image external validation and a separate four-phase reader experiment; the fourth phase randomized assistance conditions.
- Still unknown: Review limited to abstract and original-server version/corresponding-institution metadata; full paper and historical v1/v2 contents not assessed. DATE/ID MONTH CONFLICT: publication becomes 2026-11-08 while stable ID retains 2026-10.
- AI role: Ensemble classified 12-lead ECG images; its predictions and Grad-CAM maps were shown to readers.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A%2210.64898%2F2026.10.15.26365116%22&resultType=core&format=json · https://api.biorxiv.org/details/medrxiv/10.64898/2026.10.15.26365116
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Prospective study of 196 people at five US sites, compared with 24-hour ambulatory blood pressure measurement: 65.8% sensitivity and 90.0% specificity for screening, and 78.4% and 90.9% in the confirmatory test (48 participants). A feasibility study; it does not replace the cuff, and many cases are missed.
Technology: AI-PPG-ACC-HTN (photoplethysmography and accelerometer)
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: A prospective study of 196 participants at five US sites compared smartwatch screening with 24-hour ambulatory blood pressure monitoring: 65.8% sensitivity and 90.0% specificity, with 78.4% and 90.9% in a confirmatory subgroup of 48.
- Still unknown: The authors call it early feasibility research; the smartwatch does not replace a cuff, many true cases are missed, the confirmatory subgroup is small, and generalizability is unclear.
- AI role: A 1-D convolutional network pretrained with self-supervised contrastive learning on PPG and accelerometer waveforms produced embeddings; a logistic regression output a hypertension probability.
Evidence sources: https://research.google/blog/detecting-signs-of-hypertension-using-wearable-sensors/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In a prospective UK Biobank cohort of 27,429 participants without baseline chronic kidney disease, the study evaluated 2,920 plasma proteins and found 205 associated with incident CKD after protein-wide Cox regression with Bonferroni correction. LASSO reduced these to 23 candidates and LightGBM feature selection identified EDA2R, GDF15, HAVCR1 and SCARB2 as a four-protein panel. The protein panel alone had an AUC of 0.796 versus 0.805 for demographic variables; adding the proteins to the demographic model raised AUC to 0.830 in the study data.
Technology: Least absolute shrinkage and selection operator (LASSO) and Light Gradient Boosting Machine (LightGBM) feature selection
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In a prospective UK Biobank cohort of 27,429 participants without baseline chronic kidney disease, the study evaluated 2,920 plasma proteins and found 205 associated with incident CKD after protein-wide Cox regression with Bonferroni correction. Protein selection and prediction were assessed internally within UK Biobank; prospective cohort collection does not establish prospective evaluation of a previously locked predictor.
- Still unknown: The abstract reports a prospective UK Biobank cohort and internal analyses; the four-protein model did not outperform the demographic model alone (AUC 0.796 vs 0.805, p=0.14), though combining the proteins with demographics improved AUC to 0.830. The authors state external validation is needed before clinical application. Protein associations and model selection do not establish causal roles or clinical utility.
- AI role: After protein-wide Cox association screening, LASSO selected 23 candidate proteins and LightGBM-based feature selection identified four proteins for the incident-CKD prediction panel. The study assessed their predictive contribution with demographic covariates and sensitivity analyses; these algorithms selected risk markers rather than demonstrating causal protein effects.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/42968231/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Anthropic reports early results with six partners: a CAR T-cell receptor design about 70% shorter that enabled immune cells to produce about 10 times more receptors; about 35,000 antibody designs in one month, yielding 20 candidates; and a document review that found all 11 human-identified issues plus seven more in 89% less time. The work is mostly preclinical and reported by Anthropic.
Technology: Claude
Family Claude: profile · models page
Publication: Announcement only · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Announcement only
- Test type: direct test
- Tested: Partner lab tests and a document review reported by Anthropic: a CAR T receptor design was tested in immune cells, antibody designs were screened for IgE binding, and a review of 1,061 pages was compared with 11 human-identified issues.
- Still unknown: The work is mostly preclinical with no human tests; partner reports give limited methodological detail, and the page does not say whether the seven extra flags were confirmed.
- AI role: Claude proposed molecular and receptor designs, generated about 35,000 antibody designs, reviewed manufacturing documents, and drafted regulatory documents.
Evidence sources: https://www.anthropic.com/research/early-progress-drug-development
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Iambic reported updated results from an open-label Phase 1/1b study of its AI-designed HER2 inhibitor IAM1363. At the August 31, 2026 cutoff, 122 participants had received treatment across four study parts; the company reported antitumor and intracranial responses and that more than half of participants treated at 960 mg remained on treatment. This summary is limited to the company release of October 26, describing an October 23 conference poster. These uncontrolled early results do not establish comparative efficacy.
Technology: Iambic molecular superintelligence platform
Publication: Announcement only · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Announcement only
- Test type: direct test
- Tested: Company-reported safety and preliminary response outcomes from an ongoing open-label Phase 1/1b trial.
- Still unknown: Source checking does not establish independent confirmation. Review date: 2026-11-15.
- AI role: The molecule was 'designed using Iambic's molecular superintelligence platform' and progressed to clinic in about two years, as stated by the company.
Evidence sources: https://ir.iambic.ai/news-releases/news-release-details/iambic-presents-updated-iam1363-clinical-data-esmo-2026-showing
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Nexus AI says it has deployed Google Research's chest X-ray AI as a certified diagnostic tool at about 40 facilities in six countries: more than 25,000 X-rays assessed by over 90 clinicians, with response times under 45 seconds. These are author-reported deployment figures, with no sensitivity or patient outcome data; WHO and FDA approvals are still in progress.
Technology: Foundation models for chest X-rays
Publication: Announcement only · Test context: Test context unspecified in annotation. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Announcement only
- Test type: not reported
- Tested: The post reports deployment figures (about 40 facilities, over 25,000 X-rays, over 90 clinicians) without sensitivity, specificity or patient outcome data from this deployment; it cites earlier peer-reviewed studies for performance.
- Still unknown: Deployment-level accuracy and outcomes are not given, WHO prequalification and FDA clearance are not granted, and the facility count across countries is unclear.
- AI role: The AI analyzed chest X-rays and flagged TB-suggestive findings for triage in under 45 seconds; clinicians made final decisions.
Evidence sources: https://research.google/blog/bringing-foundational-models-to-the-front-lines-of-tb-screening/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 4/5 · Validation 1/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Machine-learning screening of LKB1-pathway genes in GEO data prioritized SIK1. In a PTZ-induced rat epilepsy model, SIK1 knockdown delayed seizures and shortened their duration, whereas overexpression worsened severity. The paper abstract also reports that restoring downstream NR4A2 counteracted SIK1-related effects in rescue and neuronal experiments. These are preclinical findings, not evidence of treatment efficacy in people. This summary is limited to the abstract and publication metadata.
Technology: Machine learning screening of LKB1 pathway genes on GEO dataset GSE143272
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Gene prioritization from GEO data followed by rat SIK1 perturbations, NR4A2 rescue and neuronal electrophysiology.
- Still unknown: Source checking does not establish independent confirmation. Review date: 2026-11-15.
- AI role: Machine learning screened LKB1 pathway genes and ranked SIK1 as the top epilepsy risk gene for experimental follow-up.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID%3A42991733&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The Virtual Biotech journal abstract reports a human-guided multi-agent analysis of 55,984 trials. Drugs targeting cell-type-specific genes were associated with a 48% greater likelihood of reaching market and 32% fewer adverse events. The system also proposed a lung-cancer strategy and inferred possible reasons for a terminated ulcerative-colitis trial. These are retrospective associations and hypotheses, not demonstrated treatment benefits. The date represents the 2026-10-22 journal version; the linked preprint, including the same reported association, first appeared on 2026-02-23.
Technology: Virtual Biotech multi-agent AI framework (more than 37,000 agents)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Retrospective trial-outcome/target-feature analysis across 55,984 trials, plus computational therapeutic and trial-failure hypotheses.
- Still unknown: Review limited to the indexed abstract and publication metadata; full-paper methods and additional limitations were not assessed.
- AI role: More than 37,000 AI agents annotated trial outcomes and integrated multimodal evidence to propose and analyze therapeutic decisions.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A%2210.1126%2Fscience.aeg6779%22&resultType=core&format=json · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID%3APPR1222685&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The medRxiv abstract reports APOLLAI evaluation on video/audio recordings from 295 suspected-stroke patients at Nîmes University Hospital, against seven-neurologist consensus labels for five NIHSS items. Global sensitivity was 78.5% versus 59.4% for EMS personnel, specificity 87.0% versus 85.9%, and AUC 0.882. These are diagnostic comparisons on recorded patient data; the authors call for prospective validation in real EMS conditions.
Technology: APOLLAI (computer vision, audio deep learning and SVM fusion classifier)
Publication: Preprint · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: retrospective or benchmark
- Tested: Recorded cases from 295 suspected-stroke patients; AI and EMS assessments compared with consensus labels for five neurological tasks.
- Still unknown: Complete abstract and original-server metadata reviewed; full methods, model-selection timing and external EMS generalizability were not assessed. Authors explicitly call for real-world prospective validation.
- AI role: A multimodal machine-learning system detected stroke-related neurological deficits from video and audio recordings and was compared with clinicians' assessments.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A%2210.64898%2F2026.10.16.26365784%22&resultType=core&format=json · https://api.biorxiv.org/details/medrxiv/10.64898/2026.10.16.26365784
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Prospective study of 385 pregnant women in Chicago and Nairobi: the model estimates gestational age from scans taken by minimally trained operators with a mean error of 4.18 days, non-inferior to the 4.48 days of expert sonographers. This is a non-inferiority result from only two sites, both relatively urban.
Technology: Ultrasound model for estimating gestational age
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: A prospective multi-center study of 385 pregnant women at two sites (Chicago and Nairobi) compared AI gestational-age estimates from blind sweep scans by minimally trained operators with expert sonographer biometry: mean error 4.18 vs 4.48 days.
- Still unknown: The source does not state the non-inferiority margin or confidence intervals; only two relatively urban sites and one commercial probe were used, and clinical trust and confidence safeguards are not validated.
- AI role: The model estimated gestational age from blind sweep ultrasound scans and ran live on mobile devices in clinics.
Evidence sources: https://research.google/blog/empowering-frontline-maternal-care-with-ai-assisted-ultrasound/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In a mostly autonomous 64-hour campaign, Claude designed minibinders against five neurotoxins. External labs tested 211 designs, 17 of which met the criteria; the best (Cn2-B1 and Cn2-B2) had affinities in the low nanomolar range. Only recombinant toxins were tested, with no neutralization tests in cells or animals; Anthropic does not claim to have produced an antivenom.
Technology: Claude
Family Claude: profile · models page
Publication: Announcement only · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Announcement only
- Test type: direct test
- Tested: External labs tested 211 designs by surface plasmon resonance: Adaptyv Bio in cell-free expression and Twist Bioscience in human kidney cells; a binder needed KD of 1 µM or tighter in every replicate at both labs and no CLEC12A signal, giving 17 binders. The two collaborating external laboratories tested candidates from the discovery project; this establishes direct testing rather than a separately established independent follow-up replication.
- Still unknown: Only recombinant toxins were tested, with no neutralization in cells or animals; the authors do not know whether the binders neutralize venom and do not claim an antivenom; multitoxin designs failed.
- AI role: Claude selected toxin structures and hotspots, generated 318,484 designs, filtered and co-folded them, ran about 24 hours autonomously, then produced 180 selected designs after human follow-ups.
Evidence sources: https://www.anthropic.com/research/claude-scorpion-toxin-binder-design
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The PDFM model increased the explained variance in MMR vaccination coverage from 16% to 22% across 146 counties on the US–Canada border, and improved weekly correct cholera-risk-area rankings in the DRC from 1.78 to 2.10. Gains for cardiovascular mortality and postpartum depression were small or not significant.
Technology: Population Dynamics Foundation Model (PDFM), TimesFM
Publication: Preprint · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: retrospective or benchmark
- Tested: Five partner-led evaluations compared PDFM embeddings with baselines: MMR explained variance rose from 16% to 22% across 146 border counties and cholera Precision@5 improved from 1.78 to 2.10; cardiovascular gains were not significant.
- Still unknown: Several results were non-significant or small, cholera gains were not significant at one or two weeks, and the authors cite static embeddings as a limitation.
- AI role: PDFM combines search trends, mobility, built-environment and environmental data into location embeddings used without task fine-tuning; for dengue it was paired with TimesFM 2.0.
Evidence sources: https://research.google/blog/earth-ais-planetary-geospatial-foundation-models-for-global-public-health/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A PCA enrichment map and machine-learning virtual screening pipeline prioritized a commercial library for beta-haematin and parasite assays. The primary indexed paper reports several chemotypes evaluated for antiplasmodial activity, beta-haematin inhibition and haemozoin formation inhibition. This is an in-vitro campaign; results should not be conflated across assays or with clinical efficacy.
Technology: PCA enrichment mapping; support-vector machine classification; virtual screening
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: PMC-hosted primary text reports PCA/ML screen and experimental parasite/haemozoin assays.
- Still unknown: Exact structure-level overlaps with earlier UCT screens and detailed full-text quantitative results should be cross-checked before final prioritization.
- AI role: PCA map and classifier prioritize compounds for biochemical and cell assays.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/42857431/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: PMC-indexed primary article; PubMed primary metadata. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Combining marine natural-product fragment mining, AI-based molecular generation and structure-guided selection, the authors designed optimized analogues Ib18 and It12 targeting the ABC transporters P-glycoprotein (ABCB1) and BCRP (ABCG2). Both analogues reversed transporter-mediated resistance in overexpressing cells and outperformed reference inhibitors. Target-engagement assays supported transporter inhibition without expression downregulation. In xenografts, Ib18 increased mitoxantrone antitumor activity and tumor accumulation without a detected increase in systemic toxicity.
Technology: AI-based molecular generation integrated with marine natural-product fragment mining and structure-guided prioritization
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Target-engagement assays supported transporter inhibition without expression downregulation.
- Still unknown: The evidence is cellular and preclinical xenograft evidence, not patient efficacy or established clinical safety. The abstract reports no systemic toxicity increase in the studied xenograft setting, which should not be generalized. It does not give quantitative potency values or detailed comparator identities in the abstract.
- AI role: AI-based generation contributed candidates to a natural-product-inspired library; structure-guided prioritization selected optimized analogues for synthesis and functional tests. The authors tested Ib18 and It12 in transporter-overexpressing cells and evaluated Ib18 with mitoxantrone in xenografts.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/42720471/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Profiling 5,416 plasma proteins in Korean cohorts, the study found distinct signatures across four biopsy-proven primary glomerular diseases. An elastic-net model using 93 proteins differentiated disease subtypes and controls in discovery and external validation cohorts. It achieved AUCs above 0.8 for minimal change disease, membranous nephropathy and IgA nephropathy; the model correctly classified 14 of 15 minimal-change cases and 20 of 32 IgA-nephropathy cases, but only 3 of 14 focal-segmental glomerulosclerosis cases. Functional analysis highlighted hemostasis-related proteins in minimal change disease.
Technology: Elastic-net-regularized logistic regression using plasma proteomic features
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Profiling 5,416 plasma proteins in Korean cohorts, the study found distinct signatures across four biopsy-proven primary glomerular diseases.
- Still unknown: The discovery cohort contained 147 participants and the external validation cohort 85; subtype-level validation samples were small. Classification was strong for minimal change disease, membranous nephropathy and IgA nephropathy but poor for focal segmental glomerulosclerosis (3/14 correctly classified). The findings support cohort-level proteomic differentiation and do not establish a clinically deployable noninvasive replacement for kidney biopsy or causal roles for the selected proteins.
- AI role: The model used elastic-net regularization to select and combine a 93-protein plasma signature for classifying biopsy-proven primary glomerular disease subtypes and controls. The model was evaluated in an independent external validation cohort. Functional analysis of key proteins was used to characterize subtype-associated pathways, including hemostasis in minimal change disease.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41779447/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The Neuron abstract reports a deep-learning framework trained on trial-resolved recordings from a bidirectional human visual-cortex implant. A learned inverse network and gradient-based optimizer shaped stimulation-evoked population activity, achieved targets at lower currents and elicited more consistent perception than conventional methods. This is an experimental neural-control result, not evidence of restored functional sight. The paper was first published online on 2026-08-07; review here is limited to its abstract and metadata.
Technology: Deep learning inverse network and gradient-based optimizer for neural stimulation
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Within-study human visual-cortex stimulation experiments comparing two learned control approaches with conventional methods; lower currents and more consistent reported percepts.
- Still unknown: Complete abstract and metadata reviewed. Participant count, implant duration, long-term performance and functional-vision outcomes were not assessed; full-text XML retrieval returned HTTP 500.
- AI role: Deep learning model trained on trial-resolved neural recordings to synthesize and optimize stimulation patterns.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A%2210.1016%2Fj.neuron.2026.07.006%22&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The XunZi AI-biologist integrated literature reasoning with multimodal molecular data and nominated CHK2 and IRAK4 kinase activation in Parkinson’s disease models. Follow-up experiments found that pharmacological or genetic Chk2 inhibition rescued dopaminergic-neuron loss and motor deficits in PD mouse models, supporting CHK2 as a disease-associated mediator in the tested systems.
Technology: XunZi AI biologist
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Follow-up experiments found that pharmacological or genetic Chk2 inhibition rescued dopaminergic-neuron loss and motor deficits in PD mouse models, supporting CHK2 as a disease-associated mediator in the tested systems.
- Still unknown: The neuroprotective evidence is from experimental Parkinson’s disease models and mice, not human patients or clinical efficacy. XunZi also nominated IRAK4, but the abstract specifically reports Chk2 inhibition rescue; do not imply equivalent causal validation for every AI-nominated target. The Nature article’s complete indexed text was read; direct open may be blocked by a cookie redirect.
- AI role: XunZi integrated logical reasoning with multimodal data fusion across biomedical literature and molecular datasets to generate and rank de novo disease-target hypotheses. Researchers then tested the CHK2 hypothesis with cellular and mouse experiments, including pharmacological/genetic inhibition; the AI nominated the target, while experiments established the reported effects.
Evidence sources: https://www.nature.com/articles/s41551-026-01769-6
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Confounder-aware machine-learning feature selection on plasma proteomics identified a seven-protein signature—AHSG, CLEC3B, COMP, F9, LRG1, MCAM and MRC1—to classify remission versus active ANCA-associated vasculitis (AAV). After targeted PRM mass-spectrometry assay development, a generalized linear model was evaluated in an independent cohort of 108 AAV patients and achieved AUC 0.94 (95% CI 0.90–0.98); combined discovery and validation performance was AUC 0.97. In the study cohorts, the panel outperformed routine CRP and ANCA titer measurements.
Technology: MetaDeconfoundR confounder-aware feature analysis, LASSO and Boruta feature selection, and a generalized linear model applied to targeted PRM mass-spectrometry data
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: After targeted PRM mass-spectrometry assay development, a generalized linear model was evaluated in an independent cohort of 108 AAV patients and achieved AUC 0.94 (95% CI 0.90–0.98); combined discovery and validation performance was AUC 0.97.
- Still unknown: This is cross-sectional classification of disease state in patients already diagnosed with AAV, not a prospective prediction of relapse, a validated basis for stopping immunosuppression, or evidence of improved clinical outcomes. The two cohorts together included just over 200 patients with a rare disease; the authors note uncertainty from sample size and treatment heterogeneity, and the panel remains a starting point for clinical-tool development. It is an adjunct biomarker result, not proof that the seven proteins cause remission or vasculitis activity.
- AI role: Machine-learning methods accounted for clinical covariates including CRP, kidney function and ANCA-related measures, prioritized candidate plasma proteins, and reduced these to a seven-protein panel. Targeted PRM-MS quantified the selected proteins, and the GLM classified AAV remission versus active disease in an independent cohort. The measured validation performance and protein signature are the specific AI-enabled diagnostic finding.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/42481524/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A six-cohort plasma proteomics study used cross-validated LASSO to select a 21-protein multiplex panel for dementia differential diagnosis. In the new DLB/FTD results, ITGAV and ITGAM were reduced in dementia with Lewy bodies and also tracked Lewy-body pathology in independent autopsy-confirmed cohorts; a panel including ITGAV, ITGAM and ERBB3 distinguished DLB from controls and Alzheimer dementia in an independent multicenter cohort. For frontotemporal dementia, NfL and B4GAT1 contributed to the panel distinguishing FTD from controls. Validation-set AUCs were 0.83 for DLB versus controls, 0.78 for DLB versus Alzheimer dementia, 0.85 for FTD versus controls and 0.77 for FTD versus Alzheimer dementia.
Technology: Cross-validated LASSO regression and multivariable logistic-regression models applied to Olink proximity-extension plasma proteomics
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A six-cohort plasma proteomics study used cross-validated LASSO to select a 21-protein multiplex panel for dementia differential diagnosis.
- Still unknown: These are observational plasma biomarker associations and retrospective diagnostic-validation results, not evidence that the proteins cause disease or improve patient outcomes. The work reports moderate rather than definitive discrimination, especially DLB versus Alzheimer dementia (validation AUC 0.78) and FTD versus Alzheimer dementia (0.77); external prospective utility remains unestablished. The later study reuses the bPRIDE cohorts and includes Alzheimer-disease analyses overlapping the group’s earlier 2025 bPRIDE plasma-proteomics paper; this entry is limited to the distinct DLB/FTD differential-marker and independent 21-plex validation findings. No individual biomarker is presented as a stand-alone clinical test.
- AI role: The analysis used 100-fold cross-validated LASSO feature selection to prioritize a limited set of disease-associated proteins and choose 21 markers for a custom multiplex assay. Pairwise logistic-regression models used selected markers to distinguish DLB and FTD from controls and Alzheimer dementia; the targeted panel was then measured in an independent multicenter validation cohort.
Evidence sources: https://www.nature.com/articles/s43587-026-01162-7
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A computational histology AI platform built a prognostic signature from diagnostic whole-slide images in 507 CHAARTED participants and evaluated the locked signature in 684 ENZAMET participants. In the independent ENZAMET cohort, the unfavorable-risk group had worse overall survival (HR 2.6, 95% CI 2.0–3.4) and progression-free survival (HR 2.2, 95% CI 1.7–2.7); associations remained after adjustment for clinical variables. The article also reports treatment-interaction analyses, but this retrospective secondary analysis does not establish prospective treatment-selection benefit.
Technology: Computational Histology Artificial Intelligence (CHAI) platform
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In the independent ENZAMET cohort, the unfavorable-risk group had worse overall survival (HR 2.6, 95% CI 2.0–3.4) and progression-free survival (HR 2.2, 95% CI 1.7–2.7); associations remained after adjustment for clinical variables.
- Still unknown: The locked image-only biomarker was independently evaluated across two prospective randomized-trial datasets, but this article is a post hoc secondary analysis, not a prospective biomarker-directed treatment trial. The treatment-interaction result is suggestive and does not prove that choosing triplet therapy by this score improves outcomes. No clinical deployment or benefit claim is made. Primary journal abstract checked; no independent replication assessed.
- AI role: CHAI extracted quantitative histomorphologic features from H&E diagnostic whole-slide images and learned an image-only risk signature on CHAARTED data; the locked signature was tested in ENZAMET. Humans specified cohorts/endpoints and analyzed the trial outcomes.
Evidence sources: https://ascopubs.org/doi/10.1200/PO-26-00321
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The Nature paper, published online on 2026-06-24, reports a deep-learning ECG biomarker evaluated retrospectively in Swedish data and external US and Taiwanese datasets. Its high-risk group comprised 2.2% of the sample and had a 7.0% annual sudden-cardiac-death rate, versus 4.6% for reduced LVEF; 86.1% were not flagged by LVEF. Among high-risk patients with defibrillators, sudden cardiac death was 54.4% lower than model-expected, an observational association subject to confounding and not proof of benefit.
Technology: Deep learning ECG model with a generative ECG waveform model for visualization
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Existing Swedish ECG/death-certificate data, a held-out lockbox created before analysis, external US ventricular-arrhythmia and Taiwanese arrhythmic-arrest evaluations; observational defibrillator associations.
- Still unknown: Main paper reviewed; supplementary attachments not read. The authors explicitly identify residual confounding and the need for randomized testing of defibrillator benefit in model-high-risk patients.
- AI role: Deep learning model discovered the predictive ECG waveform pattern; generative model used to visualize it.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A%2210.1038%2Fs41586-026-10674-6%22&resultType=core&format=json · https://www.ebi.ac.uk/europepmc/webservices/rest/PMC13323061/fullTextXML
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A screen of about six million compounds found candidates active against resistant Neisseria gonorrhoeae. A1 reduced bacteria in animal models, and proteomics, genetics, and biochemistry confirmed its target, alanine racemase. These are preclinical results, published in Science Translational Medicine.
Technology: Deep learning for molecule screening
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Phenotypic screen of 38,650 molecules trained a graph neural network, which screened about 6 million compounds; 213 were validated experimentally, 83 inhibited growth. Two hits were tested in vitro against multidrug-resistant strains, by proteomics (alanine racemase target), in a vagina-on-a-chip model and in a mouse vaginal infection model.
- Still unknown: Not reported (the abstract describes the in vivo and organ-chip results as showing only early promise).
- AI role: A graph neural network trained on phenotypic screening data, used to virtually screen the compound library before experimental validation.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1126/scitranslmed.ads4699&resultType=core&format=json · https://news.ki.se/ai-helps-identify-new-antibiotic-candidates-against-drug-resistant-gonorrhoea
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Among 376 unresolved cases, o3 Deep Research proposed explanations reviewed by specialists: 18 diagnoses were clinically confirmed, seven of which had already been established elsewhere but were missing from local records. This was a retrospective study across heterogeneous cohorts, without a measure of time saved or effect on care; clinicians made the decisions.
Technology: o3 Deep Research
Family o1 / o3: profile · models page
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Retrospective multicohort reanalysis of 376 unresolved cases; a diagnosis required a pathogenic or likely pathogenic variant confirmed in a CLIA-certified lab and returned to families, and seven rediscoveries were also reported.
- Still unknown: The abstract states that the retrospective design motivates prospective multicenter evaluation with predefined endpoints, calibration reporting and comparator baselines.
- AI role: An LLM ingested clinician notes, HPO terms and a filtered variant table and proposed candidate hypotheses for expert adjudication under ACMG/AMP criteria; experts made the classifications.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1056/AIcs2501343&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A LightGBM classifier trained on routine clinical and laboratory data distinguished serum immunofixation-positive monoclonal immunoglobulin cases from negative cases. In an independent three-hospital cohort of 2,270 patients referred for immunofixation testing, the model achieved an AUC of 0.945, with 87.0% sensitivity and 89.6% specificity. In a subset with serum protein electrophoresis results, model sensitivity was 84.6% versus 75.3% for electrophoresis; in a separate 627-patient time-extended cohort, sensitivity was 88.2%, above each of three nonspecialist clinicians in that study.
Technology: LightGBM classifier selected from eight machine-learning models
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In an independent three-hospital cohort of 2,270 patients referred for immunofixation testing, the model achieved an AUC of 0.945, with 87.0% sensitivity and 89.6% specificity.
- Still unknown: This is retrospective diagnostic validation, not evidence that screening with the model improves health outcomes or shortens diagnosis in practice. All participants had been referred for immunofixation testing at tertiary or regional hospitals; an unselected community or primary-care population was not studied. The 627-patient later cohort was time-extended but not strictly prospective. The model is an adjunct for flagging patients for confirmatory tests; immunofixation remained the reference standard, and the paper states broader population validation and clinical utility remain to be established.
- AI role: Researchers used five feature-selection algorithms to identify shared predictors and trained/evaluated eight classifiers on routine clinical and laboratory measurements. The selected LightGBM model produced patient-level MIg-positive probabilities; its diagnostic performance was measured against serum immunofixation results in independent multi-center and later-collected cohorts, including direct comparisons with serum protein electrophoresis and nonspecialist clinicians.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13314525/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In Gary Peltz's Stanford lab, two of the three existing drugs proposed by Co-Scientist blocked fibrosis and promoted regeneration in human liver cells, while Peltz's own two choices showed no benefit. The anticancer drug vorinostat blocked 91% of a damage response that can lead to scarring. Cell experiments only; published in Advanced Science.
Technology: Co-Scientist
Family AI Co-Scientist: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The anti-fibrotic efficacy and toxicity of 25 drugs were assessed serially in human liver organoids grown in microwells; Co-Scientist's candidates were tested in cells alongside the authors' own picks.
- Still unknown: Not reported.
- AI role: The AI co-scientist multi-agent system proposed three candidate drugs with reasoning, and helped direct their experimental characterization.
Evidence sources: https://deepmind.google/blog/uncovering-repurposed-medicines-to-fight-liver-fibrosis/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1002/advs.202508751&resultType=core&format=json
The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 27 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Filippo Menolascina (Edinburgh) used Co-Scientist to search the literature for combinations of MASH therapies. The tool proposed the NLRP3 inflammasome as a link between inflammation and metabolism, and the post says the hypothesis was later tested experimentally. No numbers are given; the drug combinations were suggested for testing, not demonstrated.
Technology: Co-Scientist
Family AI Co-Scientist: profile · models page
Publication: Announcement only · Test context: Test context unspecified in annotation. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Announcement only
- Test type: not reported
- Tested: The article says the NLRP3 hypothesis was later experimentally verified but does not describe the experiments, who carried them out, or their results.
- Still unknown: Not reported (the article does not state limitations or whether the work is published).
- AI role: Co-Scientist searched the literature, proposed drug combinations for MASH therapy and proposed the NLRP3 inflammasome as the link between inflammation and metabolism.
Evidence sources: https://deepmind.google/blog/accelerating-discovery-of-liver-disease-mechanisms/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 2/5 · Validation 1/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
MIDAS, a multimodal graph-neural-network model, ranked candidate immuno-oncology targets from gene-interaction, patient multi-omic and immune-biology data. In eight stage III/IV melanoma patient-derived explants, researchers blocked OSM–OSMR signalling with an anti-OSM antibody. The paper reports reduced dysfunctional CD8+ T-cell populations and lower CCL4 levels; PTPN22 inhibition did not produce comparable changes in this assay.
Technology: MIDAS, a multimodal graph neural network for immuno-oncology target ranking
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The paper reports reduced dysfunctional CD8+ T-cell populations and lower CCL4 levels; PTPN22 inhibition did not produce comparable changes in this assay.
- Still unknown: Functional follow-up used only eight stage III/IV melanoma patient-derived explants. This is an ex-vivo preclinical result, not treatment of patients or evidence of clinical benefit. OSM–OSMR biology has prior literature in other tumour settings; the new paper-specific contribution is MIDAS target nomination and measured perturbation effects in melanoma explants. Do not generalize to other cancers or claim a validated therapy.
- AI role: MIDAS integrated gene-interaction networks with patient multi-omics, immune-cell biology and genetic-perturbation evidence to rank candidate immunotherapy targets. Researchers selected OSM–OSMR for functional follow-up and tested pathway blockade in patient-derived tumour explants; the model nominated the target, while the ex-vivo experiments measured the T-cell and cytokine outcomes.
Evidence sources: https://www.nature.com/articles/s42256-026-01201-3
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Researchers trained cell-survival predictors on image-based screening data from six patient-derived glioblastoma stem-cell lines and screened more than 12,000 compounds. Experimental follow-up identified three compounds with activity across the GBM phenotype; HSP90 inhibitor XL-888 eliminated all six tested lines at nanomolar IC50 values, with analyses consistent with HSP90 inhibition and downstream client-protein disruption.
Technology: Machine-learning cell-survival predictors trained on high-throughput phenotypic screening
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Experimental follow-up identified three compounds with activity across the GBM phenotype; HSP90 inhibitor XL-888 eliminated all six tested lines at nanomolar IC50 values, with analyses consistent with HSP90 inhibition and downstream client-protein disruption.
- Still unknown: This is an in-vitro lead-discovery study across six patient-derived cell lines, not clinical efficacy. XL-888 is an existing HSP90 inhibitor and its proposed development as a GBM lead needs medicinal-chemistry optimization, including improved blood–brain-barrier penetration; no patient outcomes are reported.
- AI role: ML models trained on in-house imaging/compound-response data predicted cell survival and prioritized compounds from a >12,000-compound screen; experimental assays across patient-derived GBM stem-cell models validated three leads and tested mechanisms. Researchers performed the wet-lab work and mechanism analyses.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/42158926/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
BioGDR combines molecular structure with learned, predicted gene-expression and kinase-effect features and transcriptomic cell representations. Prospective in-vitro tests confirmed differential sensitivity to Golgicide A-2, including T84 colorectal cells (reported IC50 1.09 μM). This is a cell-line sensitivity result, not evidence of clinical benefit or discovery of the compound itself.
Technology: BioGDR multimodal interpretable deep learning; pathway graph attention
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The primary source reports the study-specific result summarized here.
- Still unknown: Independent replication and clinical benefit are not established by this source review.
- AI role: The model integrates predicted compound effects and cell transcriptomes to rank drug responses; the study prospectively tests candidate sensitivity in cell lines.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13396495/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: Primary source text reviewed; source_checks specify accessible sections..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The MISPOP ensemble screened a natural peptide library of 1,033 sequences, prioritized 16 oncolytic-peptide candidates and selected five for synthesis and testing. Dermaseptin-S9 showed membrane disruption and immunogenic-cell-death readouts in vitro and over 92% tumor-growth inhibition in a B16F10 melanoma mouse model.
Technology: MISPOP mechanism-informed ensemble combining XGBoost, deep neural networks and transfer learning with physicochemical priors
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The MISPOP ensemble screened a natural peptide library of 1,033 sequences, prioritized 16 oncolytic-peptide candidates and selected five for synthesis and testing.
- Still unknown: The active peptide is a natural sequence rather than a new AI-designed molecule. Findings are preclinical: three tumor cell lines and a B16F10 mouse melanoma model (n=5 per group shown in article figures); they do not establish human efficacy or absence of toxicity beyond the tested model/doses. Only five of 16 model-prioritized candidates were synthesized and evaluated.
- AI role: The machine-learning ensemble integrated three predictors and mechanism-related physicochemical features to prioritize candidate oncolytic peptides from a natural sequence library. Five shortlisted peptides were synthesized and evaluated; Dermaseptin-S9 was tested in cell-based membrane-disruption/ICD assays and a mouse melanoma model.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13336043/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Among nearly 2,000 abdominal CT scans originally considered normal, an AI radiomics model identified 73% of prediagnostic pancreatic cancers, with a median lead time of about 16 months. Validation included images from multiple institutions and protocols. This analysis used scans taken before diagnosis; clinical benefit and false positives in practice still need prospective evaluation.
Technology: REDMOD (Radiomics-based Early Detection Model)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: REDMOD was trained on 969 patients from a multi-institutional cohort and tested on an independent set of 493 patients (63 pre-diagnostic), with external specificity checks on further datasets and a comparison with radiologists; AUC 0.82 and 73.0% sensitivity, versus 38.9% for radiologists.
- Still unknown: The article states that prospective validation in high-risk cohorts is the necessary next step; no explicit limitations section.
- AI role: A fully automated radiomics framework with AI segmentation and an ensemble classifier on a 40-feature signature from standard-of-care CT scans.
Evidence sources: https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-ai-detects-pancreatic-cancer-up-to-3-years-before-diagnosis-in-landmark-validation-study/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1136/gutjnl-2025-337266&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In a two-center cohort of 364 participants with type 2 diabetes and controls, targeted serum/urine metabolite measurements found a high-serum/low-urine pattern for indoxyl sulfate and related metabolites in early diabetic kidney disease (DKD), consistent with reduced tubular secretion. Computer vision quantified urine foam stability and chromaticity; Random Forest recursive feature elimination selected these image features together with metabolite ratios and clinical variables for the FluxPro-DKD classifier. It distinguished DKD from diabetes without kidney disease with AUC 0.90 in discovery and 0.85 in a geographically distinct external cohort of 82.
Technology: Computer-vision urine phenotyping and Random Forest recursive feature elimination (RF-RFE) for multimodal feature selection
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In a two-center cohort of 364 participants with type 2 diabetes and controls, targeted serum/urine metabolite measurements found a high-serum/low-urine pattern for indoxyl sulfate and related metabolites in early diabetic kidney disease (DKD), consistent with reduced tubular secretion.
- Still unknown: The external cohort validation was cross-sectional; the paper says longitudinal follow-up for hard kidney outcomes is ongoing. Its projected three-year event rates are theoretical Monte Carlo simulations based on cross-sectional data and are not observed outcomes. The study did not measure proximal-tubule transporter expression or compare directly against KIM-1 or NGAL, and generalization beyond the two Chinese centers and population requires further validation. Metabolite flux supports, but does not prove, tubular transport dysfunction.
- AI role: Computer vision quantified urine foam half-life and chromaticity from standardized sample images. RF-RFE selected eight predictors, including digital urine features and serum-to-urine metabolite ratios, for the fusion classifier distinguishing early DKD from type 2 diabetes without DKD. The paper reports external cohort evaluation. The biochemical interpretation of flux mismatch as reduced tubular secretory capacity is based on measured metabolite ratios and literature-supported interpretation; transporter expression was not measured.
Evidence sources: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2026.1802447/full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Five machine-learning classifiers integrated clinical and serum-proteomic data from carotid atherosclerotic stenosis (60 participants), dyslipidemia (55) and healthy controls (66). A consensus approach identified a six-protein panel (B2M, GPV, MMP9, PLF4, TSP1 and fibrinogen/FB isoforms) that distinguished the atherosclerosis group from the comparison groups, with reported ROC-AUC above 0.9 across the tested classifiers. Protein levels were evaluated by flow cytometry and ELISA in an independent external cohort that included patients with acute atherothrombotic stroke.
Technology: Five machine-learning classifiers: Naive Bayes, linear SVM, random forest, Extra Trees and AdaBoost
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A consensus approach identified a six-protein panel (B2M, GPV, MMP9, PLF4, TSP1 and fibrinogen/FB isoforms) that distinguished the atherosclerosis group from the comparison groups, with reported ROC-AUC above 0.9 across the tested classifiers.
- Still unknown: The discovery cohorts were small (60 atherosclerosis, 55 dyslipidemia and 66 healthy controls); external validation supports the measured panel but does not establish population-wide performance, prospective clinical utility, or improved patient outcomes. The proteins have prior biological associations, so the finding is the specific integrated panel and cohort discrimination rather than discovery of six new proteins or a new mechanism.
- AI role: Five classifiers integrated clinical and serum-proteomic features and selected a consensus six-protein panel for patient-group discrimination. The authors then evaluated the selected proteins in an independent clinical cohort using flow cytometry and ELISA.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41961364/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A stability-based feature-selection workflow combining LASSO, random forest and SVM recursive feature elimination identified serum IL-8 and CCL3 as a two-protein signature distinguishing Stage I silicosis from controls. The study used a discovery cohort of 57 cases and 57 matched controls, then assessed the signature in an independent, unmatched cohort of 40 cases and 40 controls. The article reports validation AUC 0.973, specificity 95.0% and sensitivity 77.5%; both proteins were lower in silicosis cases.
Technology: Stability-based ensemble feature selection using LASSO, random forest and SVM recursive feature elimination, followed by logistic regression
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: The study used a discovery cohort of 57 cases and 57 matched controls, then assessed the signature in an independent, unmatched cohort of 40 cases and 40 controls.
- Still unknown: The discovery cohort was small (57 cases/57 matched controls); the validation cohort was also small and unmatched (40/40), with 77.5% sensitivity despite high specificity. This is retrospective biomarker validation and does not establish population screening performance, clinical utility, or causal involvement of IL-8 or CCL3 in silicosis.
- AI role: Across 100 iterations, the machine-learning feature-selection framework selected a stable two-protein signature from targeted serum proteomics. A logistic-regression classifier used those selected features and was evaluated by cross-validation and an independent validation cohort. The study reports reduced IL-8 and CCL3 as the signature components.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41937675/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A multiscale graph embedding workflow prioritized LC-61, which the study experimentally evaluated against L. infantum. The finding is a specific in-vitro compound result; it does not establish clinical efficacy, safety or a validated target.
Technology: Multiscale-aware graph embedding and machine learning
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary article/PubMed and institutional manuscript identify LC-61 and its experimental parasite assay.
- Still unknown: Exact prior structures and broader dose/replication details remain open.
- AI role: Graph embedding ranks candidate molecules for assay; human selection and experimental testing follow.
Evidence sources: https://doi.org/10.1021/acs.jcim.5c02947
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: author-institution primary full-text PDF; PubMed primary metadata. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The BarFlare assay and an interpretable multi-criteria decision-making classification-fusion machine-learning framework combined extracellular-vesicle SCC and MMP13 biomarkers with clinical factors. The model was evaluated in prospective multicentre diagnostic cohorts and two population cohorts; the longitudinal cohort contained baseline samples from 30 people who later developed oesophageal squamous cell carcinoma, with a reported median lead time of 34.9 months and AUC 0.864. The paper also reports external diagnostic validation in two cohorts.
Technology: Multi-criteria decision-making Classification Fusion (MCF) machine-learning framework; 289 candidate feature-selector/classifier pairs were compared and three base models fused
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: The BarFlare assay and an interpretable multi-criteria decision-making classification-fusion machine-learning framework combined extracellular-vesicle SCC and MMP13 biomarkers with clinical factors.
- Still unknown: This is a prospective observational diagnostic study, not an intervention trial or proof that screening improves outcomes. The longitudinal preclinical cohort had 30 incident cases and matched controls; performance estimates require external replication in larger populations. The source reports an association and lead time, not guaranteed individual prediction. Primary publisher full text and abstract checked; no independent replication assessed.
- AI role: The MCF framework integrated newly identified EV biomarkers with clinical variables, selected and fused machine-learning classifiers, and produced the risk score evaluated in diagnostic and prospective population cohorts. BarFlare is the high-sensitivity EV assay platform, not the AI model.
Evidence sources: https://isevjournals.onlinelibrary.wiley.com/doi/10.1002/jev2.70246
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A protein-language-model pipeline, HMD-AMP, screened host and gut-microorganism genomes from nine mammalian species and nominated antimicrobial peptides, including candidates with little similarity to known AMPs. Of 91 high-confidence peptides selected for experiments, 74 showed strong antibacterial activity and 48 were evolutionarily remote from known AMPs. Four tested peptides had broad-spectrum activity at low effective concentrations and low toxicity; the most potent reported candidate showed efficacy in a mouse peritoneal E. coli infection model.
Technology: HMD-AMP protein-language-model pipeline
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Of 91 high-confidence peptides selected for experiments, 74 showed strong antibacterial activity and 48 were evolutionarily remote from known AMPs.
- Still unknown: These are in-vitro peptide activity results plus a single reported mouse peritoneal E. coli infection experiment; they do not establish human safety or efficacy, clinical antibiotic utility, or activity against every pathogen. Only 91 of the many predicted sequences were tested, and 74 showed strong activity under the authors’ assays. The entry is one paper-level finding; other AMP discovery records in this ledger use different candidate sequences, sources or design workflows. The model acronym overlaps an earlier 2021 HMD-AMP classifier preprint, but this 2026 paper is a separate study with mammalian metagenomic mining and experimental outcomes; they are not conflated.
- AI role: HMD-AMP used protein language-model representations and a hierarchical classifier to identify and rank candidate antimicrobial peptides from host and gut-microorganism metagenomic/genomic sequences. The researchers experimentally tested 91 high-confidence candidates; 74 showed strong antibacterial activity, including 48 evolutionarily remote sequences, and four had the reported broad-spectrum/low-toxicity profile. The strongest candidate was then evaluated in a mouse infection model.
Evidence sources: https://www.nature.com/articles/s41551-026-01630-w
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A University of Hong Kong-led team used a conditional variational autoencoder constrained by biochemical properties and a random-forest activity classifier to generate and prioritize antimicrobial peptides. In vitro testing of 54 generated peptides found 18.5% with MIC ≤10 μg/mL and 38.9% with MIC ≤50 μg/mL against the study’s E. coli model; nine peptides were classified as both active and non-toxic in the reported assays.
Technology: CVAE-BIO: conditional variational autoencoder with biochemical constraints and a random-forest antimicrobial-activity classifier
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: In vitro testing of 54 generated peptides found 18.5% with MIC ≤10 μg/mL and 38.9% with MIC ≤50 μg/mL against the study’s E. coli model; nine peptides were classified as both active and non-toxic in the reported assays.
- Still unknown: Validation is in vitro, primarily against E. coli ATCC 25922; it is not evidence of treatment efficacy in animals or humans. The reported nine active/non-toxic peptides are assay-defined candidate hits, not validated drugs. This paper generated a different peptide set and used different training/design and testing workflows from the earlier C. acnes deep-learning, bullfrog-genome AMPlify, and LSTM Klebsiella sepsis studies in this ledger; do not treat the general AMP topic as a duplicate.
- AI role: The CVAE generated peptide sequences subject to predefined biochemical constraints; the random forest ranked activity using 30 biochemical descriptors. Researchers synthesized/tested 54 generated peptides in vitro, measured MIC and hemolysis, and reported the active/non-toxic subset.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41849223/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The CHAI computational-histology platform generated a locked H&E-based biomarker intended to distinguish advanced pancreatic ductal adenocarcinoma patients with differential outcomes on fluoropyrimidine-based versus gemcitabine-based chemotherapy. In an independent validation cohort of 299 patients from the prospectively collected COMPASS and Know Your Tumor cohorts, the 173 patients classified F-pref had longer time to next treatment or death (8.6 vs 7.5 months, P=.035) and overall survival (14.4 vs 11.7 months, P=.003) on F- versus G-based therapy. Among 126 G-pref patients, G-based therapy was associated with longer time to next treatment or death (9.6 vs 7.2 months, P=.038), but not significantly different overall survival.
Technology: Computational Histology Artificial Intelligence (CHAI) platform
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In an independent validation cohort of 299 patients from the prospectively collected COMPASS and Know Your Tumor cohorts, the 173 patients classified F-pref had longer time to next treatment or death (8.6 vs 7.5 months, P=.035) and overall survival (14.4 vs 11.7 months, P=.003) on F- versus G-based therapy. The locked biomarker was applied to assembled data from prospectively collected cohorts; prospective validation of treatment selection is still needed.
- Still unknown: Validation used 299 patients in two prospectively collected but nonrandomized cohorts; treatment assignment was not randomized, and the authors also used propensity weighting and target-trial emulation. The primary endpoint was time to next treatment or death, not progression-free survival. In the biomarker’s G-pref subgroup, the OS comparison was not significant. The authors call for further prospective validation before clinical adoption. An earlier CHAI study concerned adjuvant gemcitabine outcomes in resected disease; this entry is limited to the distinct locked first-line fluoropyrimidine-versus-gemcitabine biomarker and external-cohort results in advanced disease.
- AI role: Deep-learning models segmented H&E biopsy slides and quantified more than 30,000 histomorphologic features. Using the development cohort, the investigators statistically selected and weighted features into a treatment-preference biomarker and locked its threshold before applying it to an independent validation cohort. The platform supplied the image-derived feature measurements used in the biomarker; this is a biomarker-development and validation result, not autonomous treatment assignment.
Evidence sources: https://ascopubs.org/doi/pdfdirect/10.1200/JCO-25-02199
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
SurvFinder analyzed 6,950 H&E slides from 1,604 stage II colorectal cancer patients across four cohorts and identified tertiary lymphoid structures (TLSs) as prognostic tissue features. Its multi-view model integrated TLS morphology and spatial location; explainable analysis highlighted TLS maturity and position near the tumor periphery as features associated with relapse-free survival and adjuvant-chemotherapy outcome patterns across the retrospective datasets.
Technology: SurvFinder, a multi-component deep-learning pipeline: WSINet for prognosis-associated tissue features, SegNet for TLS segmentation/subtyping, and MVNet for multi-view risk prediction
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: SurvFinder analyzed 6,950 H&E slides from 1,604 stage II colorectal cancer patients across four cohorts and identified tertiary lymphoid structures (TLSs) as prognostic tissue features.
- Still unknown: This was a retrospective analysis of patients enrolled in 2012–2018; results do not establish prospective clinical utility. Associations between predicted risk, TLS features and adjuvant-chemotherapy outcomes are observational and do not prove treatment benefit or that TLS features causally determine relapse. The authors identify absence of prospective validation and real-world deployment as limitations.
- AI role: Deep learning autonomously identified prognosis-associated tissue features in whole-slide images, segmented and subtyped TLSs, and integrated morphological and spatial features for risk prediction. Explainable-AI attribution identified TLS location near the tumor margin and TLS maturity state as important prognostic features.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41532433/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The study experimentally tested the previously model-predicted drug tranylcypromine against L. major promastigotes and intracellular amastigotes. It reports IC50 values of 83.6 and 31.6 µg/mL, respectively, and macrophage CC50 of 282.3 µg/mL. These relatively high in-vitro concentrations do not establish achievable exposure, patient safety or clinical efficacy; human monoamine oxidase mechanism is not shown as the parasite target.
Technology: Prior machine-learning drug-repurposing pipeline (the present study is experimental validation)
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary full text reports promastigote and intracellular amastigote assays with dose responses and host-cell cytotoxicity.
- Still unknown: Prior drug/species work, tolerability and mechanism remain unresolved; no clinical inference.
- AI role: Study experimentally validates a model-prioritized repurposing candidate from earlier research.
Evidence sources: https://doi.org/10.3389/fmicb.2025.1756231
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: publisher primary full text; PubMed primary metadata/abstract. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
HEX, a pathology-image AI model, predicts spatial expression of 40 protein biomarkers from routine H&E slides. In retrospective NSCLC cohorts, combining HEX-derived virtual spatial proteomics with histology improved prognosis prediction and, in a separate 148-patient immune-checkpoint-inhibitor cohort, improved response prediction over H&E-only and virtual-proteomics-only models. The authors interpreted virtual maps as showing co-localized T-helper and cytotoxic T-cell niches among responders and immunosuppressive macrophage/neutrophil aggregates among non-responders.
Technology: HEX (H&E to protein expression), using a pathology foundation-model backbone; MICA (multimodal integration via co-attention)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In retrospective NSCLC cohorts, combining HEX-derived virtual spatial proteomics with histology improved prognosis prediction and, in a separate 148-patient immune-checkpoint-inhibitor cohort, improved response prediction over H&E-only and virtual-proteomics-only models.
- Still unknown: Retrospective observational cohorts; predictive associations do not establish causal mechanisms or improved patient outcomes from model-guided treatment. The 148-patient immunotherapy cohort is separate from the prognosis cohorts. The paper itself says extensive clinical validation remains necessary; do not describe the finding as a clinically validated diagnostic or prospective treatment-selection tool.
- AI role: HEX predicts expression of 40 proteins and produces spatially resolved virtual proteomics from H&E images; MICA fuses the original image with AI-derived maps for outcome prediction. Researchers used predicted marker distributions to interpret therapy-associated tumor–immune spatial patterns. These are retrospective model analyses with cohort-based clinical associations, not prospective treatment evidence.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12823406/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A machine-learning pipeline selected a seven-gene lactylation-related transcriptomic score (LDS) from nine Alzheimer disease cohorts. The study evaluated the signature in seven independent brain transcriptomic datasets and a single-center clinical plasma cohort of 540 participants (180 controls, 90 with amnestic mild cognitive impairment and 270 with Alzheimer disease). Plasma LDS had AUC 0.772 for Alzheimer disease; combining LDS with p-tau181 and p-tau217 had AUC 0.859. LDS scores increased across control, aMCI and Alzheimer groups and correlated with MMSE and Braak stage.
Technology: Lactylation-Derived Score (LDS), a random-forest feature-screening and partial least-squares logistic-regression model
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A machine-learning pipeline selected a seven-gene lactylation-related transcriptomic score (LDS) from nine Alzheimer disease cohorts.
- Still unknown: The plasma validation cohort was recruited at one center and the analyses are retrospective and observational. The score does not establish lactylation as a causal mechanism, clinical benefit, or readiness for routine diagnosis; broader and prospective validation is needed. This is a transcriptomic signature and a different result from previously reported Alzheimer spectral-protein/chemical biomarker studies.
- AI role: Machine learning selected a seven-gene expression signature from lactylation-related genes across multi-cohort brain transcriptomic data; the resulting score was measured by RT-qPCR in a separate clinical plasma cohort and evaluated alone and with plasma p-tau markers.
Evidence sources: https://www.nature.com/articles/s41746-025-02305-7
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The retrospective multicenter SMFIF study screened routine laboratory data and used multi-algorithm feature selection, SHAP ranking and a stacked ensemble to construct a 16-feature Sjögren disease model. Across a 34,958-patient source population from three Chinese hospitals, reported AUCs were 0.923 in testing, 0.934 in internal validation and 0.964 in a 545-person external cohort. The study also compared the model with conventional autoantibody and laboratory markers and evaluated discrimination from rheumatoid arthritis, lupus, systemic sclerosis and osteoarthritis.
Technology: SMFIF, a stacked ensemble of five selected classifiers built from multi-algorithm feature selection and SHAP-ranked routine laboratory features
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Across a 34,958-patient source population from three Chinese hospitals, reported AUCs were 0.923 in testing, 0.934 in internal validation and 0.964 in a 545-person external cohort.
- Still unknown: All cohorts were retrospective and drawn from three hospitals in China; the external cohort had 545 people, including 139 Sjögren cases. External calibration showed greater variability, and the authors call for prospective and multinational validation. Case groups had longer recorded symptom duration than controls and higher organ involvement, which may contribute to discrimination. The study does not show clinical impact, improved outcomes, or replacement of diagnostic criteria/clinical assessment.
- AI role: The AI pipeline screened 70 candidate features from routine laboratory tests, selected a 16-feature set using multiple feature-selection methods and SHAP ranking, and combined five base classifiers in a stacking model. The resulting score estimated Sjögren disease probability and was evaluated on a held-out test set, internal validation set and external-hospital cohort.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12660861/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
TARSA combines reinforcement learning and posterior sampling to search a 36-million-sequence library of experimentally resolved helical peptides. The study reports that 15 of 105 selected candidates showed cytotoxic activity against triple-negative breast cancer cells in vitro; the three leads were further tested against other breast cancer subtypes and peripheral blood cells. The source also reports toxicity against normal breast cells, so these findings do not establish therapeutic safety or clinical efficacy.
Technology: TARSA reinforcement learning; MCMC posterior sampling; learned cytotoxicity models
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: 105 selected peptides were experimentally evaluated; 15 showed activity in the reported breast-cancer-cell assays.
- Still unknown: Cell-culture results do not establish therapeutic efficacy; the source reports normal-breast-cell toxicity, and independent replication remains unknown.
- AI role: TARSA reinforcement learning and posterior sampling guide exploration of a very large peptide library, with learned potency/toxicity models used to select candidates for assays.
Evidence sources: https://www.nature.com/articles/s41467-025-66748-y
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Publisher full article including publication date, model description, methods and experimental results..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
At the University of Missouri, Zachary Berndsen and Keith Cassidy used AlphaFold to predict the structure of apoB100, the scaffold of LDL particles, and refined it using cryo-electron microscopy data. The result is a cage-like shell with a ribbon belt. The post gives no figures such as resolution and no clinical validation.
Technology: AlphaFold
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Cryo-EM images were refined with AlphaFold2 predictions; the resulting apoB100 structure was compared with more than 200 intramolecular cross-links and showed close agreement, with subnanometre resolution in most regions.
- Still unknown: The article states that clinical applications will take time and the structure's implications are not yet realized; it gives no resolution figures or clinical validation, and the abstract states that resolution is subnanometre only in most regions.
- AI role: AlphaFold2 generated the initial atomic-resolution structure predictions, which were refined against cryo-EM data.
Evidence sources: https://deepmind.google/blog/revealing-a-key-protein-behind-heart-disease/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-024-08467-w&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 48 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Applied to about 30,000 patients with severe undiagnosed developmental disorders, it led to a diagnosis in about one-third of cases and identified variants in 123 previously unknown genes, 25 of which were independently confirmed by other labs. This is preliminary clinical use; further checks are needed before adoption, and the page gives no detailed metrics.
Technology: popEVE (variant-effect prediction model)
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: popEVE was tested on documented variants and case studies, and applied to about 30,000 undiagnosed patients, leading to a diagnosis in about one-third; 123 novel gene candidates were identified, and 25 were independently confirmed by other labs.
- Still unknown: The press article says popEVE will need further verification for safety and accuracy before wide clinical adoption, and gives no accuracy metrics; it is not yet in routine clinical use.
- AI role: A deep generative model extending EVE with a protein language model, producing a calibrated disease-likelihood score for each variant.
Evidence sources: https://hms.harvard.edu/news/new-artificial-intelligence-model-could-speed-rare-disease-diagnosis · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41588-025-02400-1&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 4/5 · Validation 4/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Ensemble supervised classifiers trained on curated phenotypic activity data prioritized eight repurposing compounds for clinically relevant parasite-stage assays. The article reports six selected compounds with predicted trypanocidal effects, while identifying cytotoxicity as a caveat for two amastigote candidates; mifepristone showed trypomastigote activity. These are in-vitro strain-specific outcomes, not clinical efficacy or novel molecular entities.
Technology: Ensemble molecular-descriptor linear classifiers
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary article reports eight in-silico hits and selected-stage experimental confirmation; tables qualify cytotoxicity caveats.
- Still unknown: Prior compound activity and some full model/supplement details remain for later audit; selected repurposed compounds are not novel molecules.
- AI role: Data-centric supervised ensembles prioritize repurposing candidates for distinct parasite-stage assays.
Evidence sources: https://doi.org/10.3390/pharmaceutics17121513
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: publisher primary full text and tables. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In a single-centre cohort of 183 patients with idiopathic inflammatory myopathy and 104 healthy controls, seven machine-learning classifiers and LASSO feature selection were used with plasma and PBMC metabolomics to distinguish anti-MDA5-positive dermatomyositis. DHEAS and citrate were selected across the integrated analyses; plasma assays showed lower levels in anti-MDA5-positive cases, with concordant patterns reported in a separate 33-patient/33-control validation cohort. Within cases, DHEAS correlated inversely with rapidly progressive interstitial lung disease and citrate with rash.
Technology: Seven machine-learning classifiers (including random forest and XGBoost) with LASSO feature selection
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In a single-centre cohort of 183 patients with idiopathic inflammatory myopathy and 104 healthy controls, seven machine-learning classifiers and LASSO feature selection were used with plasma and PBMC metabolomics to distinguish anti-MDA5-positive dermatomyositis.
- Still unknown: Single-centre study with a relatively small validation group (33 anti-MDA5-positive cases and 33 controls). The metabolite associations with RP-ILD and rash are observational and do not establish causality. Reported discrimination is exploratory and does not establish a clinical diagnostic test or patient benefit; no treatment response was studied. DHEAS and citrate are known metabolites; the paper-specific result is their measured profile and candidate biomarker association in this disease cohort.
- AI role: The models ranked discriminatory metabolites and selected features for disease classification; the team integrated these with pathway results to prioritize candidate biomarkers. DHEAS and citrate were then measured using ELISA and a biochemical assay, with patterns assessed in the validation cohort. Machine learning aided biomarker selection and classification; assays and clinical data supplied validation.
Evidence sources: https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-025-03676-8
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Across seven cohorts and five medical centers, targeted metabolomics confirmed six metabolites—imidazoleacetic acid, ergothioneine, N-acetyl-L-methionine, 2-keto-3-deoxy-D-gluconic acid, 1-methylnicotinamide and dehydroepiandrosterone sulfate—as a panel for classifying rheumatoid arthritis against healthy controls and osteoarthritis. LASSO selected the six features, and logistic regression, random forest and XGBoost models were externally evaluated in geographically distinct cohorts; reported AUCs were 0.8375–0.9280 for RA versus healthy controls and 0.7340–0.8181 for RA versus osteoarthritis in three validation cohorts.
Technology: LASSO feature selection and logistic regression, random forest, support vector machine and XGBoost classifiers applied to untargeted and targeted metabolomics
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Across seven cohorts and five medical centers, targeted metabolomics confirmed six metabolites—imidazoleacetic acid, ergothioneine, N-acetyl-L-methionine, 2-keto-3-deoxy-D-gluconic acid, 1-methylnicotinamide and dehydroepiandrosterone sulfate—as a panel for classifying rheumatoid arthritis against healthy controls and osteoarthritis.
- Still unknown: This is a cross-sectional case–control diagnostic study, not prospective screening or evidence of improved patient outcomes. The authors note that disease activity and treatment effects were not assessed, so prognostic and treatment-monitoring uses are not established. Performance varied across cohorts and was lower for RA-versus-OA than RA-versus-healthy-control classification; stronger platform-specific than sample-type effects were observed. Some mechanistic relevance of the six metabolites remains uncertain.
- AI role: Machine-learning feature selection narrowed targeted-validated metabolites to a six-analyte panel, and supervised classifiers combined the measurements to distinguish RA from healthy controls and osteoarthritis in multiple independent cohorts. Targeted mass spectrometry provided absolute quantification; the models produced the reported cross-cohort diagnostic discrimination.
Evidence sources: https://link.springer.com/article/10.1186/s12967-025-07265-w
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 88 of works of the same type, year and subfield (OpenAlex work metrics, 5 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In six participants, a language-model pipeline translated fMRI responses to viewed videos into descriptions of their semantic content. Video identification reached about 50% among 100 candidates, compared with 1% chance. Results also extended to instructed video recall and persisted when the canonical language network was excluded, supporting a shared semantic representation beyond that network. The experiment used extensive participant-specific training; it was not unrestricted reading of private thoughts or a clinical aphasia trial.
Technology: Deep language model semantic-feature decoder with text generation search
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Video viewing and instructed recall in six participants; 2,180 unique videos in training and comparisons with analyses excluding the canonical language network.
- Still unknown: Small participant group and extensive per-person training. Clinical communication benefits and arbitrary private-thought decoding were not tested.
- AI role: Linear decoders mapped fMRI signals to deep-language-model semantic features; a language model guided text optimization.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12588295/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A%2210.1126%2Fsciadv.adw1464%22&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 15 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 5/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In two multicenter cohorts totaling 597 people, LASSO feature selection and five machine-learning classifiers produced a six-metabolite plasma panel for gastric-cancer diagnosis, with AUCs of 0.947–0.982 in discovery and 0.920–0.951 in validation. The panel included isovalerylcarnitine (C5), which was lower in cancer plasma and paired tumor tissue; the paper further reported a Mendelian-randomization association and cell-assay evidence linking C5 treatment to reduced gastric-cancer cell migration and invasion through calpain-associated changes in VE-cadherin and MMP2.
Technology: LASSO regression score feature selection with neural-network, support-vector-machine, ridge-regression, logistic-regression and naive-Bayes classifiers
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In two multicenter cohorts totaling 597 people, LASSO feature selection and five machine-learning classifiers produced a six-metabolite plasma panel for gastric-cancer diagnosis, with AUCs of 0.947–0.982 in discovery and 0.920–0.951 in validation.
- Still unknown: The cohorts were case-control clinical samples and do not establish population-screening performance or improved patient outcomes. The validation cohort contained 453 participants from seven centers; no prospective care-impact trial was reported. Mendelian-randomization evidence is observational genetic-instrument analysis, and cell migration/invasion experiments do not establish a treatment effect in animals or people. The 2024 IDDF abstract (DOI 10.1136/gutjnl-2024-IDDF.267) is an earlier disclosure of this same project, not a separate discovery. Source checked; independent replication not assessed.
- AI role: Machine-learning feature selection narrowed replicated plasma metabolite signals to a six-feature diagnostic panel, and the specified classifiers constructed/evaluated diagnostic models. The C5 mechanistic work was follow-up metabolomics, Mendelian-randomization, proteomic-correlation and in-vitro experimentation; the record does not imply that machine learning alone established the mechanism.
Evidence sources: https://link.springer.com/article/10.1038/s44321-025-00325-0
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 86 of works of the same type, year and subfield (OpenAlex work metrics, 9 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Genentech and collaborators trained the deep-learning model GNEprop on high-throughput screening data and screened more than 1.4 billion synthetically accessible molecules. In follow-up experiments, 82 selected compounds showed antibacterial activity against the sensitized E. coli ΔtolC strain; the paper reports a 90-fold higher hit rate than the training screen and describes chemically diverse hits, some with activity beyond that strain and validated biological targets.
Technology: GNEprop deep-learning antibacterial activity predictor
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: In follow-up experiments, 82 selected compounds showed antibacterial activity against the sensitized E. coli ΔtolC strain; the paper reports a 90-fold higher hit rate than the training screen and describes chemically diverse hits, some with activity beyond that strain and validated biological targets.
- Still unknown: The 82 confirmed hits were tested for single-dose activity against the sensitized E. coli ΔtolC screening strain; this is not evidence that all 82 work against wild-type bacteria or in infections. The 90-fold improvement refers to hit rate relative to the HTS training experiment. Some additional compounds were selected for dose-response testing; do not imply all virtual hits were validated. A publisher correction fixed a coauthor’s misspelled first name and did not change results.
- AI role: GNEprop was trained on approximately two million small molecules screened against E. coli ΔtolC and used to rank a much larger synthetically accessible library for experimental prioritization. The follow-up assays confirmed antibacterial activity for 82 compounds; biological characterization also investigated specific targets.
Evidence sources: https://www.nature.com/articles/s41587-025-02814-6
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 38 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
For insertions and deletions, it reaches 90% with Illumina data versus 80% for the best other tool, and over 80% with PacBio versus under 50%. In eight pediatric leukemia samples, it recovered known variants and flagged ten new ones that have not been independently validated. The tool and CASTLE dataset are open.
Technology: DeepSomatic (convolutional neural network)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: DeepSomatic was benchmarked against SomaticSniper, MuTect2, Strelka2 and ClairS on the CASTLE cell-line dataset with held-out chromosomes and genomes, across Illumina, PacBio and other platforms.
- Still unknown: The benchmark uses research cell lines rather than patient tumors, the glioblastoma result rests on one sample, and the 10 new leukemia variants are not stated to be validated.
- AI role: A convolutional neural network applied to sequencing data converted to images separated germline, somatic and error signals to call tumor variants.
Evidence sources: https://research.google/blog/using-ai-to-identify-genetic-variants-in-tumors-with-deepsomatic/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41587-025-02839-x&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 59 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The 27-billion-parameter single-cell model, built on Gemma with Yale, predicted that silmitasertib would increase antigen presentation only in an immune-positive context. In human neuroendocrine cell models with low-dose interferon, the increase was about 50%. Validation is in cells only; the authors call this ‘a first step.’
Technology: C2S-Scale 27B (Gemma)
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: The model's prediction that silmitasertib boosts antigen presentation with low-dose interferon was tested experimentally in human neuroendocrine cell models not seen in training, with a roughly 50% synergistic increase reported.
- Still unknown: The article calls this an early first step, validation is in cell models only, and clinical use is not shown.
- AI role: The 27B single-cell language model C2S-Scale ran a dual-context virtual screen of over 4,000 drugs and generated the hypothesis.
Evidence sources: https://blog.google/technology/ai/google-gemma-ai-cancer-therapy-discovery/ · https://www.biorxiv.org/content/10.1101/2025.04.14.648850
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Untargeted metabolomics and machine learning identified upper-respiratory-swab signatures for SARS-CoV-2 positivity, followed by targeted LC-MS/MS profiling. Across 1,226 samples (521 SARS-CoV-2-positive, 97 influenza A, 96 RSV, 211 other respiratory viruses and 301 virus-negative), the best SARS-CoV-2 LightGBM model had AUC 0.99, sensitivity 0.96 and specificity 0.95. Separate models reported AUC 0.97 for influenza A and 0.99 for RSV. The top-ranked SARS-CoV-2 features included 3-oxo-heneicosanoic acid and 2-(4-hydroxyphenyl) ethanol.
Technology: Light Gradient Boosting Machine and other machine-learning classifiers applied to mass-spectrometry metabolomics
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Separate models reported AUC 0.97 for influenza A and 0.99 for RSV.
- Still unknown: This is an assay-validation study using stored respiratory specimens, not a prospective clinical-impact trial. Results establish classification in the studied cohorts and do not show improved patient outcomes or routine deployment. The source notes unresolved oxo-position/isomer assignment for several features. The metabolite signals are candidate host-response markers, not proof of virus-specific causal biology.
- AI role: Machine-learning feature ranking identified metabolite signatures in untargeted profiles; the team adapted candidate signatures to targeted LC-MS/MS, and evaluated classification in respiratory-virus sample cohorts. The models supplied the sample-level classification and feature ranking, while mass spectrometry measured the metabolites.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41065362/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 0 of works of the same type, year and subfield (OpenAlex work metrics, 0 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A 2025 study added four cohorts to evaluate the seven-protein-marker OncoSeek test, which combines blood protein tumor markers and clinical variables with AI. Across seven cohorts from seven centres in China, Brazil and the United States, totaling 15,122 participants, the reported overall sensitivity was 58.4% at 92.0% specificity; the symptomatic cohort had 73.1% sensitivity at 90.6% specificity. The study also tested performance across four platforms and two sample types.
Technology: OncoSeek AI-empowered blood test combining seven protein tumor markers with individual clinical data
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A 2025 study added four cohorts to evaluate the seven-protein-marker OncoSeek test, which combines blood protein tumor markers and clinical variables with AI.
- Still unknown: This is a retrospective/observational cohort validation of a blood test, not evidence that screening improves outcomes or reduces mortality. Aggregate sensitivity was 58.4% and performance varied by cancer type; several cancer-specific groups were small. The article adds validation to a previously published OncoSeek test, so this record is limited to the new expanded-cohort/platform result, not a claim of first test discovery.
- AI role: The AI-assisted test integrated measured protein-marker values and clinical variables for multicancer classification. This paper evaluated its performance in four additional validation cohorts, including a prospective blinded study and symptomatic case-control cohort, and aggregated results across seven cohorts.
Evidence sources: https://www.nature.com/articles/s41698-025-01105-2.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 78 of works of the same type, year and subfield (OpenAlex work metrics, 5 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
An SVM-based screen of untargeted plasma metabolomics identified candidate renal-cell-carcinoma metabolites, which were confirmed by targeted analysis and used in the RCAID AI diagnostic model. In 1,680 participants across five hospitals, seven plasma metabolites supported AUROCs of 0.977, 0.911, 0.945 and 0.972 in internal, external, multicenter and temporal validation cohorts, respectively; validation also included late-stage and non-clear-cell RCC. The authors report six associated dysregulated pathways from multi-omic analyses.
Technology: Support-vector-machine metabolite selection and the Renal Cell Carcinoma Artificial Intelligence Detector (RCAID)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: An SVM-based screen of untargeted plasma metabolomics identified candidate renal-cell-carcinoma metabolites, which were confirmed by targeted analysis and used in the RCAID AI diagnostic model.
- Still unknown: The study used diagnostic case-control cohorts with healthy controls, so reported discrimination does not establish population-screening performance, clinical utility, or improved outcomes. Most cases were clear-cell RCC (81%) and stage I (69%); subtype and cohort composition may affect generalizability. The abstract reports multi-omic pathway associations but does not establish causal mechanisms. Samples were collected 2019–2023; source publication date is the 2025 online-first date. Source checked; independent replication not assessed.
- AI role: The source states that an SVM was used to identify candidate metabolites from untargeted plasma profiles; targeted metabolomics confirmed selected metabolites. The resulting seven-feature AI-aided RCAID model was evaluated in six independent internal, external, multicenter, temporal, late-stage and non-clear-cell validation cohorts.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41047317/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 83 of works of the same type, year and subfield (OpenAlex work metrics, 8 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
An AI screen of over 10,000 molecules identified enterololin, and DiffDock predicted its binding to LolCDE within minutes, confirmed by resistant E. coli mutants, RNA-seq, and CRISPR. The mechanism was clarified in about six months versus 18–24 with traditional methods. In mice, in Crohn's-like inflammation models, healing was faster than with vancomycin. Early stage; no human testing.
Technology: Machine-learning screening and DiffDock
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Enterololin was tested in mouse Crohn's-like inflammation models against vancomycin, with resistant mutant sequencing, RNA-seq and CRISPR knockdown used to clarify its mechanism.
- Still unknown: The source states it is early-stage development, no human data are reported, and clinical trials are not yet started.
- AI role: DiffDock predicted binding of enterololin to the LolCDE complex within minutes, guiding lab experiments on the mechanism.
Evidence sources: https://news.mit.edu/2025/ai-maps-how-new-antibiotic-targets-gut-bacteria-1003 · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41564-025-02142-0&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 28 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In the prospective SEPSIS-SHIELD study, a machine-learning blood test using isothermal amplification of 29 host-response mRNAs was evaluated in adults presenting to 22 emergency departments with suspected infection or sepsis. Among 1,222 patients with valid results, its bacterial and viral scores distinguished clinically adjudicated infection status with AUROCs of 0.83 and 0.91, respectively, and the system also produced a separate score for risk of ICU-level care within seven days. The test’s high/very-high and low/very-low interpretation bands had 92–99% sensitivities and specificities for selected infection/severity endpoints.
Technology: TriVerity on the Myrna instrument, using logistic-regression classifiers on expression measurements for 29 host-response mRNAs
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: In the prospective SEPSIS-SHIELD study, a machine-learning blood test using isothermal amplification of 29 host-response mRNAs was evaluated in adults presenting to 22 emergency departments with suspected infection or sepsis.
- Still unknown: This is prospective diagnostic/prognostic validation of a specific host-response test, not discovery of a causal infection mechanism and not evidence that use of the score improves patient outcomes or antibiotic decisions. Of 1,441 enrolled patients, 1,222 had valid test results; the main diagnostic analysis used 729 consensus-adjudicated patients, and 1,120 were evaluable for prognosis. Clinical adjudication is not a perfect microbiological gold standard, and the study reports lower accuracy when uncertain adjudications are included. Performance and predictive values may vary with local infection prevalence and case mix. This is distinct from the earlier VB10 10-gene signature paper (DOI 10.1016/j.ebiom.2021.103352), which used different genes, cohorts and a different diagnostic score.
- AI role: The locked machine-learning classifiers convert the amplified host-response mRNA profile into separate likelihood scores for bacterial infection, viral infection and need for critical-care interventions within seven days. The multicenter clinical study measured how those AI-generated scores performed against blinded physician adjudication and near-term clinical endpoints.
Evidence sources: https://www.nature.com/articles/s41591-025-03933-y
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 48 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A deep-learning model trained on digitized minor salivary-gland biopsy slides from five expert centres and externally validated at a sixth classified focus score and Sjögren disease in a retrospective cohort of 545 participants. Explainable-model analysis identified a histological pattern of CD8-positive T cells around acinar epithelial cells associated with Sjögren disease. External-validation AUROC was 0.89 for disease classification and 0.92 among patients negative for anti-SSA antibodies.
Technology: Deep-learning histopathology classifier with Shapley-value interpretation
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A deep-learning model trained on digitized minor salivary-gland biopsy slides from five expert centres and externally validated at a sixth classified focus score and Sjögren disease in a retrospective cohort of 545 participants.
- Still unknown: Retrospective multicentre cohort; external validation used one held-out expert centre. The authors state further validation is needed. The CD8 acinar-infiltration pattern was associated with disease classification and is not established as causal, pathognomonic, or clinically actionable. The study does not establish improved patient outcomes or replace expert pathology.
- AI role: The authors trained the deep-learning model on digitalized biopsy slides to classify focus score and Sjögren disease, tested generalization at a held-out centre, and used Shapley-value explanations to identify histological patterns associated with model decisions. The study reports acinar CD8-positive T-cell infiltration as a disease-associated pattern.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41038216/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 10 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The September 2025 Nature version reports a GPT-style transformer trained on about 0.4 million UK Biobank participants and evaluated without retraining on 1.9 million Danish individuals. It models rates for more than 1,000 diseases and generates potential health trajectories up to 20 years ahead. This is retrospective risk modelling, with training-population biases; it does not establish a clinical benefit. The work also has a medRxiv preprint first indexed in June 2024.
Technology: Delphi-2M (GPT-style generative transformer)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Existing-record predictions in UK Biobank and Danish registries.
- Still unknown: Not assessed: supplementary analyses and clinical deployment; population biases are discussed in the paper.
- AI role: A modified generative transformer models disease events and timing.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12589094/ · https://pmc.ncbi.nlm.nih.gov/articles/PMC12657216/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 161 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
KPPepGen combines Gene Ontology and pathogen-knowledge-graph prompts with a diffusion model to generate pathogen-conditioned peptide sequences. The paper reports valid peptide generation for 56 pathogens and wet-lab evaluation of nine novel peptides for Escherichia coli and Staphylococcus aureus, reporting antimicrobial activity and low cytotoxicity. Its Magainin 2 optimization result is a separate model-comparison metric, not a clinical outcome.
Technology: KPPepGen knowledge-aware prompt diffusion model
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The paper reports valid peptide generation for 56 pathogens and wet-lab evaluation of nine novel peptides for Escherichia coli and Staphylococcus aureus, reporting antimicrobial activity and low cytotoxicity.
- Still unknown: The source reports nine experimentally evaluated peptides for E. coli and S. aureus, not experimental validation for all 56 pathogens. Antimicrobial activity and cytotoxicity are in-vitro outcomes; therapeutic efficacy, safety in animals or people, and resistance outcomes are not established by this report.
- AI role: The model used pathogen-specific knowledge prompts to generate and optimize antimicrobial peptide sequences; researchers synthesized candidates and evaluated the nine reported novel peptides in wet-lab antimicrobial and cytotoxicity assays.
Evidence sources: https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202507457
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 8 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
An ensemble machine-learning screen of natural products prioritized protoberberine alkaloids as candidate RORγt inhibitors. In vitro assays found that berberine and coptisine inhibited Th17 differentiation and directly bound RORγt by surface plasmon resonance; coptisine also showed efficacy in a preclinical mouse psoriasis model.
Technology: Ensemble machine-learning models for natural-product RORγt activity and counter-screening, combining graph neural networks and molecular-fingerprint random forests
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: In vitro assays found that berberine and coptisine inhibited Th17 differentiation and directly bound RORγt by surface plasmon resonance; coptisine also showed efficacy in a preclinical mouse psoriasis model.
- Still unknown: Berberine and coptisine are known natural products; the novelty is their prioritization and experimental characterization as RORγt inhibitors in this workflow, not discovery of new chemical entities. The mouse result is preclinical and does not establish psoriasis treatment in humans. The catalog already contains an unrelated RORγt result involving topotecan; this paper's compounds and evidence are distinct.
- AI role: Ensemble models screened a natural-product library and prioritized predicted RORγt inhibitors. Chemotaxonomic analysis narrowed candidates to protoberberines; six were experimentally evaluated, and berberine/coptisine showed in-vitro effects and direct target binding, with coptisine tested in a mouse psoriasis model.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13227160/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 82 of works of the same type, year and subfield (OpenAlex work metrics, 6 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In discovery samples from 49 people with amyotrophic lateral sclerosis (ALS) and 54 controls, mass spectrometry detected 876 tear-fluid proteins, of which 106 differed in abundance. Biostatistical and machine-learning analyses produced a six-protein signature (CRYM, PFKL, CAPZA2, ALDH16A1, SERPINC1 and HP). In an independent cohort of 51 ALS cases and 52 controls, Western blots replicated significant group differences for SERPINC1 and HP; their combination had the best reported in-silico discrimination.
Technology: Machine-learning models applied to data-independent acquisition mass-spectrometry proteomics and biomarker-panel discrimination
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: In an independent cohort of 51 ALS cases and 52 controls, Western blots replicated significant group differences for SERPINC1 and HP; their combination had the best reported in-silico discrimination.
- Still unknown: This is an exploratory biomarker study with modest discovery and validation cohorts, not a clinically validated diagnostic assay. The article reports that only SERPINC1 and HP differences replicated significantly across cohorts; the six-protein signature is a candidate and its best discriminatory performance was evaluated in silico. It does not establish ALS-specific causality or clinical utility.
- AI role: Machine learning contributed to identification of ALS-associated differential proteins and pathways and evaluated discrimination by the derived signature. The selected tear-fluid proteins were then assayed in an independent patient/control cohort by Western blot; only SERPINC1 and HP differences are explicitly reported as replicated across cohorts.
Evidence sources: https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-025-02109-6
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 6 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In a plasma-proteomics study, machine learning selected a 17-protein panel from 33 proteins that differed between 183 people with ALS and 309 controls. The panel distinguished ALS from healthy participants and other neurological diseases in a held-out test set (AUC 96.2%, balanced accuracy 89.3%) and was assessed in independent cohorts, including UK Biobank samples. Applying the model to presymptomatic samples from people who later developed ALS showed risk-score shifts up to about 10 years before symptom onset.
Technology: Machine-learning classification model trained on Olink plasma proteomic features
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: The panel distinguished ALS from healthy participants and other neurological diseases in a held-out test set (AUC 96.2%, balanced accuracy 89.3%) and was assessed in independent cohorts, including UK Biobank samples.
- Still unknown: This is a candidate biomarker result, not a clinically available diagnostic or screening test. The discovery and neurological-disease test cohorts are modest; the presymptomatic analysis is retrospective, and broader ancestry representation and prospective longitudinal validation remain needed. The paper reports multiple cohort-specific metrics; the summary uses the detailed held-out test-set AUC and balanced accuracy rather than the abstract’s 98.3% model figure.
- AI role: The model selected a multiplex protein signature and classified ALS versus healthy and neurological-disease controls; the researchers then applied its risk score to presymptomatic samples to estimate disease-associated changes before onset.
Evidence sources: https://www.nature.com/articles/s41591-025-03890-6
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 65 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In a discovery cohort of 43 patients with asymptomatic large-artery atherosclerosis and a validation cohort of 39, investigators combined serum proteomics with machine learning to distinguish acute ischemic stroke from large-artery atherosclerosis. XGBoost selected a three-protein panel (RNASE4, HBA1 and ATF6B; reported AUC 0.917, specificity 80%) and a six-protein panel distinguishing patients from healthy controls (reported AUC 0.971, specificity 86%). ELISA assays confirmed higher GUCA2A and FLNA in patient groups.
Technology: XGBoost machine-learning models applied to serum proteomics; DeepPRM-Stellar targeted mass spectrometry supported peptide validation and panel optimization
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: In a discovery cohort of 43 patients with asymptomatic large-artery atherosclerosis and a validation cohort of 39, investigators combined serum proteomics with machine learning to distinguish acute ischemic stroke from large-artery atherosclerosis.
- Still unknown: The abstract reports 43 discovery and 39 validation participants, but does not establish prospective prediction or external clinical deployment. The signatures are candidate biomarkers, not a validated clinical test. Reported performance comes from this study and should not be interpreted as patient benefit or causal evidence. ELISA confirmation is reported for GUCA2A and FLNA, not every protein in the ML panels.
- AI role: The study reports that machine-learning techniques were used to identify circulating biomarkers of progression and that XGBoost selected the three- and six-protein signatures from targeted proteomic measurements. ELISA follow-up confirmed GUCA2A and FLNA group differences. The models are retrospective cohort analyses; the study did not prospectively predict future stroke events.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/40692393/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 42 of works of the same type, year and subfield (OpenAlex work metrics, 2 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Over 36 million possible compounds were screened computationally: candidate NG1 killed resistant Neisseria gonorrhoeae in a dish and in a mouse model, while DN1 cleared a MRSA skin infection in mice. Only 2 of 80 fragment candidates could be synthesized; these are preclinical results.
Technology: Generative AI for molecule design
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Generative models screened more than 10^7 chemical fragments in silico against N. gonorrhoeae or S. aureus, plus unconstrained design. Of 24 synthesized compounds, seven showed selective antibacterial activity; two leads reduced bacterial burden in mouse infection models.
- Still unknown: Mouse results only; no human testing is stated. The paper's abstract was read, not the full text.
- AI role: Genetic algorithms and variational autoencoders generated fragment-based and de novo compounds; researchers synthesized and tested selected compounds.
Evidence sources: https://www.cell.com/cell/abstract/S0092-8674(25)00855-4
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Original institutional announcement checked for the specific results, AI contribution and limitations cited in the antibiotic dossier or mathematical follow-up pilot. Full-paper reanalysis, external replication and an exhaustive follow-up search were not performed..
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 127 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
Directed relationships from this entry; they do not merge catalog counts.
- 2020-02-halicin · extends: The source names this earlier screening result as program background for moving to de novo generative design. New compounds and experiments; not a clinical follow-up or replication of the earlier candidate. Source
- 2023-05-abaucina · extends: The source names this earlier screening result as program background for moving to de novo generative design. New compounds and experiments; not a clinical follow-up or replication of the earlier candidate. Source
In four people with severe motor and speech impairments, researchers found imagined-speech signals in the motor cortex and decoded them with machine learning. They also tested filters and a trigger phrase to limit unintended decoding. This is a proof of principle with implanted electrodes: free, rapid inner speech cannot be decoded accurately, and attempted speech remains more accurate.
Technology: Brain-computer interface and machine learning
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Imagined-speech signals were recorded from motor cortex in four participants with implanted electrodes and decoded in real time, with filters and a trigger phrase tested to limit unintended decoding.
- Still unknown: The source states this is a proof of principle, free inner speech cannot yet be decoded accurately, and attempted speech remains more accurate.
- AI role: Machine learning decoded the imagined-speech neural signals.
Evidence sources: https://news.stanford.edu/stories/2025/08/study-inner-speech-decoding-device-patients-paralysis · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1016/j.cell.2025.06.015&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 87 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Using UK Biobank measurements of 2,937 plasma proteins, researchers found 446 dysregulated proteins in incident Parkinson cases and used machine learning to select a 23-protein panel for prediction. The panel achieved test AUCs of 0.78 in incident and 0.795 in prevalent cases; nine selected proteins were already dysregulated 10–14 years before diagnosis. In a separate Parkinson’s Progression Markers Initiative cohort, a 16-protein subset shared between platforms achieved validation AUC up to 0.76.
Technology: Support vector machine and other machine-learning models, with recursive feature elimination for panel selection
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Using UK Biobank measurements of 2,937 plasma proteins, researchers found 446 dysregulated proteins in incident Parkinson cases and used machine learning to select a 23-protein panel for prediction.
- Still unknown: The result is a retrospective biomarker/prediction study, not a validated screening test or evidence that intervention based on the panel improves outcomes. The external PPMI analysis retrained and tested models in that cohort rather than evaluating a frozen UK Biobank model; validation AUCs varied by visit definition, and the reported maximum was 0.76. Protein associations and co-expression modules do not establish causal mechanisms. It is distinct from the earlier 2024 iRBD study in this ledger (DOI 10.1038/s41467-024-48961-3): separate cohorts and a different 23-protein/14-year result versus an eight-protein targeted panel and up-to-seven-year conversion finding; this record does not claim first discovery of presymptomatic plasma signals in Parkinson disease.
- AI role: Machine-learning classifiers were trained on UK Biobank plasma proteomic measurements to predict incident Parkinson disease; recursive feature elimination selected a 23-protein subset. The authors then tested the shared protein subset in the separate PPMI cohort using its own train/test split.
Evidence sources: https://academic.oup.com/brain/article/149/4/1254/8234010
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 6 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A machine-learning framework applied to blood DNA-methylation profiles identified 540 CpG sites that classified brain insulin resistance in adults without type 2 diabetes. In the 167-person discovery cohort, the selected methylation signature was tested in two separate replication cohorts of 33 and 24 participants, with reported classification accuracy of 83–94%. The CpGs mapped to 445 genes enriched for neuronal-development and axonogenesis annotations; 98 sites showed significant blood–brain methylation correlation.
Technology: Supervised machine-learning framework using blood DNA-methylation profiles; a multi-fold elastic-net approach was described in the associated institutional and conference materials
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In the 167-person discovery cohort, the selected methylation signature was tested in two separate replication cohorts of 33 and 24 participants, with reported classification accuracy of 83–94%.
- Still unknown: This is a biomarker-classification study, not a prospective clinical screening or intervention study. The discovery cohort had 167 participants and the replication cohorts were small (n=33 and n=24); replication accuracy is reported as 83–94%, and larger independent cohorts are needed to establish transportability. Blood–brain methylation correlations at 98 sites support a proxy relationship but do not show that peripheral methylation causes brain insulin resistance. The authors describe potential future diagnostic use rather than demonstrated clinical utility.
- AI role: The supervised model selected a 540-CpG methylation signature from peripheral blood measurements to classify participants with and without brain insulin resistance, and the signature was assessed in two replication cohorts. The model-derived CpG set was then used for differential-methylation, gene-annotation and blood–brain correlation analyses.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/40768600/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 47 of works of the same type, year and subfield (OpenAlex work metrics, 2 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Investigators applied a deep-learning model to diagnosis text in the electronic health records of 92,428 pediatric patients. It flagged 171 patients above a prespecified Noonan syndrome risk threshold for chart review; genetic sequencing and specialist assessment identified two previously undiagnosed Noonan syndrome cases among evaluated patients, in addition to three patients diagnosed during the study period. The confirmed cases had pathogenic variants in Noonan-associated genes, including PTPN11 and LZTR1. This supplies real-world evidence that EHR-based model screening can surface rare-disease cases for clinical genetic evaluation.
Technology: Deep convolutional neural network trained on structured electronic-health-record diagnosis text to estimate Noonan syndrome risk
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: The confirmed cases had pathogenic variants in Noonan-associated genes, including PTPN11 and LZTR1.
- Still unknown: This was a real-world retrospective screening evaluation at one pediatric biobank, not a prospective screening trial. Sequencing identified two cases among 83 patients evaluated, and the overall precision among the 171 high-risk patients was 2.92%; the model therefore required substantial chart review and genetic confirmation. Retrospective risk trajectories suggest possible earlier recognition but do not establish earlier care or improved outcomes.
- AI role: The previously developed deep-learning model scored 92,428 patient records and ranked 171 individuals above a prespecified risk threshold. The study team reviewed high-risk records, then used clinical genetic assessment and sequencing to evaluate patients without a prior diagnosis; these follow-up tests confirmed two previously undiagnosed cases. Model risk trajectories were also reconstructed from cumulative EHR diagnoses to assess whether the signal appeared before final diagnosis.
Evidence sources: https://www.nature.com/articles/s41525-025-00512-5
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 80 of works of the same type, year and subfield (OpenAlex work metrics, 5 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
EchoNext was trained on more than one million heart-rhythm and imaging records to detect structural heart disease. The journal abstract reports internal and external validation, a controlled comparison outperforming cardiologists, and prospective clinical-trial evaluation in patients without previous cardiac imaging that identified undiagnosed disease. This supports a screening study, not proof that deployment improves patient outcomes. The authors also released model weights and an annotated dataset.
Technology: EchoNext (deep learning model on 12-lead ECG)
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: Internal/external diagnostic validation, a controlled cardiologist comparison and prospective clinical-trial screening of patients without previous cardiac imaging.
- Still unknown: Abstract and publication metadata reviewed. No claim of mortality reduction, universal clinical generalization or independent replication is made.
- AI role: A deep-learning model estimated structural-heart-disease risk from electrocardiograms to guide imaging-based screening.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A%2210.1038%2Fs41586-025-09227-0%22&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 163 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 5/5 · Validation 4/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The APEX deep-learning model screened 16,123 venom proteins by generating and scoring 40,626,260 venom-encrypted peptides. After activity prediction and filtering for low similarity to known antimicrobial peptides, the authors selected 58 for experiments; 53 showed antimicrobial activity against at least one tested pathogen. Three selected peptides reduced bacterial counts after topical treatment in a mouse Acinetobacter baumannii skin-abscess model; the wolf-spider-derived Arachnoserver-5 peptide produced a reported three-log reduction versus untreated controls through day four, without significant body-weight change under the study conditions.
Technology: APEX deep-learning model for bacterial strain-specific minimum inhibitory concentration prediction
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: After activity prediction and filtering for low similarity to known antimicrobial peptides, the authors selected 58 for experiments; 53 showed antimicrobial activity against at least one tested pathogen.
- Still unknown: Only 58 of the 386 low-similarity candidates were experimentally tested, and activity was measured against a defined panel of 11 strains; some tested peptides were cytotoxic. The mouse study was a topical single-dose skin-abscess model with six animals per group, not systemic treatment or human efficacy. The paper notes possible ion-channel activity for many candidates and calls for follow-up safety testing. A related APEX study mined archaeal proteomes (10.1038/s41564-025-02061-0); this entry is limited to the separate venom-protein source library and its distinct peptide set and experiments.
- AI role: APEX scored 40.6 million candidate peptide fragments generated from venom proteins for predicted antimicrobial activity. The authors filtered predicted hits for sequence dissimilarity to known antimicrobial peptides, synthesized a selected subset, and experimentally tested antimicrobial activity, cytotoxicity and selected animal-model efficacy. The AI model narrowed an otherwise very large peptide search space; assays established which selected candidates were active.
Evidence sources: https://www.nature.com/articles/s41467-025-60051-6.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 61 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A fine-tuned Prov-GigaPath ViT-g model, named EAGLE, predicted EGFR mutation status from routine H&E slides plus clinical features in lung adenocarcinoma. Across an international dataset of 8,461 slides it achieved mean AUC 0.847 internally and 0.870 in external cohorts. In a four-month prospective silent trial on 197 primary lung-adenocarcinoma samples, EAGLE achieved AUC 0.890. Simulated AI-assisted triage thresholds reduced rapid molecular EGFR tests by up to 43% while maintaining the study’s performance criteria.
Technology: EAGLE, a task-specific model fine-tuned from the Prov-GigaPath ViT-g pathology foundation model, combining H&E whole-slide image features with clinical variables for EGFR mutation prediction
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: Across an international dataset of 8,461 slides it achieved mean AUC 0.847 internally and 0.870 in external cohorts.
- Still unknown: The four-month prospective trial was silent: AI outputs did not guide care or replace standard testing. The 43% reduction is a simulated triage workflow at a selected score threshold, not an observed reduction in tests or evidence of improved outcomes. The cohort was 197 primary cases at one real-time deployment site, while broader retrospective/external cohorts supported generalization. EAGLE predicts presence of EGFR mutation but does not identify the mutation subtype; sequencing remains necessary before treatment. Performance was lower on metastatic samples. The paper is a distinct 2025 model iteration and validation study in the lineage of the group’s 2022 arXiv proof of concept (10.48550/arXiv.2206.10573); the prior work is cited as antecedent, not treated as a second alias or hidden as the first-ever pathology-image EGFR result.
- AI role: The AI model predicted tumor EGFR mutation status directly from routine H&E digital slides, using sequencing results as ground truth. Fine-tuning the pathology foundation model produced cross-institution validation, and real-time inference in a prospective silent trial tested generalization on newly processed clinical slides. The model score was evaluated as a screening/triage layer alongside rapid molecular testing; it did not replace genomic sequencing.
Evidence sources: https://www.nature.com/articles/s41591-025-03780-x
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 106 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Machine-learning integration of plasma functional-omics data in two discovery cohorts and a validation cohort identified biosignatures that distinguished active tuberculosis from nontuberculous mycobacterial infection, latent TB infection and other lung diseases. Cohorts included 76 people in the TB–NTM discovery set, 72 in the TB–LTBI–other-lung-disease set, and 68 TB plus 30 LTBI participants in the validation set. PC(14:0_22:6) was the most important predictor and was lower in active TB; additional external datasets yielded reported AUCs of 0.77–1.00.
Technology: Multi-omics integration and machine-learning predictive models for feature selection and classification
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Machine-learning integration of plasma functional-omics data in two discovery cohorts and a validation cohort identified biosignatures that distinguished active tuberculosis from nontuberculous mycobacterial infection, latent TB infection and other lung diseases.
- Still unknown: The article calls PC(14:0_22:6) a candidate differential-diagnostic biomarker. Reported AUCs vary by comparator group and dataset; they do not establish prospective performance, clinical utility, or replacement of microbiological diagnosis. The PubMed abstract does not provide all cohort-level assay details, so this summary remains bounded to abstract-reported information.
- AI role: The authors used machine-learning predictive modeling across integrated functional-omics measurements to identify and prioritize plasma signatures that discriminate active TB from clinically relevant non-TB groups. PC(14:0_22:6) emerged as the leading lipid feature; the analysis was evaluated across discovery, validation and two external datasets.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/40598791/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 12 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A brain-computer interface decoding 256 microelectrodes in the ventral precentral gyrus synthesized the participant's intended voice causally, with a reported latency of about 10 ms per decoding step. Listeners understood almost 60% of synthesized words, compared with 4% when he was not using the device, and he could modulate intonation and sing short melodies. Caveat: a single participant with ALS, within the BrainGate2 trial, and the authors describe the technology as early stage.
Technology: Deep neural network speech decoder for intracortical recordings
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: A single participant with ALS used a neural decoder on 256 microelectrodes with closed-loop audio feedback to produce synthesized voice in near real time, and could modulate intonation and sing short melodies.
- Still unknown: A single participant within a trial; the abstract states no explicit limitations, and the authors describe the technology as early stage.
- AI role: A neural decoder translated attempted-speech activity into synthesized voice; the abstract does not say whether it uses machine learning.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-025-09127-3&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 123 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 5/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In the GENESIS-IPF study of 71 patients with idiopathic pulmonary fibrosis at 22 centers (placebo versus three doses, 12 weeks), the 60 mg/day group had a mean FVC change of +98.4 mL versus −20.3 mL for placebo. Groups were small, so larger studies are needed; biomarker analysis was exploratory.
Technology: Pharma.AI (generative AI for targets and molecules)
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: Phase 2a, multicenter, double-blind, randomized, placebo-controlled, 71 patients for 12 weeks. Primary endpoint (patients with at least one treatment-emergent adverse event) was similar across arms: 70.6% to 83.3%. Treatment-related serious adverse events were low and comparable.
- Still unknown: Efficacy in larger and longer trials is not established by this phase 2a study.
- AI role: Generative AI was used to discover the TNIK target and the small-molecule inhibitor, per the paper's title and abstract.
Evidence sources: https://doi.org/10.1038/s41591-025-03743-2
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 239 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 4/5 · Novelty 5/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The study profiled plasma and excised vegetation samples from 238 infective-endocarditis patients and 100 controls, then used an ensemble machine-learning pipeline to select a 10-protein plasma diagnostic panel. The paper reports AUCs of 0.97 in the held-out discovery test set and 0.98 and 0.94 in two external plasma cohorts. Integrating proteomic and clinical features also produced a prognostic model for severe heart-failure status (abstract AUC 0.87). LRG1 and NDUFB4 were associated with infection severity in the cohort analyses.
Technology: Ensemble machine-learning diagnostic and prognostic models; the diagnostic workflow compared six algorithms and used recursive feature elimination with cross-validation to select a 10-protein panel
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: The paper reports AUCs of 0.97 in the held-out discovery test set and 0.98 and 0.94 in two external plasma cohorts.
- Still unknown: The study is an observational proteomic cohort analysis; it does not demonstrate that use of the panel improves patient outcomes or can replace current diagnostic criteria. The development comparison included 238 IE patients and 100 controls, so case-control separation may not reflect performance in an unselected real-world diagnostic population. External evaluation used two additional plasma cohorts (combined n=328); the prognostic endpoint and biomarkers are associations, not causal mechanisms. The paper's proposed NET-related therapeutic implications are hypothesis-generating and are not counted as demonstrated treatment benefit.
- AI role: Machine-learning feature-importance analysis and recursive feature elimination selected a 10-protein plasma combination for distinguishing infective endocarditis from non-endocarditis samples. The models were evaluated in a held-out discovery cohort and two external plasma cohorts. A separate model combined proteomic and clinical features to classify severe heart-failure status.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/40447567/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 10 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A plasma-proteomics study of 48 active ankylosing-spondylitis (AS) patients, 21 stable-stage patients and 35 healthy controls combined random-forest and OPLS-DA scores to prioritize candidate markers. SAA1, FERMT3, ILK and TLN1 were elevated in active-stage AS and returned toward control levels in stable-stage patients; ELISA in a separate cohort (27 active, 28 stable, 24 controls) reproduced these patterns. A combined ELISA model distinguished active AS from healthy controls with AUC 0.932. FERMT3, ILK and TLN1 are integrin-pathway proteins.
Technology: Machine-learning biomarker scoring matrix combining random forest and OPLS-DA
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: SAA1, FERMT3, ILK and TLN1 were elevated in active-stage AS and returned toward control levels in stable-stage patients; ELISA in a separate cohort (27 active, 28 stable, 24 controls) reproduced these patterns.
- Still unknown: This is an observational, cross-sectional plasma-biomarker study; it does not establish causal integrin-pathway activity, prognosis over time, treatment response, or clinical utility. The independent ELISA cohort had 79 participants and was drawn from the same clinical setting. The combined AUC 0.932 applies to active AS versus healthy controls; discrimination against other inflammatory diseases was not demonstrated. SAA1 has been previously reported as an AS-associated marker; the AI-supported novelty is the combined panel and the integrin-related proteins, not discovery of SAA1 itself.
- AI role: Random-forest classification accuracy/Gini importance and OPLS-DA variable-importance scores were combined with proteomic fold-change and significance terms to rank candidate proteins. The team then measured the four prioritized proteins by ELISA in an independent cohort.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/40436140/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 85 of works of the same type, year and subfield (OpenAlex work metrics, 4 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
FutureHouse's multi-agent system generated hypotheses, experiments, and analyses and identified ripasudil, already used for glaucoma, as a candidate against dry macular degeneration. Lab testing of ten candidates found that a ROCK inhibitor increases phagocytosis by retinal pigment epithelial cells; human researchers carried out the experiments. Announced May 20, 2025, and published in Nature May 19, 2026. Preclinical data.
Technology: Robin (Crow, Falcon, and Finch agents)
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: Human researchers lab-tested ten candidates proposed by Robin, and a ROCK inhibitor was found to increase phagocytosis by retinal pigment epithelial cells.
- Still unknown: The source calls ripasudil a candidate, not a proven treatment, and the mechanism proposed by Robin is not stated to have been tested.
- AI role: A multi-agent system generated hypotheses, chose experiments, analyzed data and drafted main figures.
Evidence sources: https://www.futurehouse.org/research/demonstrating-end-to-end-scientific-discovery-with-robin-a-multi-agent-system · https://arxiv.org/abs/2505.13400
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A three-stage analysis of plasma proteomics from 1,270 people with clinical Alzheimer’s disease (AD) and 2,096 cognitively normal controls identified 416 proteins associated with clinical AD, including 294 that the paper classified as not previously associated with AD in large-scale plasma or CSF proteomic studies. A LASSO-selected seven-protein model predicted clinical AD and biomarker-defined AD status, with validation in external cohorts and orthogonal assays; the signature also stratified later progression to symptomatic AD among initially cognitively normal participants.
Technology: LASSO feature selection with logistic regression, using five-fold cross-validation and age/sex covariates
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A LASSO-selected seven-protein model predicted clinical AD and biomarker-defined AD status, with validation in external cohorts and orthogonal assays; the signature also stratified later progression to symptomatic AD among initially cognitively normal participants.
- Still unknown: The cohort analysis is observational and does not establish that the associated proteins cause AD. The model’s clinical-status AUC was 0.72 in replication; performance was comparable to p-tau217 in the study’s comparison, but the reported AUC for frontotemporal dementia was also 0.73, limiting disease specificity. Orthogonal platform validation covered only subsets of the seven proteins (four proteins on Olink and two on Alamar), and the authors state that further work is needed before clinical use. The reported “new” designation is relative to prior large-scale plasma/CSF proteomic studies, not proof that each protein is biologically novel.
- AI role: The team used LASSO to select a compact protein panel from the proteins associated with AD in discovery and replication analyses, then retrained logistic regression to predict clinical AD status. This model-driven panel was evaluated against amyloid and tau biomarkers, external cohorts and orthogonal protein platforms; the analysis also tested associations with progression to symptomatic AD and memory decline.
Evidence sources: https://pure.amsterdamumc.nl/ws/portalfiles/portal/140778915/Large-scale-plasma-proteomic-profiling-unveils-diagnostic-biomarkers-and-pathways-for-alzheimers-disease.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 63 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The Predictive Biomarker Modeling Framework (PBMF), an ensemble neural network trained with a treatment-versus-control contrastive objective, identified a composite clinicogenomic biomarker using phase 2 POPLAR data for atezolizumab versus docetaxel. When applied retrospectively to the phase 3 OAK trial, its biomarker-positive group had a treatment-versus-control overall-survival hazard ratio of 0.59 (95% CI 0.47–0.74); an interpretable distilled decision tree produced HR 0.55 (95% CI 0.43–0.70). The tree used baseline ctDNA maximum allele frequency, lesion diameter, and mutation status in KMT2D, TSC1, ATM, PDGFRA and LRP1B.
Technology: Predictive Biomarker Modeling Framework (PBMF), an ensemble of neural networks using a contrastive treatment/control objective; knowledge-distilled decision tree
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: The Predictive Biomarker Modeling Framework (PBMF), an ensemble neural network trained with a treatment-versus-control contrastive objective, identified a composite clinicogenomic biomarker using phase 2 POPLAR data for atezolizumab versus docetaxel.
- Still unknown: Retrospective reanalysis; the biomarker has not prospectively guided patient selection or treatment. The outcome comparisons do not establish benefit from applying PBMF clinically. The authors call for prospective validation and note potential cohort comparability limitations. The identified feature set includes previously studied biomarkers; the paper’s novel result is the composite PBMF-derived predictive subgroup and retrospective generalization, not discovery of each individual feature.
- AI role: PBMF searched clinicogenomic features for a treatment-specific predictive subgroup, using phase 2 POPLAR training data and contrasting atezolizumab against docetaxel outcomes. Researchers transferred the derived model/biomarker to phase 3 OAK data and distilled it into an interpretable tree. This was a retrospective analysis of trial data, not prospective trial stratification.
Evidence sources: https://ellykipkogei.io/assets/pdf/1-s2.0-S1535610825001308-main.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 65 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Researchers independently trained PheWASNet on ECG and electronic health-record data from Stanford Health Care and Cedars-Sinai to assess 1,243 disease phenotypes. In held-out patient splits at both centers, the study reported previously unrecognized ECG associations for disorders including respiratory failure, neutropenia and menstrual disorders (AUCs 0.86, 0.83 and 0.84 at Stanford, respectively). Cross-condition model-output analysis found that 35 of 37 strongly detectable non-cardiac phenotypes shared signals with only four other disease outputs, and simple ECG measurement models explained some findings.
Technology: PheWASNet, a multi-task deep-learning model based on a one-dimensional EfficientNet architecture
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In held-out patient splits at both centers, the study reported previously unrecognized ECG associations for disorders including respiratory failure, neutropenia and menstrual disorders (AUCs 0.86, 0.83 and 0.84 at Stanford, respectively).
- Still unknown: This retrospective EHR-linked study establishes model-detectable associations, not causal physiology, screening benefit or clinical utility. The disease labels are diagnostic codes associated with ECGs within 30 days; results may reflect comorbidity or care context. The authors caution that generalization to other health systems and populations is not assured. Some detectable signals were explained by simple conventional ECG measurements, and the paper does not claim that deep learning is required for every association.
- AI role: The researchers trained separate deep-learning models on raw 12-lead ECG waveforms linked to EHR diagnoses at two medical centers, then used held-out patient test sets to identify disease phenotypes whose signals were detectable from ECGs. Cross-phenotype prediction comparisons and simple-model analyses were used to characterize shared and interpretable signals.
Evidence sources: https://academic.oup.com/ehjdh/article/6/4/595/8126967
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 5 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The Penn State/University of Minnesota team used the Lead Informed Machine Interrogation of Therapeutic Sequences (LIMITS) workflow to train random-forest and neural-network predictors on approximately 100 host-defense peptides, using lead mutational scans and biophysical sequence features. Experimentally tested neural-network-designed MAD5.1 and MAD5.3 showed reported MICs of 5 μM against M. tuberculosis H37Rv, selectivity indices >16 against an eight-organism non-mycobacterial panel, and mammalian-cell toxicity indices >100. The study identifies peptide length as a potentially underappreciated activity determinant.
Technology: LIMITS (Lead Informed Machine Interrogation of Therapeutic Sequences), using random-forest and feed-forward neural-network predictors
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Experimentally tested neural-network-designed MAD5.1 and MAD5.3 showed reported MICs of 5 μM against M. tuberculosis H37Rv, selectivity indices >16 against an eight-organism non-mycobacterial panel, and mammalian-cell toxicity indices >100.
- Still unknown: This is preclinical in-vitro peptide evidence, not animal efficacy or clinical treatment. The paper reports that MAD5.3 did not produce a statistically significant reduction in H37Rv viability after seven days of culture despite its MIC and selectivity/toxicity metrics; do not generalize the headline activity to every candidate or assay. MAD2.2 was moderately hemolytic. The 5 μM H37Rv MIC and high indices apply to selected peptides and stated assay conditions.
- AI role: Lead-candidate mutational scanning informed feature selection and training on a limited ~100-peptide dataset; the models iteratively selected candidate anti-TB peptide sequences for synthesis and bacteriological testing. NN-predicted MAD5 sequences were assayed against virulent and avirulent M. tuberculosis strains and counter-screened against other bacteria and mammalian cells.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/40310992/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 7 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Three research groups used machine-learning models trained on 496 measured PANC-1 drug pairs to nominate additional combinations. Of 88 nominated pairs tested, 51 met the study’s synergy threshold. The article also reports 307 synergistic combinations including the 256-pair training screen; the 307 total is not a count of new AI-nominated hits. The result is limited to cell assays.
Technology: Random forests; XGBoost; deep neural networks; graph convolutional networks
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The primary source reports the study-specific result summarized here.
- Still unknown: Independent replication and broad deployment are not established by this review.
- AI role: Models trained on measured drug-combination assays rank candidates from a virtual library; nominated combinations are tested in PANC-1 cell assays.
Evidence sources: https://www.nature.com/articles/s41467-025-56818-6
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: Primary-source indexed article or abstract and bibliographic metadata reviewed; complete source scope is given in source_checks..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In a blinded remote OSCE with 149 case scenarios, AMIE and primary care physicians held text consultations with simulated patients. Specialist physicians rated AMIE superior on 30 of 32 axes and patient actors on 25 of 26, and non-inferior on the rest. The evidence comes from simulated scenarios, not real patients, and the authors state that further research is needed before real-world use.
Technology: AMIE (Articulate Medical Intelligence Explorer), a large language model agent for diagnostic dialogue
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: A randomized, double-blind crossover study of text consultations with patient-actors across 159 case scenarios compared AMIE with 20 primary care physicians, rated by specialist physicians and patient actors on several axes.
- Still unknown: The authors note the unfamiliar synchronous text-chat format and state that further research is needed before real-world use.
- AI role: AMIE, an LLM-based diagnostic dialogue system trained by self-play with automated feedback, conducted the consultations.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-025-08866-7&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 824 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The team mined 216,408 bacterial genomes, identifying 335,024 NRPS clusters and 328 dereplicated peptide scaffolds. Deep-learning scoring selected five synthesized peptides; P2 showed MIC50 values of 1–2 μM against Vibrio parahaemolyticus and V. alginolyticus. Deep-learning-guided sequence optimization produced P2.2, which showed increased antibacterial activity, membrane effects and reduced hemolysis in assays.
Technology: Deep-learning peptide activity scoring and sequence-optimization algorithms
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Deep-learning-guided sequence optimization produced P2.2, which showed increased antibacterial activity, membrane effects and reduced hemolysis in assays.
- Still unknown: The study calls the peptides naturally inspired; it did not establish that the synthesized sequences are the native products of the mined clusters. P2's MIC50 of 1–2 μM did not mean 80% inhibition: its MIC80 exceeded 128 μM under the reported 24-hour conditions. P2.2's measured MIC80 values were 32 μM for V. parahaemolyticus and 64 μM for V. alginolyticus. These are in-vitro findings, not clinical efficacy.
- AI role: AI-ranked peptide candidates inspired by nonribosomal peptide synthetase cluster scaffolds from bacterial genomes and guided amino-acid optimization of P2 into P2.2; the selected sequences were synthesized and tested in vitro.
Evidence sources: https://homepage.zjut.edu.cn/_upload/article/files/51/c3/6b78dffc40f7932148ad26cbf65b/e1d2421e-c600-4dac-82a5-bc29fa545929.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 12 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
LogiRx, a mechanistic machine-learning model, predicted an off-target serotonin-receptor/PI3Kγ pathway for escitalopram’s antihypertrophic effect. The authors report mechanistic experiments in cultured cardiomyocytes, reduced hypertrophy in a mouse model, and retrospective patient-database associations. The drug and initial compound screen predated LogiRx; patient associations do not establish causation or clinical benefit.
Technology: LogiRx logic-based mechanistic machine learning
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary abstract reports experimental pathway validation, cardiomyocyte and mouse outcomes, and patient database associations.
- Still unknown: Independent replication and broader application are not established by this bounded review.
- AI role: LogiRx combines a mechanistic network and drug-target data to predict drug-induced pathways for experimental follow-up; the compound screen and drugs were prior inputs.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/40035765/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Primary PubMed metadata/abstract and publisher full-text PDF indexed result; retrospective human association caveat preserved..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Mal-ID analyzed B-cell and T-cell receptor repertoires from 593 people, including patients with COVID-19, HIV, systemic lupus erythematosus and type-1 diabetes, influenza-vaccination recipients and healthy controls. Its combined models classified held-out immune states and highlighted disease-associated receptor patterns; interpretation identified distinct autoreactivity features in lupus and type-1 diabetes and antigen-associated receptor sequences in COVID-19. The authors also evaluated classification on independent COVID-19 cohorts.
Technology: Mal-ID (MAchine Learning for Immunological Diagnosis), an ensemble using repertoire feature models and ESM-2 protein-language-model embeddings
Family ESM / ESMFold: profile · models page
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: The authors also evaluated classification on independent COVID-19 cohorts.
- Still unknown: This is a patient-sample diagnostic-validation and immune-biology study, not evidence of clinical deployment or benefit. Validation cohorts and disease-specific sample sizes are limited; external COVID-19 classification involved small cohorts and thresholds were tuned in some analyses. Additional disease-specific validation, threshold calibration, sequencing-depth assessment and interpretation alongside standard clinical assessment remain necessary. Its 2024 bioRxiv preprint is the same work, not a separate finding.
- AI role: Three machine-learning representations of B-cell and T-cell receptor data were combined to classify immune states and prioritize disease-associated receptor sequences, gene segments and isotypes for biological interpretation.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/39977494/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 132 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A previously developed multimodal AI score was retrospectively applied to archived diagnostic biopsies and follow-up from a prospectively collected Swedish prostatectomy cohort. The score, derived from digitized diagnostic prostate-biopsy images plus age, PSA and clinical T-stage, was associated with post-surgical biochemical recurrence and adverse pathology. Among 143 men with evaluable data and median 8.8-year follow-up, the continuous score was associated with recurrence (subdistribution HR 2.45, 95% CI 1.77–3.38); among 88 evaluable for adverse pathology, OR was 4.85 (95% CI 2.54–10.78). Estimated 5-year recurrence was 25% in intermediate/high score versus 4% in low score.
Technology: Artera multimodal artificial-intelligence (MMAI) prostate biomarker combining deep-learning features from digitized biopsy histopathology with age, PSA and clinical T-stage
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A previously developed multimodal AI score was retrospectively applied to archived diagnostic biopsies and follow-up from a prospectively collected Swedish prostatectomy cohort.
- Still unknown: This is retrospective external prognostic validation using specimens and follow-up from a prospectively collected cohort; it is not prospective AI-guided care, a randomized test of biomarker-guided treatment, or evidence that using the score improves outcomes. Only 143 patients had evaluable images and complete covariates, and 88 were evaluable for adverse pathology; it is a single tertiary Swedish center. The model’s earlier development setting involved men receiving radiation in North America, so this tests transport to a different population/treatment context. A 2025 conference abstract describing this cohort is an earlier presentation of the same study, not another record.
- AI role: The locked MMAI score converted diagnostic biopsy images and clinical variables into patient-level prognostic scores. The prospective Swedish cohort tested whether that model-derived score associated with the distinct post-prostatectomy outcomes biochemical recurrence and adverse pathology; associations persisted after adjustment for standard NCCN/CAPRA clinical risk measures.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11995000/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 25 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A system based on Gemini 2.0 that generates hypotheses and research proposals. In the lab, three drugs it suggested for repurposing against acute myeloid leukemia reduced cancer-cell viability, and all suggested treatments for liver fibrosis showed activity. Expert assessments covered only 11 targets; fibrosis results awaited a Stanford report.
Technology: AI co-scientist (Gemini 2.0, multi-agent)
Family AI Co-Scientist: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Elo auto-evaluation over 203 research goals; 15 expert-curated goals; blinded experts rated 11 goals (preference rank 2.36). In vitro on four AML cell lines: binimetinib, pacritinib, cerivastatin reduced viability; KIRA6 IC50 10 nM in KG-1a versus 180 nM in TK6. Seven combinations tested.
- Still unknown: The paper calls validation preliminary and in vitro only. KIRA6 was far less effective in MOLM-13 and HL-60. Expert evaluation was small and subjective; Elo is not ground truth. Liver fibrosis and AMR details are summarized only.
- AI role: A Gemini-based multi-agent system generated, debated and ranked hypotheses; experts selected candidates and prioritized lab experiments.
Evidence sources: https://doi.org/10.1038/s41586-026-10644-y
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A latent-diffusion and molecular-dynamics pipeline generated and filtered peptide sequences; 40 synthesized candidates were tested, and 25 met the study's MIC threshold for antibacterial or antifungal activity. AMP-29 showed activity against Candida glabrata and efficacy in a murine skin-infection model, while AMP-24 showed in-vitro Gram-negative activity and efficacy in murine Acinetobacter baumannii skin and lung infection models.
Technology: Latent diffusion model coupled to molecular dynamics and peptide filtering/ranking
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: A latent-diffusion and molecular-dynamics pipeline generated and filtered peptide sequences; 40 synthesized candidates were tested, and 25 met the study's MIC threshold for antibacterial or antifungal activity.
- Still unknown: Twenty-five of 40 tested peptides met the authors' stated MIC ≤200 μM activity threshold, which includes a broad range of potency. The murine efficacy reports concern selected peptides and infection models, not human treatment. Some fungal peptides showed hemolysis; favorable safety cannot be generalized to the whole set.
- AI role: The diffusion model generated a diverse peptide sequence set, and computational filtering selected 40 candidates for chemical synthesis and experimental antimicrobial testing; the selected peptides included leads taken into mouse infection models.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11797553/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 103 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
CHANCE, a supervised machine-learning model integrating patient-specific coding and non-coding mutations with drug and protein-interaction information, screened 5,197 TCGA/ICGC tumors against 923 FDA-approved non-oncology drugs. For ex-vivo validation, the investigators sequenced tumor cells from seven patients with pancreatic or esophageal cancer and tested CHANCE-prioritized drugs; at least one predicted non-oncology drug showed anticancer activity in tumor cells from five of the seven patients. This is patient-specific cell-assay validation, not a treatment-response study in patients.
Technology: CHANCE, a supervised gradient-boosted-tree model integrating coding/non-coding variants, protein–protein interaction networks, drug targets and drug-response data
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: For ex-vivo validation, the investigators sequenced tumor cells from seven patients with pancreatic or esophageal cancer and tested CHANCE-prioritized drugs; at least one predicted non-oncology drug showed anticancer activity in tumor cells from five of the seven patients.
- Still unknown: Only seven patient-derived samples were tested, from pancreatic or esophageal cancers; at least one prioritized non-oncology drug showed activity in five. This was an ex-vivo drug-sensitivity assay, not clinical treatment, and the study does not establish efficacy, safety, dosing or patient benefit. The 5,197-tumor/923-drug screen is computational prediction; only the small patient-derived subset had experimental validation. Drug-response predictions may include drugs represented in training, as the article notes 149 of 923 screened drugs were in the training data.
- AI role: Trained on drug-sensitivity measurements from 318 cancer cell lines across 647 drugs, CHANCE maps each patient tumor’s whole-genome mutations to drug-target/pathway features and ranks non-oncology drugs by predicted patient-specific anticancer activity. Investigators used these predictions to select drugs for ex-vivo testing in tumor cells from seven patients; the reported five-patient activity result tests the model’s personalized prioritization.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11794852/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 79 of works of the same type, year and subfield (OpenAlex work metrics, 5 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A random-forest classifier screened investigational compounds; after applicability, similarity, diversity, availability and cost filters, six compounds were purchased and tested. CEP-37440 and AZD-1480 had reported P. falciparum IC50 values of 1.22 and 4.00 µM. These are in-vitro findings for existing compounds, not evidence of malaria clinical safety or a confirmed parasite target.
Technology: Random-forest classifier
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary article reports tested CEP-37440/AZD-1480 antiplasmodial activity.
- Still unknown: Selected six are filtered, not a random sample; proposed parasite kinase mechanisms and patient efficacy are unverified.
- AI role: RF ranks investigational compounds from a drug database; human filters determine purchase/assay set.
Evidence sources: https://doi.org/10.1186/s13065-025-01395-4
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: publisher primary full text. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Deep graph neural networks trained on 13,490 Minisci reaction outcomes predicted reaction feasibility for a virtual library of 26,375 compounds derived from moderate MAGL inhibitors. Combined with physicochemical and structure-based scoring, this workflow prioritized 212 candidates; 14 were synthesized and showed subnanomolar MAGL inhibition, with reported potency improvements up to 4,500-fold over the starting hit. This is an AI-assisted, human-selected laboratory optimization result, not an autonomous workflow or a therapeutic outcome.
Technology: Deep graph neural networks for reaction outcome prediction; multi-objective molecular optimization
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: Fourteen selected synthesized compounds were reported with subnanomolar MAGL inhibition and co-crystal structures for three ligands.
- Still unknown: Independent replication, clinical activity and version 1 claim correspondence were not established.
- AI role: Reaction-prediction models trained on high-throughput Minisci experiments contributed to candidate feasibility scoring; other computational scores and human selection also shaped the experimental set.
Evidence sources: https://www.cambridge.org/engage/chemrxiv/article-details/6798ae2881d2151a024590d5
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Primary ChemRxiv v2 abstract and version metadata reviewed; full manuscript and supplements not inspected..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A process combining quantum and classical computing with Chemistry42 selected 15 candidates; two showed activity against mutated KRAS variants in living cells. Published in Nature Biotechnology, this is a proof of principle, with no significant quantum advantage or demonstrated superiority over compounds obtained by classical methods.
Technology: Chemistry42 and hybrid quantum-classical models
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Fifteen candidates from the hybrid process were tested in the lab, and two strongly targeted mutated KRAS variants in living cells.
- Still unknown: The source states it is a proof-of-principle study with no significant quantum advantage and no demonstrated superiority over classically designed molecules.
- AI role: Generative AI (Chemistry42) and a quantum-classical process designed molecules, narrowed to 15 candidates.
Evidence sources: https://www.utoronto.ca/news/ai-quantum-computing-used-target-undruggable-cancer-protein
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 125 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Small, stable proteins designed with AI bind and neutralize three-finger toxins from cobras and mambas in the lab; in mice, they yield 80–100% survival against lethal neurotoxin doses, depending on the toxin. Laboratory and animal studies only; traditional antivenoms remain central.
Technology: AI protein design (RFdiffusion)
Family RFdiffusion: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Lab tests showed the designed proteins neutralized multiple subtypes of three-finger toxins; in mice they gave complete protection from lethal neurotoxin exposure, with 80-100% survival depending on the toxin and antitoxin.
- Still unknown: The page does not mention human trials, toxin types other than elapid three-finger toxins, and traditional antivenoms remain central to treatment.
- AI role: Designed small, stable proteins on the computer that bind key regions of the toxins.
Evidence sources: https://www.ipd.uw.edu/2025/01/neutralizing-deadly-snake-toxins/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 196 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In a prospective study of over 460,000 women at twelve German sites, AI-assisted reading detected 6.7 cancers per thousand exams versus 5.7 without AI. Recall rates for further assessment were 37.4 versus 38.3 per thousand. This observational study does not show a survival benefit, and estimates of workload reduction with automated reading come from simulations.
Technology: AI support for mammogram reading (Vara)
Publication: Publication status unspecified in annotation · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Not reported
- Test type: prospective or independent check
- Tested: A prospective study of over 460,000 women at twelve German sites (2021-2023) compared AI-assisted reading with standard double reading by radiologists: 6.7 vs 5.7 cancers per 1,000 exams.
- Still unknown: No survival benefit is shown; workload and skipped-review figures come from simulations, and the effect on prognosis is still to be studied.
- AI role: AI read about half of the mammograms, marking cases as normal or suspicious, with the rest read by double reading.
Evidence sources: https://www.uni-luebeck.de/aktuelles/pressemitteilung/artikel/ki-verbessert-brustkrebserkennung.html
The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 280 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A workflow combining homology search, protein-language-model embeddings and regression prioritized kynureninases by predicted catalytic activity. Researchers experimentally tested four top-ranked candidates; the most active had nearly twice the turnover number of the prior best, and enzyme treatment was associated with a 3.4-fold reduction in tumor weight in a mouse comparison.
Technology: Protein language model embeddings coupled with regression in the SeekRank enzyme-prioritization workflow
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Researchers experimentally tested four top-ranked candidates; the most active had nearly twice the turnover number of the prior best, and enzyme treatment was associated with a 3.4-fold reduction in tumor weight in a mouse comparison.
- Still unknown: The evidence is a published paper abstract; it describes an enzyme/treatment experiment in a mouse tumor model, not clinical efficacy. The reported tumor-weight reduction is model-specific; no claim of human therapeutic benefit is made.
- AI role: The model represented homologous kynureninase sequences with protein-language-model embeddings and regressed kinetic activity to rank enzyme candidates. Four high-ranked candidates were tested in vitro and in vivo; the abstract reports one with nearly two-fold improved turnover number and reduced tumor weight in a mouse model.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/39777462/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 82 of works of the same type, year and subfield (OpenAlex work metrics, 14 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A virtual-screening workflow combined XGBoost and graph-neural-network models to screen 11,576 DrugBank compounds. Researchers selected 15 candidates for evaluation; four met the study’s activity cutoff against Mycobacterium tuberculosis H37Rv. Aldoxorubicin and quarfloxin were further tested against multidrug-resistant isolates, intracellular bacteria and recombinant DNA gyrase. These are laboratory repurposing results, not evidence of patient benefit or clinical safety. A same-team patent-family publication predates the journal article; this record makes no priority claim over patent disclosures. Concentration values are omitted because of inconsistent units in the rendered tables.
Technology: Ensemble virtual screening with XGBoost and graph neural networks
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The article reports follow-up testing of 15 selected compounds, four meeting the authors’ activity cutoff against H37Rv, and additional assays of aldoxorubicin and quarfloxin against multidrug-resistant isolates and recombinant DNA gyrase.
- Still unknown: All reported results are in vitro. The study does not establish patient efficacy, clinical safety or the compounds’ cellular mechanism. Precise concentration values are omitted because table units are inconsistent; an earlier patent-family publication is noted without a priority claim.
- AI role: Multiple learned models, including XGBoost and graph neural networks, predicted antitubercular activity in a DrugBank screen and contributed to selection of candidates for experimental evaluation.
Evidence sources: https://academic.oup.com/bib/article/26/1/bbae696/7934648
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary Oxford Academic full indexed article, including abstract, Methods, results, article history and author affiliations; patent-family chronology checked from the patent family page. A-version patent text was not reviewed..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Deep learning clustered cognitive and functional trajectories in 283 people with early dementia probably due to Alzheimer disease into fast- and slow-progressing groups. The trajectory groups were externally validated and independently replicated in a 2,779-person dementia cohort. A classifier using cross-sectional data at diagnosis predicted progression group in external validation with AUC 0.70 ± 0.01.
Technology: Deep-learning clustering of longitudinal cognitive/functional trajectories, followed by machine-learning classification from cross-sectional diagnosis data
Publication: Peer-reviewed paper · Test context: replication or operational use. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: replication or operational use
- Tested: The trajectory groups were externally validated and independently replicated in a 2,779-person dementia cohort.
- Still unknown: These are prognostic progression groups, not established biological disease subtypes or treatment-response predictors. The classifier had modest external discrimination (AUC 0.70 ± 0.01). Trial-size reduction and cost savings were estimated by emulating hypothetical enrichment and were not demonstrated in an actual clinical trial. The study does not show improved patient outcomes.
- AI role: Deep learning grouped patients using multivariate disease trajectories; the authors then trained a classifier to predict those progression subgroups from measurements available at diagnosis. The model-supported fast/slow progression groups were externally validated and independently replicated in a separate dementia cohort.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/39713242/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 23 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 5/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A deep-learning radiomic pipeline generated a pretreatment CT response score (CTRS) for advanced non-small-cell lung cancer treated with PD-(L)1 checkpoint inhibitors. In an independent real-world test cohort, high-response-score first-line ICI-monotherapy patients had longer progression-free and overall survival after adjustment for baseline covariates including PD-L1 (adjusted HR 0.46 and 0.50). In a secondary analysis of 54 participants from a prospective sasanlimab trial, the score was associated with overall survival (adjusted HR 0.33) but not progression-free survival.
Technology: Three-dimensional hierarchical convolutional neural network feature extractor combined with a Cox survival model (CT response score, CTRS)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In an independent real-world test cohort, high-response-score first-line ICI-monotherapy patients had longer progression-free and overall survival after adjustment for baseline covariates including PD-L1 (adjusted HR 0.46 and 0.50).
- Still unknown: The real-world data were retrospective. Association of the score with survival among treated patients does not establish that the score predicts differential treatment benefit versus an untreated or alternative-treatment control. Clinical-trial analysis was secondary and small (n=54): PFS association was not significant, while OS association was significant. Authors say larger prospective studies are needed; no improved-care or deployment outcome is shown.
- AI role: The model learned image features from pretreatment CT/PET-CT scans and combined them with a Cox survival model to produce an imaging-only response score. Researchers evaluated the score in a held-out real-world cohort and in a secondary analysis of a prospective clinical-trial cohort; it stratified PFS/OS in the first and OS in the latter.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11658027/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 19 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Spatial N-glycan imaging of hepatocellular carcinoma (HCC) tissue and paired serum identified thirteen altered glycan structures; glycoproteomics linked them to more than 50 proteins, and sixteen glycoproteins were assessed in a separate patient set. Machine-learning algorithms combining glycan/glycoprotein features with clinical variables differentiated early-stage HCC from cirrhosis in a case-control cohort of 100 HCC and 101 cirrhosis-only patients, with reported AUROC values across the algorithms of 0.88–0.97.
Technology: Machine-learning algorithms using serum N-glycan and glycoprotein features, age, sex and AFP
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Machine-learning algorithms combining glycan/glycoprotein features with clinical variables differentiated early-stage HCC from cirrhosis in a case-control cohort of 100 HCC and 101 cirrhosis-only patients, with reported AUROC values across the algorithms of 0.88–0.97.
- Still unknown: The discovery samples included 53 HCC tissues and 23 matched sera; the 201-patient testing set was a case-control cohort, not prospective surveillance. The paper notes that sialic acid was removed before analysis, excluding an important class of glycan modification. It does not establish screening benefit or prospective clinical utility. Individual glycoforms were weak classifiers; performance came from combined feature algorithms.
- AI role: Researchers used spatial glycan imaging and glycoproteomics to select altered tissue and matched-serum features, then used machine-learning algorithms to combine selected glycan/glycoprotein measurements with clinical variables for HCC-versus-cirrhosis classification. The source reports model performance in an independent case-control patient set.
Evidence sources: https://www.nature.com/articles/s43856-024-00677-7.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 86 of works of the same type, year and subfield (OpenAlex work metrics, 17 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Regularized logistic-regression and other machine-learning analyses of 178 Olink proteins identified a 29-protein preclinical Crohn disease signature. It distinguished future cases from controls with AUC 0.85 in a Swedish discovery cohort and 0.87 in an independent preclinical cohort; a separate inception cohort produced AUC 1.0. The study also reported a less predictive ulcerative-colitis signature and found that downregulated proteins related to gut-barrier integrity and macrophage function correlated with time to Crohn diagnosis.
Technology: Regularized logistic regression and additional machine-learning methods (L1-penalized regression, elastic net, support-vector machines and random forests) applied to Olink protein measurements
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: It distinguished future cases from controls with AUC 0.85 in a Swedish discovery cohort and 0.87 in an independent preclinical cohort; a separate inception cohort produced AUC 1.0.
- Still unknown: This is a nested case-control study using biobanked samples, not prospective screening or intervention evidence. The paper reports that the Crohn signature’s AUC fell to 0.58 when preclinical twins were compared with their healthy twin siblings, suggesting inherited/shared-environment factors affect discrimination. The ulcerative-colitis validation AUC was lower (0.67). Protein associations do not establish causal mechanisms; authors call for mechanistic studies. Source checked; independent replication beyond reported cohorts was not assessed.
- AI role: Machine-learning feature selection/modeling produced preclinical Crohn and ulcerative-colitis protein signatures in the discovery cohort. The fitted signature was evaluated in an external population-based preclinical cohort, an inception cohort at diagnosis, and twin comparisons. The result is predictive association from cohort data; the paper says mechanistic studies are needed.
Evidence sources: https://www.gastrojournal.org/article/S0016-5085%2824%2905741-X/pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 32 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The eDENTIFI gradient-boosted model estimated the probability of untreated infection during the next six hours from demographics, vital signs and laboratory results. Trained on 3,357 adult hospitalizations at two Illinois health systems and validated in 1,632 patients at a third, it achieved validation AUC 0.80 versus 0.64 for SIRS criteria. At the reported threshold it detected infection a median two hours before antimicrobial administration (47.6% sensitivity; 93.6% negative predictive value).
Technology: eDENTIFI, a gradient-boosted machine model using longitudinal discrete-time predictions
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Trained on 3,357 adult hospitalizations at two Illinois health systems and validated in 1,632 patients at a third, it achieved validation AUC 0.80 versus 0.64 for SIRS criteria.
- Still unknown: Retrospective derivation and validation used historical hospital records from 2006–2018, and the infection reference standard was clinician chart review. The reported 10.8% absolute/46.4% relative reduction in unnecessary IV antibiotics is a counterfactual model comparison, not observed intervention evidence. The authors state prospective validation is needed; no patient benefit or implementation outcome was established.
- AI role: The model used routinely available demographics, vital signs and laboratory results to predict clinician-chart-reviewed untreated infection over the next six hours. The study tested temporal detection performance in a separate third health system; model estimates were not prospectively used to direct care.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/39392375/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 49 of works of the same type, year and subfield (OpenAlex work metrics, 1 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Across six kidney-expression datasets, researchers identified 314 differentially expressed genes in diabetic nephropathy and used LASSO, SVM-RFE and random forest to prioritize seven candidate genes. Mendelian-randomization integration further prioritized carbonic anhydrase II (CA2); its ROC AUC exceeded 0.878 across the analyzed datasets. The authors also reported qPCR validation of CA2 in clinical patient and control samples and an association with inferred immune-cell infiltration.
Technology: LASSO, support-vector-machine recursive feature elimination and random-forest feature selection
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The authors also reported qPCR validation of CA2 in clinical patient and control samples and an association with inferred immune-cell infiltration.
- Still unknown: This is a candidate biomarker study, not evidence of a clinically deployed test or patient benefit. Reported AUC values are retrospective dataset performance; qPCR validation supports differential expression but does not establish CA2 as causal or disease-specific. The accessible abstract does not report the clinical validation sample size, so none is inferred.
- AI role: Three machine-learning approaches integrated candidate-gene selection from kidney-expression datasets; Mendelian randomization with expression-QTL data then prioritized CA2, which was evaluated as a diagnostic biomarker and measured by qPCR in clinical samples. The models supported gene prioritization and discrimination, while qPCR supplied the wet-lab follow-up.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/39370621/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 12 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Two classifiers previously prioritized approved drugs from a screened set; ten candidates were purchased for assays against L. major and L. infantum. Five showed dose-dependent effects; intracellular testing and macrophage cytotoxicity were also reported. Domperidone and dibucaine had prior antiparasitic evidence, so the bounded result concerns the study’s remaining tested drugs and assays, not ten novel therapies.
Technology: Random forest and support-vector machine classifiers
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary full text describes ten tested predicted candidates, three Leishmania strains, intracellular testing and host-cell counter-assays.
- Still unknown: Earlier drug-specific literature, concentrations, achievable exposure and clinical efficacy require separate assessment.
- AI role: Previously trained activity models selected FDA-approved drugs for experimental parasite and host-cell testing.
Evidence sources: https://doi.org/10.3389/fcimb.2024.1403589
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: publisher primary full text. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The model covers about 8,000 drugs across 17,080 diseases and is nearly 50% better than competitors at identifying candidates and 35% more accurate on contraindications. It was tested on 1.2 million medical records and on three rare diseases excluded from training. Computational predictions only, with no laboratory or clinical confirmation.
Technology: TxGNN (graph neural network)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: The model was checked against about 8,000 drugs and 17,080 diseases, validated on 1.2 million medical records, and asked to find drugs for three rare diseases excluded from training; it was compared with leading drug-repurposing models.
- Still unknown: Identified therapies would require further evaluation for dosing and delivery, and there is no laboratory or clinical confirmation.
- AI role: Proposed existing drugs for thousands of diseases, predicted contraindications and side effects, and gave a rationale for each prediction.
Evidence sources: https://hms.harvard.edu/news/researchers-harness-ai-repurpose-existing-drugs-treatment-rare-diseases
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 303 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A learned drug-target connectivity signature selected 23 predicted hits and 25 negatives for testing in four glioblastoma patient samples. Ex-vivo measurements agreed with predictions at a reported mean ROC AUC of 0.94. The small validation establishes a bounded drug-activity prediction result, not clinical response. Vortioxetine was found by the initial experimental screen and is not attributed to COSTAR nomination.
Technology: COSTAR logistic LASSO drug-target model
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Newly selected compounds were tested ex vivo across four patient samples.
- Still unknown: Patient benefit, generalization and clinical safety remain unestablished.
- AI role: COSTAR logistic LASSO drug-target model supported the stated study; experimental and interpretive work remained with researchers.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11564103/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Primary full-text model Methods and selected experimental Results, publication metadata and affiliations; supplements not reviewed..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Unsupervised clustering of 25 echocardiographic and biomarker variables in 1,199 ARIC participants with diabetes identified three phenogroups; the group with the greatest cardiac remodelling and neurohormonal-stress abnormalities had 12.1% five-year heart-failure incidence, versus 4.6% and 3.1% in the other groups. A deep-neural-network classifier trained to recognize this phenotype identified corresponding high-risk groups in the external CHS cohort (n=802) and UT Southwestern EHR cohort (n=5,071); phenotype classification was associated with incident heart failure in both.
Technology: Unsupervised hierarchical clustering and a deep neural network (DeepNN) classifier, with random forest variable-importance analysis
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Unsupervised clustering of 25 echocardiographic and biomarker variables in 1,199 ARIC participants with diabetes identified three phenogroups; the group with the greatest cardiac remodelling and neurohormonal-stress abnormalities had 12.1% five-year heart-failure incidence, versus 4.6% and 3.1% in the other groups.
- Still unknown: The cohorts were observational; association with future heart failure does not establish that model-guided intervention improves outcomes. The phenotype is an operational study definition, not a universally accepted diagnostic threshold. The authors describe potential preventive use, but it was not tested. The cohorts were external validations rather than prospective deployment trials.
- AI role: The authors used unsupervised hierarchical clustering of echocardiography and cardiac biomarkers to define outcome-associated diabetic-cardiomyopathy phenogroups, then trained and externally validated a DeepNN classifier to recognize the high-risk phenotype. Random forest permutation importance prioritized NT-proBNP, left-ventricular mass, Doppler measurements, left-atrial dimension and LV end-diastolic volume.
Evidence sources: https://onlinelibrary.wiley.com/doi/10.1002/ejhf.3443
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 88 of works of the same type, year and subfield (OpenAlex work metrics, 8 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Trained on 15 million patches and 60,000 slides and tested on more than 19,400 slides from 32 datasets and 24 hospitals: it detects cancer with about 94% accuracy across 15 datasets, predicts mutations in 54 genes with over 70% accuracy, and improves survival prediction by 8% across 17 institutions. Retrospective validation; not trained on rare diseases or premalignant tissue.
Technology: CHIEF (pathology foundation model)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Retrospective validation on more than 19,400 slides from 32 datasets at 24 hospitals; cancer detection was about 94% accurate across datasets.
- Still unknown: Validation beyond these datasets is still needed, rare and non-cancerous conditions and pre-malignant tissue were not tested, and gene prediction accuracy varies by gene and cancer type.
- AI role: Read digital tumor slides to detect cancer, predict gene mutations and survival, and generate heat maps of tissue features for pathologists.
Evidence sources: https://hms.harvard.edu/news/new-artificial-intelligence-tool-cancer
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 685 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Researchers at Hunan University and collaborators used the peptide language model deepAMP to optimize antimicrobial peptides and experimentally tested 29 candidates. More than 90% inhibited Gram-positive and Gram-negative bacteria better than the reference peptide penetratin; three candidates showed reduced resistance emergence in serial-passage assays and activity in a mouse Pseudomonas wound-infection model.
Technology: deepAMP peptide language model (deepAMP-general, deepAMP-AOM, deepAMP-POM and deepAMP-predict)
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Researchers at Hunan University and collaborators used the peptide language model deepAMP to optimize antimicrobial peptides and experimentally tested 29 candidates.
- Still unknown: This is a separate discovery study from the AMPSphere microbiome-mining paper already in the tracker: deepAMP optimizes peptide sequences, whereas AMPSphere mined microbiomes. Testing involved 29 candidates and one female mouse wound model; this is preclinical evidence, not clinical efficacy. The article itself calls for more animal-model validation.
- AI role: The generative and ranking models optimized candidate peptide sequences for antimicrobial potency and membrane-disrupting activity. Researchers synthesized and tested selected sequences in vitro and in a mouse wound infection experiment.
Evidence sources: https://doi.org/10.1038/s41467-024-51933-2
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 159 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A Gaussian naive-Bayes classifier using ECFP6 fingerprints ranked commercial compounds from a 13-million-compound library, followed by docking, property filtering and manual selection. Researchers purchased and assayed 25 candidates; three showed micromolar ULK1 inhibition, with reported IC50 values of 37.11 ± 4.41, 7.67 ± 2.82 and 3.15 ± 0.77 μM. The molecules were purchased rather than newly synthesized, and this entry does not claim absolute chemical novelty. The study’s comparator MRT68921 was more potent; the results do not establish cellular activity or clinical utility.
Technology: Gaussian naive-Bayes classifier on ECFP6 molecular fingerprints (NB-ECFP6)
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The paper reports 25 purchased candidates tested in a biochemical ULK1 kinase assay; three had measured micromolar inhibition with IC50 values 37.11 ± 4.41, 7.67 ± 2.82 and 3.15 ± 0.77 μM.
- Still unknown: The candidates were purchased, not synthesized. The reported assays do not establish cell activity or clinical effect; the reference MRT68921 was more potent in the paper’s comparison. Absolute structure novelty is not claimed here.
- AI role: The NB-ECFP6 model screened a large commercial compound set and prioritized candidates for downstream docking and biochemical testing.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11485869/ · https://pmc.ncbi.nlm.nih.gov/articles/PMC11485869/pdf/IFMC_16_2385288.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary PMC full article and linked publisher-version PDF, including methods, kinase assay results, date and author affiliation block..
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A man with ALS used a brain-computer interface with machine learning to turn attempted speech into text and synthetic voice. After further training, the system maintained 97.5% accuracy; the study reports more than 248 hours of spontaneous conversation over 32 weeks. Result from one participant with an invasive implant; still experimental.
Technology: Neural speech decoding with machine learning
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: One participant with ALS in the BrainGate2 trial completed 84 sessions over 32 weeks with over 248 hours of self-paced use; word accuracy was measured per session, with 97.5% maintained after continued data collection.
- Still unknown: The page does not state the study's limitations, and the result comes from one participant with an invasive implant.
- AI role: Machine learning decoded neural activity into phonemes and then words in real time, with continuous updates, and software generated the voice.
Evidence sources: https://www.ucdavis.edu/news/brain-computer-interface-allows-man-als-speak
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 282 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In an acute-coronary-syndrome derivation cohort matched for plaque rupture (PR) versus intact fibrous cap (IFC), quantitative mass spectrometry measured 1,121 plasma proteins. Five machine-learning algorithms screened candidate proteins; APOC3, RAB39A and KNG1 were then significantly different between PR and IFC in an independent 85-patient cohort using ELISA. The three proteins discriminated plaque rupture better than the study’s conventional biomarkers and risk factors, suggesting a candidate biomarker panel for identifying PR among ACS patients.
Technology: Unbiased machine-learning feature screening of quantitative mass-spectrometry plasma proteomics using five algorithms
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In an acute-coronary-syndrome derivation cohort matched for plaque rupture (PR) versus intact fibrous cap (IFC), quantitative mass spectrometry measured 1,121 plasma proteins.
- Still unknown: This was a small matched derivation cohort (110 ACS patients) and an 85-patient validation cohort, not prospective outcome prediction or a clinical-impact trial. The proteins are candidate diagnostic markers; the study does not show that using them improves management or outcomes, nor establish causal roles in plaque rupture. The publisher reports electronic publication 2024-08-06 and issue date 2024-09-15; the record uses online-first date.
- AI role: The ML algorithms selected nine candidate proteins from the proteomic measurements; the study subsequently tested candidates in an independent ACS cohort and confirmed three analytes—APOC3, RAB39A and KNG1—as significantly different in plaque-rupture versus intact-cap groups. ELISA provided the independent protein validation. The AI-enabled result is this prioritized, externally tested three-protein panel for a specific plaque phenotype.
Evidence sources: https://www.sciencedirect.com/science/article/pii/S0009898124021570
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 51 of works of the same type, year and subfield (OpenAlex work metrics, 1 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
ESM-IF1 scored substitutions in antibody–antigen complexes, and researchers experimentally screened variants of two clinical antibodies. The journal article reports up to 25-fold neutralization improvement against BQ.1.1 and up to 37-fold affinity improvement against XBB.1.5; these are distinct assays/variants. The preprint abstract reports a different neutralization figure, so this record uses journal values and does not backdate them to preprint v1.
Technology: ESM-IF1 inverse-folding protein model
Family ESM / ESMFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: PMC-hosted primary article reports experimental screening and improved neutralization/affinity results for antibody variants.
- Still unknown: Exact v1 result content and sequence-level overlap with earlier group studies not completely established; no clinical efficacy.
- AI role: Structure-informed inverse-folding scores guided substitutions followed by antibody binding and neutralization tests.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11616794/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: Primary source checked for identity, date, model role and bounded reported result..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A fused machine-learning and virtual-screening workflow narrowed compounds from three libraries to five candidate FtsZ inhibitors for bioactivity evaluation. The compound T3995 inhibited Staphylococcus aureus ATCC 6538 and Bacillus subtilis ATCC 9732 in reported assays, with MIC values of 32 and 2 μg/mL, respectively. Morphology and FtsZ-polymerization assays supported FtsZ-related antibacterial activity.
Technology: ROC-guided machine-learning selection combined with virtual screening, clustering and binding-model analysis
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The compound T3995 inhibited Staphylococcus aureus ATCC 6538 and Bacillus subtilis ATCC 9732 in reported assays, with MIC values of 32 and 2 μg/mL, respectively.
- Still unknown: Evidence is early in-vitro antibacterial activity and indirect support for an FtsZ-related mechanism; the abstract does not report direct target-binding measurements or in-vivo efficacy. Hemolysis was reported as safe at or below 16 μg/mL, while the MIC against S. aureus was 32 μg/mL, so this does not establish a therapeutic safety margin. The paper’s 2025 issue date follows its 2024 online publication date; the source-publication date here is the documented first online publication (23 July 2024).
- AI role: ROC-guided ML filtered candidates from three libraries; virtual screening of acquired compounds followed, then clustering and binding-model analysis prioritized five hits. Researchers performed growth, time-kill, cell-morphology, FtsZ-polymerization and hemolysis assays, including testing T3995.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/39043879/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 58 of works of the same type, year and subfield (OpenAlex work metrics, 4 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Using Virchow pathology-model embeddings, a pan-cancer detector achieved a specimen-level AUC of 0.95 across nine common and seven rare cancer types. The held-out evaluation included 6,142 specimens from Memorial Sloan Kettering Cancer Center and external institutions. Separate comparisons approached the performance of tissue-specific clinical products and exceeded them on some rare variants. This is diagnostic validation on existing specimens, not evidence that the Virchow detector itself was deployed or improved patient outcomes.
Technology: Virchow (vision transformer foundation model for pathology)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A pan-cancer detector built on Virchow embeddings was evaluated on a held-out set of 6,142 specimens from Memorial Sloan Kettering and external institutions, and compared with tissue-specific clinical products.
- Still unknown: The abstract does not establish deployment or patient-outcome benefit; no explicit limitations are stated.
- AI role: The Virchow pathology foundation model provided embeddings for the pan-cancer detector.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41591-024-03141-0&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 898 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Researchers used regularized machine-learning models to select sparse plasma-protein signatures for 10-year incidence across 218 diseases in 41,931 UK Biobank Pharma Proteomics Project participants. Five to twenty proteins improved held-out risk prediction over basic clinical information for 67 diseases and over clinical information plus routine assays for 52. The study identified TNFRSF17 as a specific predictor for future multiple myeloma and TNFRSF13B for monoclonal gammopathy of undetermined significance. In bone-marrow single-cell data from 11 newly diagnosed myeloma patients and three controls, four of five myeloma predictor proteins were most highly expressed by plasma cells; FCRLB and QPCT elevation was attributable to malignant plasma cells. Proteomic signatures also replicated improved prediction for five of six diseases tested in EPIC-Norfolk.
Technology: LASSO feature selection and regularized Cox machine-learning models integrating plasma proteomics and clinical covariates
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Five to twenty proteins improved held-out risk prediction over basic clinical information for 67 diseases and over clinical information plus routine assays for 52.
- Still unknown: The disease predictions are observational risk associations, not causal mechanisms or clinical screening outcomes. Most protein signatures were not externally replicated; EPIC-Norfolk tested six diseases, with improved prediction replicated for five. The myeloma single-cell analysis involved 11 patients and three healthy controls and supports cellular expression attribution, not prospective validation of an assay. Absolute quantification with clinical-grade assays and further validation would be needed before clinical use.
- AI role: The authors applied a three-stage machine-learning framework—feature selection, hyperparameter tuning and held-out validation—to ~2,923 proteins in UK Biobank. It selected parsimonious protein signatures for 218 future disease outcomes and identified disease-specific predictors and shared predictors. For multiple myeloma, the model-selected five-protein signature and follow-up single-cell expression analysis linked four predictors to marrow plasma cells and showed malignant-cell-associated FCRLB and QPCT expression.
Evidence sources: https://www.nature.com/articles/s41591-024-03142-z
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 273 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A multimodal AI model analyzed demographics, personal and family history, medications, cognitive and functional testing, and neuroimaging across nine datasets totaling 51,269 participants. It assigned probabilities to ten primary or contributing dementia etiologies and addressed mixed cases. The paper reports microaveraged AUROC 0.96 for dementia-etiology differentiation; model probabilities aligned with etiology-specific biomarkers and postmortem pathology. In a review of 100 cases, AI-augmented neurologist assessment outperformed neurologist-only ratings.
Technology: Multimodal machine-learning model combining clinical, neuropsychological, functional and neuroimaging data
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A multimodal AI model analyzed demographics, personal and family history, medications, cognitive and functional testing, and neuroimaging across nine datasets totaling 51,269 participants.
- Still unknown: The nine-dataset analysis is retrospective and includes in-house as well as external cohorts. The 100-case clinician comparison is small, and the study did not test prospective changes in care or patient outcomes. The authors call for prospective studies before claiming improved patient care. Model probabilities aligned with available biomarkers and postmortem evidence but are not histopathologic confirmation for every individual prediction.
- AI role: The model integrated routinely collected clinical variables and multimodal neuroimaging to estimate cognitive status and probabilities for ten dementia etiologies, including mixed etiologies and cases with incomplete features. It was evaluated across independent cohorts and compared with neurologist assessments; its output is the etiology-specific classification and probability result.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/38965435/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 209 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A multicenter observational serum multi-omics study used LASSO and Boruta to select candidate biomarkers for 28-day outcome in acute respiratory distress syndrome. Eight proteins (VCAM1, LDHB, MSN, FLG2, TAGLN2, LMNA, MBL2 and LBP) showed consistency in an independent cohort of 183 patients and were confirmed by targeted parallel-reaction-monitoring mass spectrometry. The protein model AUC was 0.802 in validation versus 0.738 for the clinical model. The discovery analysis also reported sphingosine-1-phosphate association with ARDS prognosis and an enriched sphingolipid pathway.
Technology: LASSO and Boruta feature selection; machine-learning prognostic model; targeted PRM validation
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Eight proteins (VCAM1, LDHB, MSN, FLG2, TAGLN2, LMNA, MBL2 and LBP) showed consistency in an independent cohort of 183 patients and were confirmed by targeted parallel-reaction-monitoring mass spectrometry.
- Still unknown: Observational prognostic associations do not show proteins cause outcomes or that biomarker-guided care improves survival. Discovery n=130 ARDS patients; validation n=183. PRM confirmation is not independent replication by another group; deployment and prospective benefit were not established.
- AI role: LASSO, fold-change screening and Boruta prioritized candidate 28-day ARDS prognostic proteins; candidates were tested by targeted PRM in an external cohort.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/38956604/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 41 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Researchers developed a targeted multiplex mass-spectrometry assay for eight plasma proteins and applied machine learning to distinguish Parkinson disease from healthy controls and classify people with isolated REM sleep behavior disorder (iRBD). In the reported longitudinal iRBD cohorts, the model classified 79% of participants up to seven years before motor Parkinson disease or dementia with Lewy bodies onset. The work connects a targeted protein panel to a pre-motor disease signal in measured blood samples.
Technology: Machine-learning classifier using recursive feature elimination on targeted plasma proteomic measurements
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Researchers developed a targeted multiplex mass-spectrometry assay for eight plasma proteins and applied machine learning to distinguish Parkinson disease from healthy controls and classify people with isolated REM sleep behavior disorder (iRBD).
- Still unknown: The discovery phase used only 10 Parkinson cases and 10 controls. Although the study includes larger targeted-assay cohorts, the longitudinal iRBD groups were small (18 and 54 participants), and the finding is not a validated screening test or proof that intervention changes outcomes. The model’s apparent early classification needs larger prospective cohorts.
- AI role: The classifier selected an eight-protein panel from targeted mass-spectrometry measurements, then classified motor Parkinson cases and iRBD participants; the longitudinal analysis linked panel scores with later clinical conversion.
Evidence sources: https://www.nature.com/articles/s41467-024-48961-3
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 139 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Untargeted serum metabolomics from 69 participants, including eight patients followed from HBV-related cirrhosis to hepatocellular carcinoma (HCC), was analyzed with LASSO and random forest to prioritize metabolites. 1-methylnicotinamide (1-MNAM) declined across healthy, cirrhosis and HCC groups and was lower at the HCC than cirrhosis stage in the eight progressors. Targeted mass spectrometry in a separate cohort of 25 healthy controls and 25 early-stage HCC patients confirmed lower 1-MNAM in HCC (AUC 0.954 for HCC versus healthy controls).
Technology: LASSO regression and random forest classifier applied to serum metabolomics
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Targeted mass spectrometry in a separate cohort of 25 healthy controls and 25 early-stage HCC patients confirmed lower 1-MNAM in HCC (AUC 0.954 for HCC versus healthy controls).
- Still unknown: The longitudinal transition signal comes from eight HBV-cirrhosis patients who progressed during follow-up. The independent targeted cohort compared 25 early-HCC patients with 25 healthy controls; it did not validate prediction of progression among cirrhosis patients. The authors describe the overall sample as small and call for larger prospective validation. 1-MNAM is a known endogenous metabolite; this record concerns the study-specific association and selection result, not discovery of a new compound, causal mechanism, or clinical test.
- AI role: The authors used LASSO and random forest to select ten candidate metabolites distinguishing cirrhosis from HCC, then identified 1-MNAM as the sole candidate with a consistent decline across healthy, cirrhosis and HCC groups. The algorithms prioritized the measured metabolite; targeted mass spectrometry in a separate cohort provided assay follow-up.
Evidence sources: https://link.springer.com/article/10.1007/s00432-024-05848-6
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 63 of works of the same type, year and subfield (OpenAlex work metrics, 7 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
An automated machine-learning workflow screened public blood-methylation datasets and selected IGF2BP1, CENPI and PSME4 as candidate schizophrenia-associated methylation markers. The researchers then measured these genes by targeted qMSP in 30 first-episode, drug-naive schizophrenia patients and 30 controls: IGF2BP1 methylation was higher and PSME4 lower in cases, while CENPI did not differ. A five-feature model combining the three genes with age and sex classified cases versus controls with AUC 0.755 (95% CI 0.636–0.862).
Technology: JADBio AutoML platform, comparing classifiers including support-vector machines, random forests, ridge logistic regression and decision trees with feature selection and cross-validation
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The researchers then measured these genes by targeted qMSP in 30 first-episode, drug-naive schizophrenia patients and 30 controls: IGF2BP1 methylation was higher and PSME4 lower in cases, while CENPI did not differ.
- Still unknown: The patient validation was a small case-control pilot (30 first-episode cases and 30 healthy controls); its AUC of 0.755 is modest and has a wide confidence interval. CENPI methylation did not differ in the clinical samples, so it should not be presented as independently validated. The study does not establish diagnostic performance in clinical differential-diagnosis populations, prospective utility or causality, and the authors describe the signature as potentially useful for future diagnostics rather than clinically established.
- AI role: AutoML selected gene-methylation features from genome-wide public schizophrenia methylome datasets and built predictive signatures. The authors then measured the selected markers using qMSP in a separate 30-case/30-control first-episode drug-naive cohort and trained a second model on methylation plus demographic variables.
Evidence sources: https://www.nature.com/articles/s41398-024-02946-4.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 78 of works of the same type, year and subfield (OpenAlex work metrics, 12 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In a reader study with 62 radiologists on 400 cases, the AI detected about 6.8% more clinically significant cancers at the same specificity and produced about 50% fewer false positives. On 1,000 routine-practice cases, however, non-inferiority was not confirmed (specificity 68.9% vs 69.0% at 96.1% sensitivity). The authors call for prospective validation, and the system is not available for clinical use.
Technology: PI-CAI challenge super-algorithm (ensemble of top five submitted deep learning models)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A multireader study with 62 radiologists on 400 paired cases compared AI and PI-RADS 2.1 reads, and 1,000 routine-practice cases were used to test non-inferiority against historical clinical readings.
- Still unknown: Non-inferiority to routine practice was not confirmed (specificity 68.9% vs 69.0%); the authors state prospective validation is needed and the system is not available for clinical use.
- AI role: A deep-learning system detected clinically significant prostate cancer on MRI.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:38876123%20AND%20SRC:MED&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 418 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Machine learning identified 863,498 candidate sequences in microbial genomes and metagenomes. Of 100 synthesized peptides, 63 inhibited at least one of the eleven strains tested; some showed activity in animal models. The catalog contains candidates, not hundreds of thousands of clinically validated antibiotics.
Technology: Machine learning for antimicrobial peptides
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: 100 predicted peptides were synthesized and tested in vitro and in vivo against drug-resistant pathogens and human gut commensals; 63 inhibited pathogens.
- Still unknown: The abstract states no limitations and does not name the strains or animal models used.
- AI role: Machine learning predicted antimicrobial peptides across 63,410 metagenomes and 87,920 genomes, producing a catalog of 863,498 non-redundant candidates.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1016/j.cell.2024.05.013&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 477 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A deep-learning device analyzed routine H&E whole-slide images to estimate whether advanced urothelial tumors carried selected FGFR2/FGFR3 alterations used for erdafitinib eligibility. In a separate 350-slide retrospective validation set, the device achieved 88.7% sensitivity and 31.8% specificity; it was also prospectively integrated into a non-interventional study spanning 89 sites in nine countries. The paper projected a 28.7% reduction in molecular tests assuming 15% biomarker prevalence; that estimate was simulated, not a measured population-level reduction.
Technology: FGFR Device, a multi-instance-learning attention model with a convolutional neural-network backbone
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: In a separate 350-slide retrospective validation set, the device achieved 88.7% sensitivity and 31.8% specificity; it was also prospectively integrated into a non-interventional study spanning 89 sites in nine countries.
- Still unknown: The 350-slide retrospective validation set was deliberately enriched (150 FGFR-positive and 200 negative; 43% prevalence), and the device fell slightly short of the prespecified 90% sensitivity target. Prospective real-time workflow validation covered only 17 samples in one month (15 predictions; two quality-control failures); production deployment reported 24 samples, with only 20 receiving molecular testing. The 28.7% test reduction is a simulation assuming 15% prevalence, not an observed clinical outcome. This is prescreening support, not a stand-alone diagnosis or evidence of patient benefit.
- AI role: Trained on more than 3,000 urothelial-cancer slides with molecular test labels, the deep-learning model inferred selected FGFR alteration status from H&E images and returned a likelihood for prescreening before confirmatory molecular testing. The device was prospectively integrated into a non-interventional study workflow; molecular tests remained the reference standard.
Evidence sources: https://www.nature.com/articles/s41467-024-49153-9.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 30 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A translational study combined a disease-related mouse gene-expression signature, human liver-biopsy transcriptomes and serum protein measurements to select IGFBP7, SSc5D and Sema4D as a three-protein panel for metabolic dysfunction-associated steatotic liver disease (MASLD). A LightGBM model classified biopsy-staged fibrosis, with AUCs 0.82 for F0/F1, 0.89 for F2 and 0.87 for F3/F4 in the development/testing data. In an independent Danish cohort of 156 patients, AUC was 0.84 for F0/F1 and F3/F4; performance for F2 was lower (AUC 0.62).
Technology: LightGBM classifier (TLM3) using the three serum proteins IGFBP7, SSc5D and Sema4D
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A translational study combined a disease-related mouse gene-expression signature, human liver-biopsy transcriptomes and serum protein measurements to select IGFBP7, SSc5D and Sema4D as a three-protein panel for metabolic dysfunction-associated steatotic liver disease (MASLD).
- Still unknown: The model is an early translational biomarker result. Its independent cohort replicated better classification at F0/F1 and F3/F4 (AUC 0.84) but was modest for F2 (AUC 0.62). The authors say mechanistic claims could not be tested in the single-biopsy cohorts and call for prospective and intervention studies before clinical utility is established. TNO disclosed a patent application related to the biomarkers.
- AI role: The LightGBM model combined the three protein measurements selected from a translational mouse/human fibrosis signature to classify liver-biopsy fibrosis stages. The authors compared the model with Fib-4, APRI and FibroScan in held-out and independent cohorts.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11137090/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 70 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Targeted serum metabolomics compared 89 patients with systemic lupus erythematosus (SLE) and 44 healthy participants, identifying 146 differential metabolites. The authors combined statistical screening with seven machine-learning models to prioritize eight diagnostic biomarker candidates (reported AUCs above 0.95). Two additional metabolites, N-methyl-L-glutamic acid and L-2-aminobutyric acid, were evaluated by ELISA in a 90-patient SLE validation cohort and associated with SLE Disease Activity Index scores.
Technology: Seven machine-learning classification models applied to targeted serum metabolomics
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: The authors combined statistical screening with seven machine-learning models to prioritize eight diagnostic biomarker candidates (reported AUCs above 0.95).
- Still unknown: This retrospective case-control study has modest cohorts and does not establish a clinically deployed test, causal SLE mechanism, or patient benefit. Reported diagnostic AUCs and SLEDAI associations require independent prospective replication; the validation cohort described in the abstract consists of SLE patients and does not by itself establish performance against a new external healthy/control population. The authors’ pathway interpretation is hypothesis-generating.
- AI role: The study iteratively compared seven machine-learning models to select candidate metabolites for SLE classification and combined the selected features with statistical screening. N-methyl-L-glutamic acid and L-2-aminobutyric acid were subsequently assessed by ELISA in a patient validation cohort; the machine-learning analysis nominated candidates, while the assays supplied biological measurement follow-up.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/38710348/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 19 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A mixed workflow using deep reinforcement learning, pharmacophore and shape filters, docking and hit expansion reports three SARS-CoV-2 main-protease inhibitor series with biochemical IC50 values of 1.3–2.3 μM. The paper combines generated and commercially sourced hits; not every final inhibitor is claimed as directly model-generated. PDB entry 8R11 was released before the article and already disclosed a bound compound structure, so no priority claim is made for that structure. These biochemical findings do not establish antiviral efficacy or clinical safety.
Technology: Deep reinforcement learning; pharmacophore/shape filtering; docking
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Publisher abstract reports three experimentally validated Mpro inhibitor series with IC50 1.3–2.3 μM; PDB 8R11 pre-dates the paper.
- Still unknown: Exact assignment of each final inhibitor to generated versus commercially sourced material and prior chemotype overlap not fully audited; no antiviral or clinical claims.
- AI role: Reinforcement learning generates candidate structures; computational filters and hit expansion guide follow-up, but commercially sourced hits also contributed.
Evidence sources: https://pubs.rsc.org/en/content/articlepdf/2024/md/d4md00106k
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Primary RSC article landing page and full-text PDF abstract; first-publication date verified. PDB identity/release was reported in input ledger and should be retained as earlier structure disclosure..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
SpliceCore’s XGBoost models used splicing-factor RNA-binding and spliceosome information to nominate NEDD4L exon 13 (NEDD4Le13) and the SSO-0205 binding site. In triple-negative breast-cancer MDA-MB-231 cells, SSO-0205 increased exon inclusion (67% versus 15% control), reduced proliferation and decreased migration by 40–50%; the effects were not observed in the non-tumorigenic MCF10A comparator under the reported assays.
Technology: SpliceCore XGBoost models with SHAP and out-of-bag feature analysis
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: In triple-negative breast-cancer MDA-MB-231 cells, SSO-0205 increased exon inclusion (67% versus 15% control), reduced proliferation and decreased migration by 40–50%; the effects were not observed in the non-tumorigenic MCF10A comparator under the reported assays.
- Still unknown: Experiments were in vitro, including three breast-cell lines and limited biological replicates; the migration assay used two to three replicates. These results do not establish tumor control in animals, patient benefit, safety or clinical efficacy. The source reports the target as novel in the studied context; this is not evidence that the SSO is a treatment.
- AI role: The models prospectively nominated the NEDD4L exon-13 splice event, predicted functional SSO binding sites, and prioritized implicated splicing factors. Researchers synthesized selected oligonucleotides and tested splicing, proliferation and migration in cell lines.
Evidence sources: https://link.springer.com/article/10.1038/s44320-024-00034-9
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 78 of works of the same type, year and subfield (OpenAlex work metrics, 12 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A generative model designed molecules from the three-dimensional surfaces of PPAR proteins: synthesized in the laboratory, they increased activity and were tested by Roche. They demonstrate the method and are not intended for commercial development; the tests do not establish safety or efficacy in humans.
Technology: Protein-surface-guided generative AI
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: ETH chemists synthesized the AI-designed molecules in the lab, and Roche ran a variety of tests showing they are stable and non-toxic.
- Still unknown: The article does not state limitations, the molecules were not developed toward market, and the tests do not establish safety or efficacy in humans.
- AI role: A generative model designed molecules from scratch matched to a protein's three-dimensional surface, without human intervention.
Evidence sources: https://ethz.ch/en/news-and-events/eth-news/news/2024/04/ai-designs-new-drugs-based-on-protein-structures.html
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 121 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Baker’s group showed RFdiffusion can be adapted to generate antibodies: in laboratory tests, designs bound influenza virus and other targets as intended. Proof-of-concept study, first circulated as a preprint in March 2024; experts quoted by Nature call it promising but an early step; no affinity values reported.
Technology: RFdiffusion
Family RFdiffusion: profile · models page
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: Laboratory tests confirmed that the designed antibodies bind influenza virus and other targets as intended; no affinity values are reported.
- Still unknown: The work is described as a proof-of-concept study, and no specific limitations are listed.
- AI role: RFdiffusion was tuned to generate antibodies from scratch.
Evidence sources: https://www.ipd.uw.edu/2024/04/nature-a-landmark-moment-scientists-use-ai-to-design-antibodies-from-scratch/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A machine-learning system selected semapimod, a known anti-inflammatory drug, for activity against dormant Gram-negative bacteria. MIT reports laboratory activity against E. coli and A. baumannii and an effect that sensitizes these bacteria to other antibiotics; the result is preclinical and does not demonstrate efficacy in patients.
Technology: Machine learning for compound screening
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Lab-only time-lapse microscopy of E. coli treated with semapimod showed activity against stationary-phase E. coli and A. baumannii and sensitization to other antibiotics.
- Still unknown: The article states no limitations, no animal or patient testing is mentioned, and no drug combinations are named.
- AI role: AI-based high-throughput screening of known drug compounds identified semapimod for antibiotic activity.
Evidence sources: https://news.mit.edu/2024/mit-scientists-are-using-artificial-intelligence-target-sleeper-bacteria-0408
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 59 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The generative model proposed about 25,000 candidates in under nine hours from more than 130,000 synthesis building blocks; of 58 synthesized, six killed a drug-resistant A. baumannii strain and two were not toxic in mice. Mechanism unknown, efficacy in infected animals untested, and four of the six compounds were not water-soluble.
Technology: SyntheMol (generative model)
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Of 58 synthesized candidates, six killed a drug-resistant A. baumannii strain in the lab, and two of those were not toxic in mice.
- Still unknown: Four of the six compounds were not water-soluble so were not tested in mice, efficacy in infected animals is untested, and the mechanism is unknown.
- AI role: A generative model proposed about 25,000 candidate antibiotics and synthesis recipes in under nine hours from over 130,000 building blocks.
Evidence sources: https://med.stanford.edu/news/all-news/2024/03/ai-drug-development.html
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Original institutional announcement checked for the specific results, AI contribution and limitations cited in the antibiotic dossier or mathematical follow-up pilot. Full-paper reanalysis, external replication and an exhaustive follow-up search were not performed..
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 221 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In 2,772 adults with diabetes from Singapore’s population-based SEED study, LASSO and gradient-boosting models screened 220 circulating metabolites and 19 clinical factors for prevalent diabetic kidney disease (DKD) and retinopathy (DR), then were externally assessed in 5,843 UK Biobank participants. Both outcomes shared diabetes duration, insulin use, age and tyrosine as important model features. DKD additionally selected cardiovascular disease history, antihypertensive use, lactate, citrate and the intermediate-density-lipoprotein cholesterol-ester/total-lipid ratio; DR additionally selected HbA1c, glucose, pulse pressure and alanine. External AUCs were 0.791 for DKD and 0.778 for DR, versus 0.691 and 0.760 for conventional adjusted logistic-regression comparators.
Technology: Least absolute shrinkage and selection operator logistic regression and gradient-boosting decision trees applied to metabolomics and clinical risk factors
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In 2,772 adults with diabetes from Singapore’s population-based SEED study, LASSO and gradient-boosting models screened 220 circulating metabolites and 19 clinical factors for prevalent diabetic kidney disease (DKD) and retinopathy (DR), then were externally assessed in 5,843 UK Biobank participants.
- Still unknown: The analysis is retrospective and cross-sectional; it classifies prevalent complications and cannot establish temporal prediction or causal effects of tyrosine, lactate, citrate, alanine or lipid features. The Singapore cohort was recruited in 2004–2011 and was multiethnic Asian; about 95% had type 2 diabetes, but the study did not separate diabetes types. UK Biobank definitions and available eye-severity measures differed, and validation of moderate-or-worse DR was not feasible. Performance is modest, particularly external AUC 0.791 DKD/0.778 DR, and does not establish clinical utility.
- AI role: ML feature selection prioritized a shared set of clinical/metabolic factors and distinct DKD- and DR-associated metabolites, then built detection models externally evaluated in UK Biobank. These models outperformed traditional adjusted logistic-regression comparators in the reported internal and external validation. The scientific result is the disease-specific feature pattern and its validated detection performance, not merely an algorithm benchmark.
Evidence sources: https://www.jmir.org/2024/1/e41065/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 30 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In two multicenter longitudinal cohorts of early multiple sclerosis (discovery n=309; validation n=232), unsupervised clustering of high-dimensional flow-cytometry and serum-proteomics profiles identified three peripheral-blood immune endophenotypes. Follow-up associated the groups with different trajectories of inflammation versus early structural damage. In the endophenotype-3 subgroup, patients subsequently treated with interferon beta had higher four-year progression and MRI activity than patients receiving other therapies.
Technology: Unsupervised clustering of high-dimensional flow-cytometry and serum-proteomics profiles (the reviewed abstract does not name the clustering algorithm)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In two multicenter longitudinal cohorts of early multiple sclerosis (discovery n=309; validation n=232), unsupervised clustering of high-dimensional flow-cytometry and serum-proteomics profiles identified three peripheral-blood immune endophenotypes.
- Still unknown: The source reports cohort associations, not randomized treatment effects. The higher progression and MRI activity among endophenotype-3 patients treated with interferon beta may be affected by treatment selection and other confounding; it does not establish that interferon beta caused worse outcomes or that the signature can guide care. The validation cohort is an independent patient cohort within the study, not independent replication by another research group. The reviewed abstract does not provide the clustering algorithm name or establish prospective clinical utility.
- AI role: The researchers combined flow-cytometry immune measurements and serum-protein profiles, then used unsupervised clustering to define three immune endophenotypes in the discovery cohort and assess them in an independent multicenter validation cohort. The clustering generated the patient groups whose longitudinal clinical and paraclinical trajectories were compared; the repository abstract does not specify the algorithm name.
Evidence sources: https://edoc.mdc-berlin.de/id/eprint/24233/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 55 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A deep-learning design pipeline combining sequence generation and classifiers, transfer learning, pretrained protein embeddings and C. acnes-specific training data produced 42 novel peptides for testing. Five showed high-potency, selective activity against C. acnes, with MICs of 2–4 µg/mL; additional in-vitro assays tested activity against other microbes, hemolysis and keratinocyte cytotoxicity.
Technology: Deep-learning peptide generators and activity/selectivity classifiers using transfer learning and pretrained protein embeddings
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: A deep-learning design pipeline combining sequence generation and classifiers, transfer learning, pretrained protein embeddings and C. acnes-specific training data produced 42 novel peptides for testing.
- Still unknown: All evidence is in vitro, with no animal or human testing. The 42 synthesized candidates are a selected subset of model output, and the abstract's five high-potency peptides have measured C. acnes MICs; activity against other organisms and toxicity is based on separate in-vitro assays. Do not imply topical efficacy or clinical safety.
- AI role: The models generated peptide sequences, ranked antimicrobial/hemolytic properties and incorporated C. acnes-focused training data. The team synthesized and tested 42 selected designs; five had reported C. acnes MICs of 2–4 µg/mL.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10894229/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 22 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In a multicenter study of 702 participants, targeted plasma metabolomics and machine learning produced a 10-metabolite gastric-cancer diagnostic model and separate 28-metabolite survival-risk model. The diagnostic model was evaluated in an independent 95-person cohort (AUROC 0.920; sensitivity 0.905, specificity 0.75) and detected stage IA disease with AUROC 0.909. Among 181 patients followed for a median 40 months, the prognostic model achieved test-set concordance index 0.83. Succinate, uridine and lactate were among diagnostic features.
Technology: LASSO, random forest and random survival forest
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The diagnostic model was evaluated in an independent 95-person cohort (AUROC 0.920; sensitivity 0.905, specificity 0.75) and detected stage IA disease with AUROC 0.909.
- Still unknown: Case-control cohorts do not establish population screening performance. External diagnostic test n=95; prognosis cohort median follow-up 40 months with right-censored outcomes. The paper says direct clinical use is premature and requires quality-control samples. Associations are not causal and no model-guided benefit was tested.
- AI role: LASSO selected ten plasma metabolites for a diagnostic model evaluated in internal and independent external cohorts. Random survival forest selected a 28-metabolite prognostic panel, evaluated in a held-out patient set.
Evidence sources: https://www.nature.com/articles/s41467-024-46043-y.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 289 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Random-forest models trained on UCSF records (749 expert-diagnosed Alzheimer’s disease cases and 250,545 controls) identified clinical features predictive up to seven years before the recorded onset; the seven-year model’s AUROC was 0.72 using clinical features alone. Matched-cohort follow-up in external University of California health-system records found faster Alzheimer’s diagnosis after osteoporosis in women. Genetic colocalization analyses supported a female-specific shared signal between Alzheimer’s disease, low heel bone mineral density and MS4A6A expression near the MS4A gene cluster. The paper also reports shared APOE-locus support for hyperlipidemia and Alzheimer’s disease.
Technology: Random-forest models on longitudinal electronic health records, interpreted with the SPOKE biomedical knowledge network
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Matched-cohort follow-up in external University of California health-system records found faster Alzheimer’s diagnosis after osteoporosis in women.
- Still unknown: This is hypothesis-generating observational work. EHR features may reflect healthcare access, clinician behavior, coding and biological processes; the authors explicitly state that further validation across omics data types is needed. Genetic colocalization and matched cohort associations do not establish that osteoporosis causes Alzheimer’s disease or that treating osteoporosis prevents it. The prediction model is not a prospective clinical-impact evaluation, and early risk discrimination is modest with the low-prevalence outcome.
- AI role: Random-forest models ranked EHR-derived clinical features associated with future Alzheimer’s diagnosis. The team used matched models to prioritize hypotheses, then used SPOKE to connect clinical predictors to biological networks and independent health-system data plus GWAS/eQTL colocalization to examine the osteoporosis and hyperlipidemia associations. The model-generated prioritization led to follow-up of the female-specific osteoporosis signal near MS4A6A.
Evidence sources: https://www.nature.com/articles/s43587-024-00573-8.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 101 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A machine-learning workflow guided virtual screening for parasite N-myristoyltransferase, followed by testing of selected compounds in parasite assays. The primary preprint reports a bounded set of measured antimalarial candidates, including LabMol-394, while target assignment remains computational. This is not clinical efficacy or proof of target engagement.
Technology: Selective-bias virtual screening; machine-learning target/activity models
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: Primary preprint full text reports tested selected candidates and parasite activity.
- Still unknown: Exact earliest journal version and compound prior art remain open; target-specific binding is not experimentally established.
- AI role: Model-based selective-bias workflow scores target/activity candidates for experimental testing.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10925453/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: PMC-indexed primary preprint full text; PubMed primary record/abstract and affiliations. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A self-supervised, attention-based deep-learning regression model predicted continuous homologous-recombination deficiency (HRD) scores and tumor-microenvironment biomarkers from H&E pathology slides. On TCGA internal validation, HRD classification AUROC exceeded 0.70 in five of seven cancer types; external CPTAC validation reached AUROC 0.81 for lung adenocarcinoma and 0.96 for endometrial cancer. In 2,297 colorectal-cancer patients in the DACHS cohort, continuous regression scores for leukocyte fraction and lymphocyte-infiltration-related signatures were independently prognostic in multivariable survival analysis.
Technology: CAMIL regression, a self-supervised contrastive-clustering and attention-based multiple-instance deep-learning model
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: On TCGA internal validation, HRD classification AUROC exceeded 0.70 in five of seven cancer types; external CPTAC validation reached AUROC 0.81 for lung adenocarcinoma and 0.96 for endometrial cancer.
- Still unknown: Retrospective computational pathology analysis; the model predicts molecular and immune-related biomarkers from slides and does not replace confirmatory molecular testing or establish treatment selection benefit. HRD performance varied by cancer type, with weak internal performance in some cohorts. The reported survival associations in DACHS are prognostic associations, not evidence that using model predictions improves patient outcomes. Scores and endpoints were tested in the named datasets.
- AI role: The model analyzed whole-slide H&E images to estimate continuous HRD and tumor-microenvironment biomarker scores. The team compared regression with classification methods across cohorts, externally validated HRD predictions in CPTAC, and tested prognostic associations of predicted scores in a separate retrospective colorectal-cancer cohort.
Evidence sources: https://www.nature.com/articles/s41467-024-45589-1.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 126 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Across two UC San Diego Health emergency departments, 6,217 adult septic patients were studied before and after nurse-facing alerts driven by the COMPOSER model. Deployment was associated with a 1.9-point absolute (17% relative) drop in in-hospital sepsis mortality (95% CI 0.3-3.5%) and a 5-point rise in bundle compliance. The design is quasi-experimental, not randomized, and several authors co-founded a company that commercializes the tools.
Technology: COMPOSER (deep learning sepsis prediction model)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A quasi-experimental before-and-after comparison across two UC San Diego emergency departments (6,217 septic patients) measured in-hospital sepsis mortality and bundle compliance before and after COMPOSER-driven nurse alerts.
- Still unknown: The design is quasi-experimental, not randomized; other limitations were not reported in the fetched abstract.
- AI role: The COMPOSER deep-learning sepsis model triggered nurse-facing alerts.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41746-023-00986-6&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 207 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 5/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In a proteomic study, researchers measured paired CSF and serum samples in a discovery cohort and used random-forest machine learning to select a 19-protein CSF panel and an eight-protein serum panel to distinguish mild cognitive impairment due to Alzheimer disease from cognitively normal participants. Targeted proteomics verified candidate proteins in an independent multicenter cohort. In small held-out test groups, the CSF panel reached AUC 0.984 and the serum panel AUC 0.881; the CSF panel also distinguished Alzheimer-related MCI from frontotemporal dementia, ALS and Huntington disease in the reported analyses.
Technology: Random-forest machine-learning classifiers on CSF and serum proteomic profiles
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: In a proteomic study, researchers measured paired CSF and serum samples in a discovery cohort and used random-forest machine learning to select a 19-protein CSF panel and an eight-protein serum panel to distinguish mild cognitive impairment due to Alzheimer disease from cognitively normal participants.
- Still unknown: The AUC test sets were small (CSF: 9 Alzheimer-related MCI and 21 controls; serum: 8 and 21). The study used separate independent multicenter targeted-proteomics validation for candidate proteins; that does not make the small classifier test cohorts large or establish clinical utility. The serum panel was less effective at distinguishing Alzheimer-related MCI from other neurodegenerative diseases than the CSF panel. These are research panels, not routine tests.
- AI role: Random forests prioritized 19 CSF proteins and eight serum proteins to form disease-specific MCI classifiers after proteomic discovery and targeted validation; the selected panels were evaluated in held-out samples and against other neurodegenerative diseases.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10794110/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 66 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A machine-learning-guided high-throughput screen identified a five-component D-amino-acid mixture (“D-mix”) with about 78% anti-biofilm activity against Pseudomonas aeruginosa at 100 μM. Combining D-mix with half the lowest effective gentamicin dose retained about 91% bacterial-growth inhibition and about 93% anti-biofilm efficacy in vitro. In a small mouse lung-infection model, gentamicin/D-mix treatment reduced measured P. aeruginosa burden by about 95% in blood and 91% in lung tissue at 72 hours.
Technology: High-throughput screening coupled to machine-learning regression and iterative global optimization of D-amino-acid mixture ratios
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: In a small mouse lung-infection model, gentamicin/D-mix treatment reduced measured P. aeruginosa burden by about 95% in blood and 91% in lung tissue at 72 hours.
- Still unknown: The in-vivo experiment used a small mouse P. aeruginosa infection model, not human treatment; study-specific bacterial counts and efficacy are reported at 72 hours. The composition is a selected mixture of five D-amino acids, with authors noting the full synergism mechanism remains unclear. D-mix alone was not bactericidal under the reported in-vitro conditions; effects are combination- and assay-dependent.
- AI role: Experimental measurements of mixture biofilm effects were used to train and iteratively update ML regression models, which guided mixture selection over design rounds. The selected D-mix was then evaluated with different antibiotics in vitro; the lead gentamicin/D-mix combination was tested in a P. aeruginosa lung-infection mouse model.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/38126652/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 85 of works of the same type, year and subfield (OpenAlex work metrics, 23 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A deep-learning model trained on about 39,000 compounds screened about 12 million commercial compounds; of about 280 purchased and tested, two from the same class reduced MRSA burden tenfold in two mouse models, with very low toxicity to human cells. Results from plates and mice; toxicity was partly predicted computationally.
Technology: Deep learning with chemical-structure explainability
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: About 283 compounds were bought and tested empirically; one structural class reduced bacterial burden in mouse skin and systemic thigh infection models, and cytotoxicity to human cells was measured.
- Still unknown: The page does not list specific study limitations; next steps are chemical property analysis and potential clinical use.
- AI role: Graph neural network ensembles trained on about 39,000 compounds with measured antibacterial and human-cell toxicity predicted both properties for about 12 million compounds and flagged candidates for purchase and testing.
Evidence sources: https://news.mit.edu/2023/using-ai-mit-researchers-identify-antibiotic-candidates-1220 · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-023-06887-8&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 538 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A staged serum-proteomics study across 1,002 individuals used random-forest machine learning to select a four-marker panel, P4 (HABP2, CD163, AFP and PIVKA-II). In an independent validation set, the panel distinguished hepatocellular carcinoma from cirrhosis (AUC 0.979; sensitivity 0.925; specificity 0.915) and from healthy controls (AUC 0.992). In a prospective external cohort of cirrhosis patients followed for HCC, it predicted conversion with AUC 0.890 and median lead time of 11.4 months before imaging diagnosis.
Technology: Random-forest machine-learning model for serum-protein panel selection and HCC classification
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In an independent validation set, the panel distinguished hepatocellular carcinoma from cirrhosis (AUC 0.979; sensitivity 0.925; specificity 0.915) and from healthy controls (AUC 0.992). The prospectively collected cirrhosis cohort was split into 177 training and 76 validation participants for predictive-model construction; collection timing alone does not establish a prospective locked-model evaluation.
- Still unknown: The prospective cohort included 253 cirrhosis patients, with 36 developing HCC; 8 of 65 participants were false positives for conversion by the reported endpoint. This is source-reported research performance, not proof of improved survival or a clinically implemented screening test. The lead time is measured relative to imaging diagnosis in the study cohorts.
- AI role: The random-forest model evaluated serum protein panels and selected the four-marker P4 panel; researchers then tested classification in an independent validation set and assessed prediction of cirrhosis-to-HCC conversion in prospective follow-up data.
Evidence sources: https://www.nature.com/articles/s41467-023-44255-2.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 104 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
PANDA was trained on non-contrast abdominal CT scans from 3,208 patients at a high-volume pancreatic cancer centre in Shanghai. In a retrospective evaluation of 20,530 consecutive patients across four clinical settings, the paper reports 92.9% sensitivity and 99.9% specificity for pancreatic lesion detection. The study also reports five cancers and 26 other pancreatic lesions missed by the initial standard of care. These results do not establish population-screening benefit; the authors call for prospective risk-benefit and cost-effectiveness studies and broader international validation.
Technology: PANDA (three-stage deep learning cascade on non-contrast CT)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In a retrospective evaluation of 20,530 consecutive patients across four clinical settings, PANDA's sensitivity and specificity for pancreatic lesion detection were reported, along with missed cancers relative to the initial standard of care.
- Still unknown: The results do not establish population-screening benefit; the authors call for prospective risk-benefit and cost-effectiveness studies and broader international validation.
- AI role: PANDA, a deep-learning model trained on non-contrast abdominal CT, detected pancreatic lesions.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41591-023-02640-w&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 403 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The MAIP malaria-activity predictor was combined with a compound-selection workflow and high-throughput cascade to prioritize public-library compounds. The paper reports eight selected hits with potency and ADME profiles and 12-fold enrichment versus a random set. That enrichment is study-specific; private training-set overlap and chemical novelty remain unresolved.
Technology: MAIP machine-learning antimalarial activity predictor
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary article reports selected hits, experimental screening and 12-fold enrichment versus random selection.
- Still unknown: Underlying partner data are partly private; selection and training overlap and exact compound prior art require review; not clinical evidence.
- AI role: Predictor enriches candidate pool, with staged workflow and human selection preceding experimental screening.
Evidence sources: https://doi.org/10.1021/acsmedchemlett.3c00369
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: publisher primary metadata/abstract; author-hosted primary full paper. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Using Olink proteomics of 1,463 proteins in CSF and plasma from two prospective Swedish cohorts, the study trained prediction models for multiple-sclerosis diagnosis, 2-year disease activity and long-term disability worsening. Lower CSF neurofilament light (NfL) predicted absence of disease activity at two years (replication AUC 0.77). A stepwise model using 11 CSF proteins (CXCL13, LTA, FCN2, ICAM3, LY9, SLAMF7, TYMP, CHI3L1, FYB1, TNFRSF1B and NfL) predicted normalized age-related MS severity; subgroup classification AUCs in the replication cohort ranged from 0.88 to 0.90.
Technology: Stepwise logistic regression for diagnosis and disease activity; stepwise linear regression for long-term disability severity
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Using Olink proteomics of 1,463 proteins in CSF and plasma from two prospective Swedish cohorts, the study trained prediction models for multiple-sclerosis diagnosis, 2-year disease activity and long-term disability worsening.
- Still unknown: The study included 143 people with early-stage MS and 43 healthy controls across discovery and replication cohorts; the replication MS cohort had 51 participants. The 2-year disease-activity comparison in replication was especially small (45 with activity versus 5 without). The 11-protein severity model predicted observational disability scores rather than treatment benefit. The plasma severity model had only 12 eligible replication samples and performed less convincingly. These are cohort-level results, not a clinically validated diagnostic assay or independent replication by another research group.
- AI role: The study used statistical differential-expression testing to select disease-associated candidate proteins, then fitted logistic-regression models to predict MS diagnosis and 2-year disease activity and a linear-regression model to predict long-term normalized age-related MS severity. Stepwise feature selection produced the protein combinations; the frozen models were evaluated in a separate prospective cohort.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10616092/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 112 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
CAIMAN is a weakly supervised deep-learning model trained on pathologist-labeled whole-slide images to classify typical, atypical non-neoplastic and atypical neoplastic bowel biopsies. In three external cohorts comprising 1,536 slides from the UK and Portugal, it detected atypical biopsies with AUROC values of 0.9431, 0.9576 and 0.9636. At 99% sensitivity, it outperformed the prior IDaRS pipeline on two external cohorts, but not the third.
Technology: CAIMAN (Colorectal AI Model for Abnormality Detection), a weakly supervised deep-learning whole-slide image classifier
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In three external cohorts comprising 1,536 slides from the UK and Portugal, it detected atypical biopsies with AUROC values of 0.9431, 0.9576 and 0.9636.
- Still unknown: Retrospective validation on archived biopsies does not establish clinical deployment or improved patient outcomes. CAIMAN did not outperform IDaRS at 99% sensitivity in one of the three external validation cohorts; the authors call for larger multicentre validation and a clinical trial. The reported 99% sensitivity is paired with cohort-specific specificity, not a universal performance guarantee.
- AI role: AI learned biopsy-level histological patterns from slide-level diagnostic labels, then classified whole-slide images into typical, atypical non-neoplastic or atypical neoplastic classes. The trained frozen model was evaluated on three external cohorts; the reported finding is a specific retrospective clinical diagnostic-validation result.
Evidence sources: https://wrap.warwick.ac.uk/id/eprint/180883/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 50 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The IRON ensemble combined baseline clinical data, CA-125, ctDNA and CT radiomics from primary and metastatic lesions to estimate tumor-volume change during neoadjuvant chemotherapy for high-grade serous ovarian carcinoma. In an independent 42-patient Barts cohort, the integrated model achieved AUC 0.78 for RECIST 1.1 response classification versus 0.47 for a clinical-only model; radiomics-containing scores significantly correlated with volume change in internal holdout. The study also measured spatial heterogeneity, with omental lesions showing better response than pelvic/ovarian disease.
Technology: IRON ensemble combining elastic net, support-vector regression and random forest
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In an independent 42-patient Barts cohort, the integrated model achieved AUC 0.78 for RECIST 1.1 response classification versus 0.47 for a clinical-only model; radiomics-containing scores significantly correlated with volume change in internal holdout. The model used historical Cambridge and Barts cohorts with baseline and post-treatment imaging, including an external retrospective test set.
- Still unknown: Model analysis of two prospective observational cohorts (training n=72, internal holdout n=20, external n=42), not a decision trial. External ctDNA unavailable and imputed to training means. Sample size limits generalizability; treatment benefit from model-guided decisions was not tested.
- AI role: Pretreatment clinical, blood and multi-lesion radiomic features predicted volumetric response to neoadjuvant chemotherapy. Held-out and external evaluation showed radiomics added predictive information beyond clinical variables.
Evidence sources: https://www.nature.com/articles/s41467-023-41820-7.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 77 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
RETFound is self-pretrained on unlabelled retinal images, reportedly about 1.6 million from Moorfields Eye Hospital, and then adapted to disease tasks. The authors report better diagnosis of sight-threatening eye diseases than comparison models, better prediction of systemic conditions such as heart failure and myocardial infarction, and strong performance with fewer labels. The evaluation is retrospective, with no clinical deployment study, and the model was released openly.
Technology: RETFound (masked-autoencoder foundation model for retinal images)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: RETFound, self-pretrained on unlabelled retinal images, was adapted to disease tasks and compared with other models on diagnosis of sight-threatening eye diseases and on prediction of heart failure and myocardial infarction.
- Still unknown: The abstract states no limitations of this work; the evaluation is retrospective with no clinical deployment study.
- AI role: A self-supervised foundation model pretrained on retinal images and fine-tuned for disease tasks.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-023-06555-x&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 1177 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
For a participant with ALS, intracortical electrodes and an AI algorithm converted attempted speech into text at 62 words per minute. With a 125,000-word vocabulary, the error rate was 23.8%, versus 9.1% for only 50 words. Proof of concept in one person, with an invasive implant and experimental device.
Technology: Neural network for phoneme decoding and language model
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: One participant with ALS attempted speech in real time; word error rates were measured at 50-word and 125,000-word vocabularies, with decoding at 62 words per minute.
- Still unknown: The abstract states no limitations; the results come from one participant, the large-vocabulary error rate (23.8%) is substantial and decoding is well below conversational speed.
- AI role: An AI algorithm decoded spiking activity from intracortical microelectrode arrays into text.
Evidence sources: https://med.stanford.edu/news/all-news/2023/08/brain-implant-speech-als.html · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-023-06377-x&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 675 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
For a participant with stroke-related paralysis, an electrode array on the cortex and AI algorithms translated attempted speech into text, synthetic voice and avatar movements. Text reached nearly 80 words per minute after individual training. Experimental study in one person; the system requires a physical connection to computers.
Technology: Neural speech decoding and AI facial animation
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: One clinical-trial participant with paralysis attempted silent speech; decoding was measured in real time at a median of 78 words per minute with a 25% median word error rate.
- Still unknown: The abstract does not explicitly state limitations; the single-participant study and 25% word error rate are the main caveats it implies.
- AI role: Deep-learning models decoded text from surface speech-cortex signals, synthesized personalized speech and animated a facial avatar.
Evidence sources: https://engineering.berkeley.edu/news/2023/08/novel-brain-implant-helps-paralyzed-woman-speak-using-a-digital-avatar/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-023-06443-4&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 600 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
AI analysis of proteins from extinct hominins identified sequences that were then synthesized and tested against pathogens in culture and in mice. Some peptides showed antimicrobial activity; these are preclinical results, with no demonstration of safety or efficacy in humans.
Technology: AI for molecular de-extinction
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Fragments were tested for antimicrobial activity in vitro, and representative fragments reduced A. baumannii infection in mouse skin abscess and thigh infection models.
- Still unknown: The abstract does not explicitly state limitations; the findings rest on in vitro work and two mouse models rather than human trials.
- AI role: A random forest model (panCleave) predicted protease cleavage sites across proteomes to find antimicrobial fragments in modern human and extinct hominin proteins.
Evidence sources: https://www.engineering.upenn.edu/stories/for-a-new-generation-of-antibiotics-scientists-are-bringing-extinct-molecules-back-to-life-and-discovering-the-hidden-genetics-of-immunity-along-the-way/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1016/j.chom.2023.07.001&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 165 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In the initial analysis of 80,033 women, AI-assisted screening detected 244 cancers versus 203 with standard double reading and reduced the reading workload by 44%. A Lund update on January 30, 2026, after more than two years and about 106,000 women, reports higher sensitivity without more false positives. The comparison is in a Swedish setting; it does not demonstrate reduced mortality.
Technology: AI for mammogram triage and marking
Publication: Publication status unspecified in annotation · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Not reported
- Test type: prospective or independent check
- Tested: A prospective randomized single-site trial compared AI-supported screening (about 40,003 women) with standard double reading (about 40,030 women), measuring cancers detected, false positives and radiologist workload.
- Still unknown: The Lund article states limits: single site, no mortality outcomes, and the main analysis awaits two-year follow-up; the January 2026 update could not be verified on the page read.
- AI role: AI flagged higher-risk mammography exams for two physicians or marked suspicious findings for a single reader.
Evidence sources: https://www.lu.se/artikel/ai-stodd-modell-saker-mammografiscreening
The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 4/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In a multicentre study, machine-learning analysis of plasma metabolic fingerprints from 1,944 retrospective participants selected a 21-metabolite panel that differentiated gastric-cancer from non-cancer cohorts; five model types achieved AUCs of 0.921–0.971 in discovery and 0.907–0.940 in external verification. Prospective testing in 264 participants using both NPELDI-MS and UPLC-MS reported diagnostic AUCs of 0.855–0.918 and 0.856–0.916, respectively. The paper also reports a four-metabolite prognostic score based on retrospective survival data.
Technology: Neural network, lasso regression, ridge regression, support-vector machine and random-forest models applied to plasma metabolic fingerprints
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: In a multicentre study, machine-learning analysis of plasma metabolic fingerprints from 1,944 retrospective participants selected a 21-metabolite panel that differentiated gastric-cancer from non-cancer cohorts; five model types achieved AUCs of 0.921–0.971 in discovery and 0.907–0.940 in external verification.
- Still unknown: The panel was evaluated in selected clinical cohorts and is not established for routine screening or clinical use. Prospective validation was at one lead center, and only six panel metabolites were robustly detected by confirmatory UPLC-MS under the reported testing. Model performance does not show that the panel is causal or improves outcomes. Primary full text/abstract checked; no independent replication assessed.
- AI role: The study used machine-learning feature selection/modeling (including logistic-regression coefficient filtering) to identify and evaluate a 21-metabolite diagnostic panel from high-throughput mass-spectrometry fingerprints; classifiers were then validated on independent retrospective and prospective cohorts.
Evidence sources: https://gut.bmj.com/content/72/11/2051
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 95 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A study built a fragment-level methylation atlas from 521 noncancer tissue samples spanning 29 human tissue types and used it with cfSort, a supervised deep neural network, to estimate tissue composition in plasma cell-free DNA. Applying cfSort to patient data, the investigators found higher cfDNA fractions from the affected tissue in liver, lung, colorectal and stomach cancer and cirrhosis cohorts than in healthy controls; the estimated fractions also increased with cancer stage. The tissue-origin signal was reproduced on an independent whole-genome-bisulfite-sequencing dataset for liver cancer. In serial samples from four non-small-cell lung cancer patients receiving anti-PD-1 therapy, estimated liver or kidney tissue fractions tracked measured biochemical markers of organ injury.
Technology: cfSort, an ensemble of two dense deep neural networks trained on simulated mixtures using a fragment-level tissue methylation atlas
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Applying cfSort to patient data, the investigators found higher cfDNA fractions from the affected tissue in liver, lung, colorectal and stomach cancer and cirrhosis cohorts than in healthy controls; the estimated fractions also increased with cancer stage.
- Still unknown: The disease cohorts were retrospective and the clinical analyses demonstrate association and measurement feasibility, not prospective diagnostic benefit or improved outcomes. The clinical groups were 21 cirrhosis patients and 201 cancer patients, with 100 healthy controls; cross-platform liver-cancer validation used 24 cases and 32 controls. Anti-PD-1 injury monitoring involved only four NSCLC patients at three timepoints. The authors note that disease-specific methylation markers could improve cancer detection beyond tissue-of-origin fractions.
- AI role: The team used the supervised cfSort model to deconvolve methylation profiles in plasma cfDNA and estimate contributions from 29 tissue types. This enabled the reported comparison of affected-tissue cfDNA fractions in cancer and cirrhosis patient cohorts versus controls and longitudinal tracking of tissue-injury signals during immunotherapy. The atlas and model were also evaluated against simulated mixtures and independent methylation data.
Evidence sources: https://par.nsf.gov/servlets/purl/10428542
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 77 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A model trained on about 7,500 compounds screened 6,680 new compounds in under two hours; of 240 tested in the laboratory, nine were antibiotics, including abaucin, which was effective against wound infections in mice. Activity is highly narrow (no effect on the other bacteria tested) and still preclinical.
Technology: Machine learning for compound screening
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: About 7,500 molecules were screened in vitro, a neural network predicted new compounds that were tested in the laboratory (about 240 tested, nine antibiotics), and abaucin controlled an A. baumannii infection in a mouse wound model.
- Still unknown: The abstract states no explicit limitations; the press release says activity is highly narrow (no effect on the other bacteria tested) and the compound remains preclinical.
- AI role: A neural network trained on screening results predicted structurally new compounds active against A. baumannii.
Evidence sources: https://news.mit.edu/2023/using-ai-scientists-combat-drug-resistant-infections-0525 · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41589-023-01349-8&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Original institutional announcement checked for the specific results, AI contribution and limitations cited in the antibiotic dossier or mathematical follow-up pilot. Full-paper reanalysis, external replication and an exhaustive follow-up search were not performed..
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 420 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
- same-team extension · 14 Aug 2025: MIT identifies halicin and abaucin as earlier screening results motivating generative design of new NG1/DN1 candidates. The later study does not establish clinical efficacy of these earlier candidates. Source. Recorded 16 Nov 2026.
Follow-up checked 16 Nov 2026 within scope: Bounded check of the original announcements cited by the events recorded here, including explicit links to later program work. This is not an exhaustive literature search or ongoing monitoring commitment..
Directed relationships from this entry; they do not merge catalog counts.
- 2020-02-halicin · extends: The source explicitly traces this A. baumannii screening study to the earlier halicin program. Distinct candidate and experiment; not independent confirmation of halicin. Source
The algorithm, based on a parsing technique from natural-language processing, finds the most stable mRNA sequence for a given protein in about eleven minutes. According to Baidu’s press release, whose study appeared in Nature, sequences produced this way showed greater stability, protein expression and antibody response than comparators in animal experiments. Figures are company-reported; the Baidu release copy on EurekAlert was reviewed, not a baidu.com page.
Technology: LinearDesign
Family LinearDesign: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: LinearDesign-designed mRNA for COVID-19 and VZV was compared with wildtype and codon-optimized sequences in animal experiments, measuring half-life, expression and antibody response; the figures are company-reported and the release describes no independent replication.
- Still unknown: The Nature abstract states no specific study limitations and the release states none; the release says benefits such as lower doses and fewer side effects are possibilities not tested.
- AI role: A parsing-based algorithm (LinearDesign) optimized mRNA structural stability and codon usage for a given protein.
Evidence sources: https://www.eurekalert.org/news-releases/987999 · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-023-06127-z&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 560 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A random-forest model trained on longitudinal electronic health records from 161,584 people across two institutions identified records associated with high-specificity autoantibody testing for systemic autoimmune rheumatic diseases (SARDs). The model achieved AUROC 0.93 in internal validation and 0.87 on the external All of Us cohort. In a separate BioMe cohort, model probabilities tracked SARD and other autoimmune diagnoses; records could predict later autoantibody testing and rheumatology encounters up to five years before those events. The study also found higher autoantibody yield among model-prioritized individuals than under the comparison clinical-testing rate.
Technology: Random-forest machine-learning model using longitudinal electronic-health-record diagnoses, medications, laboratory results and vital signs
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A random-forest model trained on longitudinal electronic health records from 161,584 people across two institutions identified records associated with high-specificity autoantibody testing for systemic autoimmune rheumatic diseases (SARDs).
- Still unknown: The model predicts clinical suspicion and need for rheumatological testing, not a SARD diagnosis. The study was retrospective and opportunistic; autoantibody testing and rheumatology encounters are imperfect proxies for clinical need, and some diseases were not included in the training target. The authors state prospective studies are needed to determine whether model-guided testing improves care or outcomes. The five-year lead is retrospective prediction of later evaluation events, not proven earlier diagnosis or patient benefit.
- AI role: The model ranked patients by probability of receiving SARD-specific autoantibody testing, using clinical data preceding the test or rheumatology encounter. Investigators evaluated performance in internal validation, the external All of Us cohort and an independent BioMe cohort, and tested whether higher scores tracked diagnosed autoimmune disease and identified later testing or encounters earlier in retrospective records.
Evidence sources: https://www.nature.com/articles/s41467-023-37996-7.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 40 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Molecular docking and Bayesian/SVM classifiers screened a ChemDiv 300k library. Researchers tested prioritized commercial compounds and reported coumarin and iminodipyridinopyrimidine chemotypes active against beta-haematin and whole-cell P. falciparum, including chloroquine-resistant parasites. This is one bounded in-vitro campaign, not clinical evidence.
Technology: Bayesian and support-vector classifiers; molecular docking
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary abstract reports prioritized compounds with beta-haematin and whole-cell parasite activity.
- Still unknown: A 2023 conference abstract may disclose an early coumarin result; the article’s specific two-chemotype campaign is retained without priority claim; no clinical evidence.
- AI role: Sequential ligand/structure virtual screening prioritizes commercial compounds for biochemical and parasite assays.
Evidence sources: https://doi.org/10.1038/s41598-023-29273-w
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: PMC-hosted primary full article; PubMed primary record/abstract. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
An untargeted analysis of 4,955 plasma proteins in the ARIC cohort identified 140 associations with incident diabetes; 64 were significant in an internal sample and 47 (including 22 reported as novel) were associated in the external Singapore Multi-Ethnic Cohort. Elastic-net Cox modeling selected a 27-protein panel for 20-year risk prediction. In internal validation, adding those proteins to conventional risk factors including fasting glucose and HbA1c increased the C statistic from 0.720 to 0.731. Genetic-instrument analyses supported possible causal roles for SHBG, ATP1B2 and GSTA1, although ATP1B2’s genetic and observational directions differed.
Technology: Elastic-net Cox regression for protein feature selection and incident-diabetes risk prediction
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: An untargeted analysis of 4,955 plasma proteins in the ARIC cohort identified 140 associations with incident diabetes; 64 were significant in an internal sample and 47 (including 22 reported as novel) were associated in the external Singapore Multi-Ethnic Cohort.
- Still unknown: The 47-protein associations were externally tested in Singapore MEC; the elastic-net predictive model itself was internally validated in ARIC, not independently externally validated. Its incremental C statistic over covariates including fasting glucose and HbA1c was modest (0.011; P=0.04), and the protein model overestimated observed diabetes risk across internal-validation deciles. The causal claims are genetic-instrument inferences, not experimental proof; ATP1B2 had opposite directions in genetic-instrument versus observational analyses. Cohort associations do not establish clinical utility.
- AI role: Elastic net selected a 27-protein combination from candidate proteins to improve 20-year incident-diabetes risk prediction beyond clinical and cardiometabolic covariates. The model was trained in the ARIC discovery subset and internally evaluated in a held-out ARIC subset. Separate Cox association and genetic-instrument analyses reported the externally validated protein associations; the record does not attribute those analyses to machine learning.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10090896/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 62 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A 121-analyte LC–MS/MS panel combined established markers, untargeted-metabolomics features and chromatographically resolved isobars with random-forest classification of California newborn-screen dried blood spots. In 883 archived infant samples, the study reports that the second-tier approach maintained 100% sensitivity while reducing false positives by 83% for glutaric acidemia type I, 84% for methylmalonic acidemia, 100% for ornithine transcarbamylase deficiency and 51% for very-long-chain acyl-CoA dehydrogenase deficiency. Several long-chain acylcarnitine and hydroxy-acylcarnitine isobar features contributed to classification, although their chemical identities were unresolved.
Technology: Random Forest classifier trained on targeted LC–MS/MS metabolite profiles
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In 883 archived infant samples, the study reports that the second-tier approach maintained 100% sensitivity while reducing false positives by 83% for glutaric acidemia type I, 84% for methylmalonic acidemia, 100% for ornithine transcarbamylase deficiency and 51% for very-long-chain acyl-CoA dehydrogenase deficiency.
- Still unknown: This was a proof-of-principle second-tier simulation on residual archived California newborn-screen specimens, not a prospective implementation study. The validation sample was not a fully independent external set, and archived-sample degradation and processing batch effects limited biomarker discovery; some discriminating isobar identities and biological significance remain unknown. The reported sensitivity and false-positive reductions are cohort-specific and do not establish improved health outcomes or routine clinical utility.
- AI role: The classifier modeled multianalyte profiles from true-positive and false-positive screen-positive samples to distinguish the groups for four inherited metabolic disorders. Feature-importance analysis showed that complex profiles, including unresolved long-chain acylcarnitine/hydroxy-acylcarnitine isobars, contributed to classification; the model's second-tier performance was assessed against known case status.
Evidence sources: https://onlinelibrary.wiley.com/doi/full/10.1002/jimd.12591
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 23 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The model predicts risk from a single CT with a six-year C-index of 0.75 (NLST), 0.81 (MGH) and 0.80 (CGMH), and a one-year ROC area between 0.86 and 0.94. Retrospective validation on three independent datasets; trained only on smokers, with prospective testing and testing in nonsmokers as next steps.
Technology: Sybil (neural network on CT scans)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: The model was trained on NLST low-dose CT scans and validated on a held-out NLST set and two independent cohorts (MGH and CGMH), with six-year C-index 0.75, 0.81 and 0.80; the abstract describes no prospective testing.
- Still unknown: The abstract states that future study is required to understand clinical applications; the press release says prospective testing and testing in nonsmokers are next steps.
- AI role: A deep learning model predicts lung-cancer risk from a single low-dose chest CT.
Evidence sources: https://news.mit.edu/2023/ai-model-can-detect-future-lung-cancer-0120 · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1200/JCO.22.01345&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 332 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Pharma.AI combined PandaOmics, Chemistry42 and an AlphaFold-predicted structure to identify a hepatocellular-carcinoma target and produce a hit molecule within 30 days of target selection, synthesizing seven compounds. A second round produced a more potent hit; an early Chemical Science study, with no clinical efficacy demonstrated.
Technology: Pharma.AI, PandaOmics, Chemistry42 and AlphaFold
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Selected compounds were synthesized and tested in biological assays: the first hit bound CDK20 (Kd about 9.2 µM) and a second AI-driven round gave a more potent compound with greater antiproliferative activity in liver cancer cells; the abstract describes no in vivo testing.
- Still unknown: The abstract notes AlphaFold predictions have varying confidence, the first hit came from only 7 synthesized compounds, and potency values vary widely; no clinical efficacy is demonstrated.
- AI role: Pharma.AI platforms (PandaOmics, Chemistry42) used AlphaFold-predicted structures to select a liver-cancer target and generate candidate molecules.
Evidence sources: https://www.utoronto.ca/news/researchers-use-ai-powered-database-design-potential-cancer-drug-30-days · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1039/D2SC05709C&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 403 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A study of biopsy-confirmed IgA nephropathy (IgAN) integrated plasma proteomics and untargeted metabolomics and used LASSO logistic regression to select PRKAR2A, IL6ST, SOS1 and palmitoleic acid as candidate discriminators from healthy controls. The panel had AUC 0.994 in the training set and 0.977 in the test split; ELISA assays in a separate 9-case/10-control sample set yielded an AUC of 0.91. Proteomic and metabolomic analyses also indicated complement/immune activation and altered energy and amino-acid metabolism in the studied cases.
Technology: LASSO logistic regression (glmnet), with tenfold cross-validation and additional random-forest/SVM model checks
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: A study of biopsy-confirmed IgA nephropathy (IgAN) integrated plasma proteomics and untargeted metabolomics and used LASSO logistic regression to select PRKAR2A, IL6ST, SOS1 and palmitoleic acid as candidate discriminators from healthy controls.
- Still unknown: This is an early candidate biomarker result, not a validated clinical test or biopsy replacement. The discovery analysis included 33 biopsy-confirmed IgAN cases and 20 healthy controls; the separate ELISA group contained only 9 IgAN cases and 10 controls from the same hospital. The test split is small, and the study did not test specificity against other kidney diseases or demonstrate prospective/clinical utility. The proposed biomarker biology remains speculative.
- AI role: LASSO feature selection on integrated proteomic and metabolomic measurements nominated the four-analyte panel; the study evaluated its classification in a held-out split and measured the selected analytes by ELISA in an independent sample batch.
Evidence sources: https://link.springer.com/article/10.1186/s12014-022-09387-5
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 40 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A random-forest and OPLS-DA prioritization pipeline applied to peripheral-blood mononuclear-cell proteomics identified candidate protein combinations for distinguishing systemic lupus erythematosus (SLE) from healthy and rheumatoid-arthritis controls and for separating active from inactive SLE. ELISA in a separate 80-person cohort supported a six-protein diagnosis panel (IFIT3, MX1, TOMM40, STAT1, STAT2 and OAS3; AUC 0.723 versus healthy controls and 0.815 versus rheumatoid arthritis) and a nine-protein activity panel (AUC 0.990). Single-cell RNA-sequencing analysis mapped several associated interferon-signature proteins to specific immune-cell populations.
Technology: POC-SLE: random-forest feature ranking with 1,000 bootstrap iterations, combined with OPLS-DA variable-importance selection
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: ELISA in a separate 80-person cohort supported a six-protein diagnosis panel (IFIT3, MX1, TOMM40, STAT1, STAT2 and OAS3; AUC 0.723 versus healthy controls and 0.815 versus rheumatoid arthritis) and a nine-protein activity panel (AUC 0.990).
- Still unknown: The study is cross-sectional and the ELISA validation cohort contained 80 people from the same clinical setting; it does not establish longitudinal flare prediction, treatment response, causal mechanisms or clinical utility. The six-protein panel had moderate discrimination versus healthy controls (AUC 0.723) and better but still cohort-specific discrimination versus rheumatoid arthritis (AUC 0.815). The activity-panel AUC of 0.990 was reported for active versus inactive groups in this validation cohort and needs broader independent validation. Authors note limited sample size/ethnic diversity and need for mechanistic study.
- AI role: The random forest ranked differentially expressed proteins from discovery-cohort PBMC proteomics; its selected proteins were intersected with OPLS-DA features to construct candidate diagnosis and activity panels. Researchers evaluated those panels with ELISA in a separate cohort and used single-cell transcriptomic data to examine immune-cell sources.
Evidence sources: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.969509/full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 73 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A target-conditioned generative deep-learning model based on a distribution-learning conditional recurrent neural network generated a tailored compound library that was screened for RIPK1 inhibition. The study reports RI-962 as a potent inhibitor with a previously unreported scaffold, validated in vitro for protection from necroptosis and in vivo in two inflammatory models.
Technology: Generative deep-learning distribution-learning conditional recurrent neural network (GDL cRNN)
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The study reports RI-962 as a potent inhibitor with a previously unreported scaffold, validated in vitro for protection from necroptosis and in vivo in two inflammatory models.
- Still unknown: Evidence is preclinical: cellular necroptosis assays and two inflammatory mouse models do not establish human efficacy or safety. The paper identifies one leading molecule from a generated library; it does not validate generative-model performance across targets generally.
- AI role: The GDL cRNN generated a target-tailored virtual compound library; virtual screening and subsequent chemical synthesis and bioactivity assays selected RI-962. This provides direct experimental testing of a model-generated molecule rather than a prediction-only hit.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/36371441/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 114 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A directed-message-passing neural network trained on a 29,537-compound Burkholderia cenocepacia screen prioritized compounds from a natural-product library. Laboratory testing found five previously uncharacterized compounds that inhibited B. cenocepacia; 22 of 43 tested prioritized compounds inhibited at least one of five ESKAPE pathogens.
Technology: Directed-message-passing neural network (D-MPNN) implemented with Chemprop
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Laboratory testing found five previously uncharacterized compounds that inhibited B. cenocepacia; 22 of 43 tested prioritized compounds inhibited at least one of five ESKAPE pathogens.
- Still unknown: The compounds were active in vitro; no clinical effect, safety or therapeutic readiness is established. Several confirmed compounds were known antimicrobials, while five natural-product hits were described as previously uncharacterized. An inferred RpoB mechanism for STL558147 was suggested by CRISPRi sensitivity rather than directly demonstrated binding.
- AI role: The D-MPNN ranked FDA-approved and natural-product library molecules for predicted antibacterial activity; researchers tested high-ranked compounds in bacterial growth assays and confirmed activity. It was a screening-prioritization tool, not evidence of clinical efficacy.
Evidence sources: https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1010613
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 59 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A deep-learning tool for contrast-enhanced CT reached 89.9% sensitivity and 95.9% specificity in an internal test set (not significantly different from the original radiologist reports, 96.1%). On 1,473 real-world Taiwanese CT studies it reached 89.7% sensitivity and 92.8% specificity, but sensitivity for cancers under 2 cm was 74.7%. The study is retrospective, with no prospective reader comparison in the abstract.
Technology: Segmentation CNN with an ensemble of five CNN classifiers for pancreatic cancer on CT
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A deep-learning CT tool was tested on an internal retrospective test set against original radiologist reports and on 1,473 real-world Taiwanese CT studies, reaching 89.7% sensitivity and 92.8% specificity in the latter.
- Still unknown: Sensitivity for tumours under 2 cm was 74.7%; the study is retrospective with no prospective reader comparison in the abstract.
- AI role: An end-to-end computer-aided detection tool (segmentation CNN plus an ensemble of five CNNs) detected pancreatic cancer on contrast CT.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1148/radiol.220152&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 207 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
An attention-based AI model extracting breathing from radio waves during sleep detected Parkinson's disease with an AUC of 0.90 on held-out data and 0.85 on external sets, across 7,671 individuals. Its severity estimates correlated with MDS-UPDRS scores (R = 0.94), and it worked for at-home assessment. Caveat: largely retrospective data and no prospective diagnostic trial reported.
Technology: Attention-based deep learning on contactless radio-wave breathing signals
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Parkinson's detection was tested on held-out data (AUC 0.90) and external test sets (AUC 0.85) across 7,671 individuals, and severity estimates were compared with MDS-UPDRS scores (R = 0.94).
- Still unknown: The authors describe the findings as initial evidence that the model may be useful for risk assessment before clinical diagnosis.
- AI role: Attention-based AI model extracting breathing from radio waves during sleep to detect and grade Parkinson's disease.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41591-022-01932-x&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 321 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 5/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A recurrent neural network generated peptide sequences and classified predicted activity and hemolysis; a genetic-algorithm route also generated analogues. After sequence and physicochemical filters, researchers synthesized and tested 33 peptides. The paper reports 11 active anticancer peptides in its cell assays, four non-hemolytic under its red-cell assay. These in-vitro results do not establish cancer-cell specificity, clinical safety or therapeutic efficacy. A related 2020 modeling paper is separate from this experimental study; no claim of absolute sequence novelty is made.
Technology: Generative recurrent neural network, genetic algorithm, and recurrent-neural-network activity and hemolysis classifiers
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The abstract reports that 33 peptides were experimentally evaluated, 11 were active in anticancer cell assays, and four of the active peptides were non-hemolytic in the reported assays.
- Still unknown: In-vitro activity and red-cell hemolysis do not establish cancer-cell specificity, clinical safety or treatment efficacy. Detailed potency measurements and absolute sequence novelty were not reassessed in this bounded review.
- AI role: RNN and genetic-algorithm generation with RNN activity and hemolysis classifiers guided peptide selection for synthesis and testing.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/35880810/ · https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.202200291
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary publisher metadata and primary PubMed abstract/affiliation block; full PMC endpoint returned a browser verification challenge in this review..
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A random forest trained on parasite activity data screened commercial compounds; 100 predicted actives and 20 predicted inactives were tested. The primary manuscript reports 18 dose-response-validated compounds with liver- and blood-stage activity among 26 liver-stage hits. The selected sets are not population samples, and assays used P. berghei liver-stage and P. falciparum blood-stage parasites.
Technology: Random-forest classifier
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary indexed Methods/Results report 18 dual-stage validated compounds and screening denominators.
- Still unknown: Chemical prior art, complete supplemental details and clinical translation remain open; do not present 18/26 as general hit rate.
- AI role: Classifier prioritizes compounds from >1.5 million virtual candidates; human structural-diversity selection and assays follow.
Evidence sources: https://doi.org/10.1021/acsinfecdis.2c00189
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: PMC-indexed primary manuscript text; publisher primary metadata/index. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A machine-learning system monitored about 590,000 patients in five hospitals, flagging sepsis risk from medical records. In the studied cohort, timely clinical confirmation of alerts was associated with lower mortality, organ failure and length of stay. Observational study: the association does not show that AI caused better outcomes.
Technology: TREWS (Targeted Real-time Early Warning System)
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: A prospective multi-site cohort of 590,736 monitored patients (five hospitals) compared outcomes of sepsis alerts confirmed by a provider within 3 hours with outcomes otherwise, adjusting for severity.
- Still unknown: The association is observational and does not show that the AI caused better outcomes.
- AI role: Machine-learning early warning system (TREWS) flagged sepsis risk from medical records.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A10.1038/s41591-022-01894-0&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 416 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
VSURF feature selection prioritized six serum metabolites—ADPR, 1-methylnicotinamide, D-ribose 5-phosphate, nicotinamide, L-tryptophan and phosphatidylcholine PC(36:2)—for one-year major adverse cardiovascular events (MACEs) after PCI in patients with type 2 diabetes. Random-forest and XGBoost models were tested in a nested case-control study and an independent prospective cohort of 301 patients; in the external cohort, reported AUCs were 0.92 and 0.94 for MACEs, respectively. The study also linked NAD+ biosynthesis perturbation to altered bioenergetics, inflammation and proliferation in high-glucose-cultured human aortic smooth-muscle cells.
Technology: VSURF random-forest variable selection; random forest and XGBoost classifiers
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Random-forest and XGBoost models were tested in a nested case-control study and an independent prospective cohort of 301 patients; in the external cohort, reported AUCs were 0.92 and 0.94 for MACEs, respectively. For the prognostic panel, the external cohort was collected before the development cohort. Separate cell experiments support the reported pathway mechanism, not prospective clinical performance of the panel.
- Still unknown: The discovery component was a matched nested case-control sample (108 cases and 108 controls) from a single center; external validation was in a separate Chinese cohort of 301 patients, so transportability to other populations is unknown. AUCs describe retrospective/prospective cohort validation, not demonstrated clinical utility or improved patient outcomes. HASMC experiments do not prove the metabolites cause clinical events, and the paper states further mechanistic work is needed.
- AI role: VSURF selected a six-metabolite feature set from serum metabolomic profiles. Random-forest and XGBoost models used that panel to predict one-year post-PCI outcomes; targeted metabolite testing evaluated the panel in a separate prospective cohort.
Evidence sources: https://link.springer.com/article/10.1186/s12933-022-01561-1
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 51 of works of the same type, year and subfield (OpenAlex work metrics, 8 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A model using electronic health records to flag mental health crises over 28 days reached an AUROC of 0.797, with 58% sensitivity at 85% specificity. In a six-month prospective workflow study at one NHS trust, clinicians rated predictions useful for managing caseloads or mitigating crisis risk in 64% of cases. This measures clinician-reported usefulness, not a demonstrated reduction in crises; generalizability remains limited by the single-trust cohort, and precision was modest (AUPRC 0.159). The study includes authors affiliated with the developer Koa Health.
Technology: Machine learning model on electronic health records
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: A six-month prospective workflow study at one NHS trust asked clinicians to rate predictions, which were judged useful for managing caseloads or mitigating crisis risk in 64% of cases; the AUROC was 0.797.
- Still unknown: Not reported; the page gives no rating scale or AUROC for the prospective usefulness measure.
- AI role: Model using electronic health records to monitor patients for risk of a mental health crisis over 28 days.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41591-022-01811-5&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 268 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Swarm learning, which trains models across partner sites without moving patient data, was applied to over 5,000 patients to predict BRAF status and microsatellite instability from H&E colorectal cancer slides. Swarm-trained models outperformed most locally trained models and matched models trained on merged datasets, and were validated on two independent UK datasets. Caveat: the outcome is a research-grade prediction from slides, not a clinical test.
Technology: Swarm learning with deep learning on histopathology images
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Swarm-trained models for BRAF status and microsatellite instability from H&E slides were compared with local and merged-data models and validated on two independent UK datasets.
- Still unknown: Not reported; the abstract includes no limitations statement.
- AI role: Swarm learning trained AI models across partner sites without moving patient data, predicting molecular alterations from colorectal cancer histopathology slides.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41591-022-01768-5&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 237 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Unsupervised image analysis detected cellular patterns not apparent by inspection in an investigation of one family with an atypical ataxia presentation. Additional cell experiments found altered ataxin-7 behavior and mitochondrial bioenergetic deficits. The proposed combined role of ATXN7 and TOP1MT variants remains a hypothesis: unaffected parents carried individual variants, and fly models did not reproduce the patient phenotype.
Technology: PhenoRipper unsupervised image-pattern analysis
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Patient-derived cells, functional measurements and fly models were examined.
- Still unknown: Clinical causality, variant interaction and diagnostic utility are not established by this small study.
- AI role: PhenoRipper unsupervised image-pattern analysis supported the stated study; experimental and interpretive work remained with researchers.
Evidence sources: https://www.nature.com/articles/s41439-022-00188-8
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Publisher abstract, selected image-analysis Methods, Results, Discussion, dates and affiliations; supplement not reviewed..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A deep learning system analysing gigapixel endomyocardial biopsy slides detected allograft rejection with an AUC of 0.962, distinguished cellular and antibody-mediated rejection (AUCs 0.958 and 0.874) and graded rejection with an AUC of 0.833. In a human reader study it was non-inferior to conventional assessment and reduced interobserver variability and assessment time. Caveat: test cohorts from the US, Turkey and Switzerland are retrospective and the authors call for clinical trials.
Technology: Deep learning on whole-slide images for endomyocardial biopsies
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Rejection detection (AUC 0.962) was measured on a curated US dataset and independent test cohorts from Turkey and Switzerland, and a human reader study found the system non-inferior to conventional assessment.
- Still unknown: The authors state that clinical trials are needed to establish the efficacy of AI-assisted biopsy assessment.
- AI role: Deep learning system analysed gigapixel endomyocardial biopsy whole-slide images to detect, subtype and grade rejection.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41591-022-01709-2&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 105 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A generative long short-term-memory recurrent neural network produced 198 candidate antimicrobial peptides; five were synthesized. PEP-38 and PEP-137 inhibited carbapenem-resistant Klebsiella isolates in vitro, and PEP-137 also inhibited Pseudomonas aeruginosa. In a small mouse K. pneumoniae sepsis experiment, PEP-137 yielded 50% survival, PEP-38 did not improve survival, and the in-vitro-inactive PEP-36 control unexpectedly yielded 66.7% survival.
Technology: Generative long short-term memory recurrent neural network trained on antimicrobial peptide sequences
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: In a small mouse K. pneumoniae sepsis experiment, PEP-137 yielded 50% survival, PEP-38 did not improve survival, and the in-vitro-inactive PEP-36 control unexpectedly yielded 66.7% survival.
- Still unknown: Only 5/198 AI-generated peptides were synthesized. The animal experiment used one administration, small groups (12 mice per group) and a simple model; PEP-36's unexpected survival effect despite no in-vitro antibacterial activity complicates interpretation. PEP-38 did not improve survival; no mechanism, pharmacokinetics, pharmacodynamics or safety was established. These are exploratory preclinical results, not a treatment claim.
- AI role: The LSTM RNN generated 198 peptide sequences, which were further filtered in silico; five selected candidates were synthesized and assayed. Two showed in-vitro activity against carbapenem-resistant isolates, and two were advanced into a mouse sepsis study.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8944797/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 26 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Machine-learning-guided virtual screening followed by surface-plasmon-resonance and biological assays identified IS20 and IS21 as compounds binding anti-apoptotic Bcl-2, Bcl-xL and Mcl-1 proteins. Both affected cancer-cell viability and induced apoptosis/autophagic flux in tested cell models; IS21 also reduced tumor growth in leukemia and melanoma mouse models.
Technology: Machine-learning-guided virtual screening (model family not named in PubMed abstract)
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Machine-learning-guided virtual screening followed by surface-plasmon-resonance and biological assays identified IS20 and IS21 as compounds binding anti-apoptotic Bcl-2, Bcl-xL and Mcl-1 proteins.
- Still unknown: The article calls the compounds potential/new leads; findings are biochemical, cell-based and mouse-model preclinical evidence. It does not establish clinical effectiveness. The PubMed abstract does not specify the machine-learning algorithm, so no specific model architecture is attributed here.
- AI role: Machine-learning-guided virtual screening prioritized putative Bcl-2-family inhibitor compounds; the candidate hits were then evaluated by surface plasmon resonance and in vitro cell assays, and IS21 was evaluated in mouse tumor models. The reported outcome is the specific assay characterization of IS20 and IS21.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/35265218/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 48 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A learned knowledge-graph model nominated candidate Alzheimer-associated genes for neuronal, autopsy and cell-assay follow-up. The study highlights candidate associations rather than establishing causes of human disease. Small samples, noisy negative labels and an internal discrepancy in reported knockdown-hit counts constrain interpretation; those counts are not treated as reconciled.
Technology: MPxgb(AD) knowledge-graph XGBoost
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Selected predicted genes received biological screening.
- Still unknown: Independent validation, human causality and therapeutic benefit remain unestablished.
- AI role: MPxgb(AD) knowledge-graph XGBoost supported the stated study; experimental and interpretive work remained with researchers.
Evidence sources: https://www.nature.com/articles/s42003-022-03068-7 · https://www.nature.com/articles/s42003-022-03068-7.pdf · https://pubmed.ncbi.nlm.nih.gov/35149761/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Indexed primary publisher PDF abstract and model description, publisher date and PubMed affiliations; detailed prior Methods review retained, direct PMC retrieval blocked..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Researchers integrated the attentive deep-learning classifier AMPlify into a genome-mining pipeline for North American bullfrog sequences. Of 101 candidate mature peptides generated from genome-annotated precursors, AMPlify predicted 75 as antimicrobial; 11 candidates were synthesized and tested, with four showing activity against tested bacteria, including a multidrug-resistant carbapenemase-producing E. coli isolate.
Technology: AMPlify, an attentive deep-learning antimicrobial-peptide sequence classifier
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Of 101 candidate mature peptides generated from genome-annotated precursors, AMPlify predicted 75 as antimicrobial; 11 candidates were synthesized and tested, with four showing activity against tested bacteria, including a multidrug-resistant carbapenemase-producing E. coli isolate.
- Still unknown: This is a small selected validation set: 11 of 75 model-predicted candidates were tested and four were active. Results are in vitro and do not establish therapeutic efficacy or safety. Candidate precursor identification also used homology/genome annotation; attribute AMPlify specifically to mature-peptide prioritization, not the whole discovery workflow.
- AI role: After bioinformatics identified candidate peptide precursors from the bullfrog genome, AMPlify scored 101 mature peptide sequences and nominated putative AMPs. The team selected 11 predicted peptides for synthesis and antimicrobial susceptibility testing; four showed activity against one or more of six tested bacterial strains, including the carbapenemase-producing E. coli clinical isolate.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8788131/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 250 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The EXAM federated model, trained on data from 20 institutes without sharing patient data, achieved an average AUC above 0.92 for predicting oxygen requirements at 24 and 72 hours. At the largest independent test site it reached sensitivity 0.950 and specificity 0.882, with a 16% average AUC gain over single-site models. Caveat: retrospective data from the pandemic period and unharmonized sites.
Technology: EXAM federated learning model (EMR data and chest X-rays)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Data from 20 institutes; average AUC above 0.92 for oxygen-requirement outcomes at 24 and 72 hours, 16% higher average AUC than single-site models; at the largest independent site, sensitivity 0.950 and specificity 0.882 for ventilation or death at 24 hours.
- Still unknown: Effect on patient care when used in practice is not reported in the abstract.
- AI role: EXAM, a model trained by federated learning on vital signs, laboratory data and chest X-rays without exchanging data between sites.
Evidence sources: https://doi.org/10.1038/s41591-021-01506-3
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 964 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 5/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
COMPOSER, a deep-learning early sepsis predictor, reached AUCs of 0.925-0.953 in ICU and 0.938-0.945 in ED across six cohorts (515,720 patients) from two US health systems. About 20% of non-septic and 8% of septic prediction windows were marked indeterminate, and the model gave a median early warning of 12.2 hours in ICU and 2.1 hours in ED before the first antibiotics order. The abstract reports no prospective deployment or patient-outcome results.
Technology: COMPOSER deep-learning model with uncertainty-based indeterminate output
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: COMPOSER's AUCs were measured across six cohorts (515,720 patients) from two US health systems in ICU and ED settings, with the share of predictions marked indeterminate and early-warning time before the first antibiotics order.
- Still unknown: The abstract reports no prospective deployment or patient-outcome results; data come from only two US health systems.
- AI role: A deep-learning model predicted early sepsis and marked unfamiliar cases as indeterminate rather than guessing.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41746-021-00504-6&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 147 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A generator–predictor–optimizer deep-learning workflow trained on quantitative delivery assays was used to design abiotic Mach miniproteins. Twelve selected predicted constructs were synthesized/tested; the strongest library construct improved phosphorodiamidate morpholino oligomer (PMO) delivery nearly 20-fold over unconjugated PMO in the standardized HeLa assay, while the authors describe the best designs as up to 50-fold more effective than prior polypeptide-based variants. PMO–Mach3/4 also produced dose-dependent reporter-protein restoration in skeletal muscle, diaphragm and heart in transgenic mice after a single intravenous dose.
Technology: Deep-learning generator–predictor–optimizer workflow: nested-LSTM sequence generator, CNN activity predictor on residue chemical fingerprints, and evolutionary optimization
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: A generator–predictor–optimizer deep-learning workflow trained on quantitative delivery assays was used to design abiotic Mach miniproteins.
- Still unknown: The paper reports improved delivery in a standardized HeLa reporter assay and transgenic mouse reporter model, not therapeutic correction of a disease. Only selected designs were synthesized (12 from hundreds of predicted sequences); mouse experiments used an EGFP reporter transgene and short seven-day follow-up. The article separately states the library's highest construct was nearly 20-fold over PMO alone and characterizes the designs as 50-fold better than previously known polypeptide variants; these denominators are not interchangeable. Safety evidence is limited to reported assays/doses and short follow-up.
- AI role: The model generated seed cell-penetrating sequences, predicted quantitative nuclear-delivery activity from peptide fingerprints, and iteratively optimized sequences for higher predicted activity subject to length, charge, similarity and solubility constraints. The team synthesized and experimentally assayed selected model-designed peptides; this linked the AI design to measured enhanced PMO delivery and animal reporter results.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8819921/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 86 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Insilico Medicine named INS018_073 a preclinical candidate after in vitro tests and testing in a mouse model of renal fibrosis. The company reports improvements in pathology, biomarkers, and histologically observed fibrosis. The candidate was proposed for IND-enabling studies; these are company-reported preclinical results, not clinical evidence or independent confirmation.
Technology: Pharma.AI / Chemistry42
Publication: Announcement only · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Announcement only
- Test type: direct test
- Tested: Company-reported in vitro potency (nanomolar) and a mouse unilateral ureteral obstruction model with histology, plus a 14-day mouse safety study.
- Still unknown: No effect sizes, doses or biomarkers are named, and no independent confirmation or peer review is stated.
- AI role: AI-driven target and compound identification (PandaOmics) produced the candidate.
Evidence sources: https://insilico.com/blog/pcc_kidney
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Neural networks decoded the attempted speech of a man with stroke-related paralysis, displaying words and sentences on a screen. With a 50-word vocabulary, the system reached up to 18 words per minute and a median accuracy of 75%. Proof of principle in one person, using an implant on the brain surface and a limited vocabulary.
Technology: Neural networks for speech and language model
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Decoding was tested in one participant over 48 sessions using a 50-word vocabulary, reaching up to 18 words per minute and a median accuracy of 75%.
- Still unknown: It is a proof of principle in one person with a limited vocabulary, per the press release.
- AI role: Deep-learning algorithms decoded attempted words from cortical activity.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A10.1056/NEJMoa2027540&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 616 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Learning from transcriptomic networks helped prioritize PRKAB1 for experimental follow-up. An agonist improved a barrier-resistance endpoint in about 80% of diseased patient-derived organoids in the tested sample. This is preclinical target-response evidence, not treatment of patients or clinical efficacy. The network direction incorporates sample labels and does not independently establish causal disease progression.
Technology: Boolean Network Explorer learned implication networks
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Patient-derived organoid barriers and preclinical models were tested.
- Still unknown: Clinical safety and benefit, independent replication and causal network direction remain unestablished.
- AI role: Boolean Network Explorer learned implication networks supported the stated study; experimental and interpretive work remained with researchers.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8275683/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Primary article metadata, affiliations, selected network Methods and organoid Results; supplements not reviewed..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Deep learning models trained on 11,374 smartphone-tablet images of HIV lateral-flow tests, captured by 60 fieldworkers, classified results with 97.8% sensitivity and 100% specificity in a pilot field study compared with human visual reading. The approach also reduced false positives and false negatives relative to human readers. Caveat: a pilot deployment in one rural setting, so wider field validation is still needed.
Technology: Deep learning image classifier on mobile-captured rapid test images
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: In a pilot field study, deep learning classification of photographed HIV rapid tests reached 97.8% sensitivity and 100% specificity, compared with human visual reading by experienced nurses.
- Still unknown: Not reported; the page describes the study only as a pilot field study.
- AI role: Deep learning models trained on 11,374 smartphone images of lateral-flow tests classified results in a mobile application.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41591-021-01384-9&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 156 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A machine-learning feature-selection pipeline integrated public whole-blood (1,885 samples) and synovial-tissue (284 samples) transcriptomic datasets and selected a 13-gene rheumatoid-arthritis score. Across five independent transcriptomic datasets, the score tracked DAS28 disease activity, distinguished rheumatoid arthritis from osteoarthritis, separated polyarticular juvenile idiopathic arthritis from healthy controls, and was associated with treatment effects. In an independent immunoblot cohort, two of six tested proteins, TNFAIP6/TSG-6 and HSP90AB1/HSP90, were confirmed.
Technology: Cross-tissue machine-learning feature-selection pipeline for transcriptomic data
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In an independent immunoblot cohort, two of six tested proteins, TNFAIP6/TSG-6 and HSP90AB1/HSP90, were confirmed.
- Still unknown: The transcriptomic inputs were previously published datasets and the reported clinical associations are observational; the study does not establish a deployable diagnostic test or causal disease mechanism. The independent protein follow-up confirmed two of six proteins tested, not the entire 13-gene panel, and validation in larger prospective cohorts is needed. Treatment-effect association should not be interpreted as prospective prediction of individual response.
- AI role: The pipeline selected a compact 13-gene signature from public blood and synovial expression datasets; the study evaluated its association with disease activity and diagnostic distinctions across five independent transcriptomic datasets, then tested six selected proteins by immunoblot in a separate patient cohort.
Evidence sources: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.638066/pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 47 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A machine-learning de novo design model was coupled with synthesis route prediction in the COVID Moonshot campaign against the SARS-CoV-2 main protease. The authors report novel chemical scaffolds that are active in biochemical and live-virus assays and were synthesized along model-generated routes. The abstract gives no potency figures, so the strength of the result should be checked in the full text.
Technology: Synthesis-directed de novo design model with synthesis route prediction
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Novel scaffolds designed with machine learning and synthesized along model-generated routes were tested in biochemical and live-virus assays.
- Still unknown: Not reported.
- AI role: Machine-learning de novo design model coupled with synthesis route prediction in the COVID Moonshot campaign.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1039/d1cc00050k&resultType=core&format=json
The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 90 of works of the same type, year and subfield (OpenAlex work metrics, 36 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Med-BERT, a transformer pretrained on structured EHR data from 28,490,650 patients, improved AUC by 1.21% to 6.14% across two disease-prediction tasks compared with prior baselines. The gains are reported on retrospective structured-data tasks, and the abstract gives no clinical deployment or outcome results.
Technology: Med-BERT, BERT-style transformer pretrained on structured electronic health records
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Med-BERT, pretrained on structured EHR data from 28,490,650 patients, was fine-tuned on two disease-prediction tasks and compared with baselines trained without pretraining, including small-data settings.
- Still unknown: The abstract states no explicit limitations and no clinical deployment or outcome results.
- AI role: A BERT-style transformer adapted to structured EHR data produced embeddings fine-tuned for prediction.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41746-021-00455-y&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 1048 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
An ensemble of neural networks trained on 107,823 fetal ultrasound images reached an AUC of 0.99, 95% sensitivity and 96% specificity in an internal test set of 4,108 fetal surveys with 0.9% CHD. Its sensitivity was comparable to that of clinicians and it stayed robust on outside-hospital and lower-quality images. Caveat: retrospective study with a low-prevalence internal test set.
Technology: Ensemble of convolutional neural networks with segmentation models
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Trained on 107,823 images from 1,326 retrospective studies; on 4,108 fetal surveys (0.9% CHD), AUC 0.99, 95% sensitivity, 96% specificity, 100% negative predictive value; comparable to clinicians and robust on outside-hospital images.
- Still unknown: Prospective screening performance is not reported in the abstract.
- AI role: An ensemble of neural networks identifies cardiac views and classifies normal versus complex congenital heart disease.
Evidence sources: https://doi.org/10.1038/s41591-021-01342-5
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 345 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A randomized study across 120 primary-care groups at 45 sites evaluated neural-network alerts on electrocardiograms from 22,641 adults. The intervention produced five additional diagnoses of low ejection fraction per thousand patients, without a global increase in echocardiography use. The result concerns identification of dysfunction, not improved clinical outcomes.
Technology: Convolutional neural network for electrocardiograms
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: A cluster-randomised trial across 120 primary-care teams (22,641 adults) compared AI-ECG alerts with usual care on new low-EF diagnoses within 90 days.
- Still unknown: Not reported in the abstract read; the trial measured diagnosis rather than clinical outcomes.
- AI role: Neural network analysed electrocardiograms and alerted clinicians to possible low ejection fraction.
Evidence sources: https://newsnetwork.mayoclinic.org/discussion/trial-demonstrates-early-ai-guided-detection-of-heart-disease-in-routine-practice/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A10.1038/s41591-021-01335-4&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 467 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
QSAR virtual screening of a natural-product database prioritized compounds for in-vitro testing against chloroquine-sensitive and multidrug-resistant P. falciparum. The paper reports two sesquiterpene lactones, LDT-597 and LDT-598, with potent and selective activity. ADME/PBPK predictions are not measured pharmacokinetics, and the assays do not establish clinical efficacy.
Technology: QSAR activity models; QSPR ADME and PBPK predictors
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary article reports experimental validation of two prioritized compounds against parasite strains and human hepatoma cells.
- Still unknown: Compound-level prior art and animal efficacy remain open; predicted PK is computational, not measured.
- AI role: QSAR screen prioritizes commercial natural products/derivatives for parasite and cytotoxicity assays.
Evidence sources: https://doi.org/10.3390/biom11030459
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: publisher primary full text. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
An AI-assisted virtual-screening cascade using shape-based and machine-learning models prioritized potential Plasmodium kinase inhibitors. Eight virtual hits were experimentally evaluated; LabMol-167 inhibited P. berghei ookinete conversion and P. falciparum blood-stage parasites at nanomolar concentrations and showed low cytotoxicity in mammalian cells. A possible additional PK5 target was proposed from computational target fishing and docking, not demonstrated experimentally. This is a preclinical hit result and does not establish therapeutic efficacy. The article appeared online on 2021-03-16.
Technology: AI-assisted virtual screening combining shape-based and machine-learning models
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Eight virtual hits were evaluated; LabMol-167 showed nanomolar activity in P. berghei ookinete conversion and P. falciparum blood-stage assays, with low mammalian-cell cytotoxicity.
- Still unknown: The PK5 dual-target mechanism is proposed from computational target fishing and docking; in-vivo efficacy and clinical benefit are not established.
- AI role: Shape-based and machine-learning virtual screening prioritized candidates for experimental evaluation; the abstract explicitly links the integrated AI-assisted screen to this candidate-identification workflow.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/33247522/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary PubMed abstract, publication metadata, and author-affiliation block; claim limited to the findings explicitly stated in the abstract..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Over 48 days, 20 candidates were designed, synthesized, and tested; two showed activity against several pathogens, including multidrug-resistant Klebsiella pneumoniae. In vitro and mouse tests only, with no demonstration of safety or efficacy in humans.
Technology: Generative autoencoder and CLaSS
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: 20 generative-model candidates were synthesised and tested; two were active against several pathogens, with in vitro and mouse tests.
- Still unknown: No demonstration of safety or efficacy in humans, and no human trials are mentioned.
- AI role: Generative models designed candidate antimicrobial peptides.
Evidence sources: https://research.ibm.com/blog/ai-finds-new-peptides · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A10.1038/s41551-021-00689-x&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 508 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
NCATS researchers used biological activity-based modeling (BABM) to infer antiviral activity from compounds’ profiles across multiple assays. Of 311 model-predicted SARS-CoV-2 candidates tested in a live-virus cell-culture assay, 99 were confirmed active (32% hit rate); follow-up assays implicated viral-entry inhibition and/or autophagy modulation among confirmed compounds.
Technology: Biological activity-based modeling (BABM) models trained on multi-assay compound-activity profiles
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: NCATS researchers used biological activity-based modeling (BABM) to infer antiviral activity from compounds’ profiles across multiple assays.
- Still unknown: Evidence is from cell-culture live-virus and mechanistic assays, not clinical treatment. 99/311 were active in the primary assay; further potency/secondary confirmations were available for subsets. Most confirmed compounds were reported to inhibit entry and/or modulate autophagy; these data do not establish safe or effective human therapy.
- AI role: BABM used prior activity signatures across assay panels to predict compounds with potential SARS-CoV-2 activity, including compounds outside conventional similar-structure hit finding. Researchers tested 311 model-predicted compounds in live-virus assays and conducted secondary/mechanistic assays on confirmed actives.
Evidence sources: https://www.nature.com/articles/s41587-021-00839-1
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 54 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Mirai, trained on over 200,000 exams, was evaluated on hospital data from the United States, Sweden, and Taiwan. In a comparison of high-risk groups at Massachusetts General Hospital, it identified nearly twice as many future diagnoses as Tyrer-Cuzick; it does not demonstrate reduced mortality.
Technology: Deep learning on mammograms
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Mirai was validated on held-out test sets from MGH, Karolinska and Chang Gung, and identified nearly twice as many future diagnoses as Tyrer-Cuzick in high-risk groups.
- Still unknown: It does not use prior imaging and is still being validated in more diverse populations, and it does not show reduced mortality.
- AI role: Deep learning predicted future breast cancer risk from mammograms.
Evidence sources: https://news.mit.edu/2021/robust-artificial-intelligence-tools-predict-future-cancer-0128 · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A10.1126/scitranslmed.aba4373&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 320 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Models trained in part on 26,838 X-rays from 4,914 patients predict deterioration up to 96 hours ahead, outperforming specialists in some retrospective comparisons. This research is for hospital resource planning, not a clinical product or evidence of better patient outcomes.
Technology: MoCo and Transformer
Publication: Preprint · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: retrospective or benchmark
- Tested: Models trained on chest X-rays are compared with specialists in some retrospective comparisons for predicting deterioration.
- Still unknown: Not reported in the arXiv abstract read; the research is for resource planning, not a clinical product.
- AI role: Self-supervised learning (MoCo) predicted COVID-19 deterioration from sequential chest X-rays.
Evidence sources: https://arxiv.org/abs/2101.04909
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Eight stage/time-specific Bayesian classifiers trained on historical phenotypic measurements guided prospective selection of predicted active and inactive commercial compounds. In-vitro assays reported 48% and 34% hit fractions for somules and adults, followed by triage of five compounds. The selected-set fractions are not unbiased head-to-head screening rates; no animal cure, clinical mechanism, safety or efficacy is established.
Technology: Bayesian classifiers
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary article reports prospective somule/adult screens and prioritized compounds after triage.
- Still unknown: Compound-specific prior evidence and complete supplementary access remain open; no clinical inference.
- AI role: Stage/time-specific Bayesian models guided selection of assay compounds, with human curation and triage.
Evidence sources: https://doi.org/10.1021/acsinfecdis.0c00754
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: PMC-indexed primary text; PubMed primary metadata. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A deep multimodal network combining CT imaging with electronic health record data reached AUROC 0.947 (95% CI 0.946-0.948) on a held-out test set for pulmonary embolism. The abstract reports no sensitivity, specificity, study size or external validation sites, so the evidence is limited to retrospective internal testing.
Technology: Multimodal deep neural network fusing CT and EHR data
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Several fusion architectures were compared on a held-out test set, and the best late-fusion model reached AUROC 0.947 against imaging-only and EMR-only models.
- Still unknown: The abstract reports no sensitivity, specificity, study size or external validation and states no limitations.
- AI role: Deep neural networks classified pulmonary embolism from CT angiography volumes combined with EHR data.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41598-020-78888-w&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 263 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A model trained on volunteer recordings recognized 98.5% of coughs associated with confirmed infections in the test reported by MIT. This is an early result on data collected online, with health status also self-reported; it is not a diagnosis or prospective clinical validation.
Technology: Neural networks for audio
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Model trained on 4,256 subjects and tested on 1,064 held-out subjects from web-collected cough recordings, with results validated against official COVID-19 test outcomes; sensitivity 98.5% and specificity 94.2% overall, but 83.2% specificity in asymptomatic subjects.
- Still unknown: Not a diagnosis for symptomatic people and does not separate Covid from flu or asthma; status was self-reported; false-positive results for healthy participants not reported; app would need approval and a larger, more diverse dataset.
- AI role: Neural networks trained on cough biomarkers (vocal cords, sentiment in speech, lung performance) combined with a muscular-degradation estimate to flag Covid-positive coughs.
Evidence sources: https://news.mit.edu/2020/covid-19-cough-cellphone-detection-1029 · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1109/OJEMB.2020.3026928&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 609 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A CNN trained on contrast-enhanced CT from a Taiwanese centre reached 98.3% sensitivity on combined local test sets versus 92.9% for radiologists (difference 5.4 points, p=0.014). On a US external test set, sensitivity fell to 79.0% with specificity 97.6% (AUC 0.920), and sensitivity for tumours under 2 cm was 63.1% in that set. The study is retrospective and the authors describe it as supplementary to radiologists.
Technology: Convolutional neural network applied to CT image patches
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A CNN trained on Taiwanese contrast CT was tested on local test sets against radiologists and on an external US test set, where it reached 79.0% sensitivity and 97.6% specificity.
- Still unknown: The study is retrospective; sensitivity for tumours under 2 cm was 63.1% on the US set, and radiologist comparisons covered only the local sets.
- AI role: A CNN classified image patches as cancerous and labelled each patient by the proportion of cancerous patches; the authors describe it as supplementary to radiologists.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33328124%20AND%20SRC:MED&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 233 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In a test on 279 patients, a system combining CT scans and clinical information reached 84% sensitivity, compared with 75% for radiologists in the reported comparison. Retrospective study on data collected in China, without evidence of effectiveness in prospective clinical use.
Technology: Multimodal deep learning
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Trained on 626 of 905 patients and tested on the remaining 279 against radiologists: sensitivity 84% versus 75%, AUC 0.92, and 68% of RT-PCR-positive cases with normal CT correctly identified.
- Still unknown: Intended for use when CT scans and clinical history are both available; CT alone may have limited negative predictive value; prospective clinical use not evaluated; specificity not reported.
- AI role: Combined chest CT findings with clinical symptoms, exposure history and lab results to identify COVID-19-positive patients.
Evidence sources: https://www.mountsinai.org/about/newsroom/2020/mount-sinai-first-in-us-to-use-artificial-intelligence-to-analyze-coronavirus-covid19-patients-pr · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41591-020-0931-3&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 1114 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The system analyzes OCT scans to predict whether the less affected eye of patients with macular degeneration will develop the wet form, outperforming specialists in the comparison described. The announcement gives no numerical metrics; preventive clinical studies were still to be planned.
Technology: Deep learning on OCT images
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Retrospective prediction of whether the second eye converts to wet AMD within 6 months: 80% sensitivity at 55% specificity, and better than five of six experts in the comparison described.
- Still unknown: Preventive use needs prospective trials that were only being considered; 56% of individual eyes were false positives at the high-sensitivity setting; dataset size and generalizability not stated.
- AI role: Models built on 3D OCT scans and automatically generated tissue maps to predict conversion to wet AMD.
Evidence sources: https://www.moorfields.nhs.uk/about-us/news-and-blogs/news/ai-to-develop-an-early-warning-system-for-amd · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41591-020-0867-7&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 307 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A COVID Symptom Study app with 2,618,862 participants and 18,401 tested users found loss of smell or taste in 65.03% of positives versus 21.71% of negatives (OR 6.74). A machine-learning model applied to 805,753 users predicted 140,312 (17.42%) as likely infected. The inputs are self-reported and the test-verified subset is small relative to the user base, so the prediction is not a clinical diagnosis.
Technology: Machine-learning symptom model on self-reported app data
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: App-reported symptoms from 2,618,862 participants were compared between 18,401 test-verified users, and a model applied to 805,753 users predicted 140,312 as likely infected.
- Still unknown: Inputs are self-reported, the test-verified subset is small relative to the user base, the prediction is not a clinical diagnosis, and the abstract does not describe model validation.
- AI role: A model combining self-reported symptoms predicted likely COVID-19; the abstract does not state the method.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41591-020-0916-2&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 1548 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A CT model trained on 1,186 patients (521 COVID-19, 665 other pneumonia) reached 95% sensitivity and 96% specificity internally, and AUC 0.90 on an independent test set. Radiologist accuracy rose from 85% to 90% with AI assistance. The study is retrospective and the independent-test performance is lower than the internal result.
Technology: Deep-learning CT classifier used as an assistant for radiologists
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A CT model was tested on an internal split and on an independent test set from separate hospitals, and six radiologists read cases unassisted and then with the model's probabilities.
- Still unknown: The abstract states no limitations section; performance on independent data was lower (87% vs 96% accuracy) and the sensitivity confidence interval is wide.
- AI role: The AI classified COVID-19 versus other pneumonia on CT slices and its probabilities were shown to radiologists as decision support.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1148/radiol.2020201491&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 385 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
PENet, a 3D deep-learning model for pulmonary embolism on CT angiography, reached AUROC 0.84 on an internal hold-out test and 0.85 on data from one unnamed external institution. The abstract does not report sensitivity, specificity or study size, and the external validation is limited to a single site.
Technology: PENet, 3D deep convolutional network on volumetric CT
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: PENet, a 3D CNN, was tested on a hold-out set from the training institution (AUROC 0.84) and on an external institution (AUROC 0.85), and was compared with other state-of-the-art 3D CNN models.
- Still unknown: The abstract states no limitations; external validation covers one institution and sensitivity, specificity and study size are not reported.
- AI role: A 77-layer 3D CNN, pretrained on Kinetics-600, detected pulmonary embolism on CT angiography and is proposed as a triage tool.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41746-020-0266-y&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 203 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A deep learning model trained on echocardiogram videos segmented the left ventricle with a Dice coefficient of 0.92 and estimated ejection fraction with a mean absolute error of 4.1% (6.0% on an external dataset from another health system). Prospective evaluation with repeated human measurements found its variance comparable to or lower than that of human experts. Caveat: training data come from one institution's echocardiograms, with external testing on a single additional system.
Technology: EchoNet-Dynamic (video deep learning model)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Segmentation and ejection fraction were tested on held-out internal data (Dice 0.92, MAE 4.1%) and an external dataset from another health system (MAE 6.0%), and repeated human measurements were compared with model variance.
- Still unknown: Not reported; the page states no limitations section.
- AI role: Deep learning model trained on echocardiogram videos to segment the left ventricle and estimate ejection fraction.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-020-2145-8&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 1292 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The COVNet 3D deep-learning model, trained on 4,352 CT scans from 3,322 patients, reached per-scan sensitivity 90% and specificity 96% (AUC 0.96) for COVID-19, and AUC 0.95 for community-acquired pneumonia. The study is retrospective and evaluated on Chinese cohorts, so performance in other populations is not established.
Technology: COVNet, a 3D convolutional neural network on chest CT
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: The COVNet 3D model, trained on 4,352 CT scans, was evaluated on an independent test set for COVID-19 (sensitivity 90%, specificity 96%, AUC 0.96) and community-acquired pneumonia.
- Still unknown: The abstract does not state limitations and does not confirm whether the test set came from outside the training hospitals; the study is retrospective.
- AI role: COVNet, a fully automatic 3D deep-learning framework, classified chest CT scans.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1148/radiol.2020200905&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 1999 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
An international crowdsourced challenge (over 1,100 participants, 126 teams, 44 countries) tested AI on screening mammograms from 144,231 US and 166,578 Swedish examinations. The best single algorithm did not beat radiologists (US AUC 0.858), but an ensemble of top algorithms combined with US radiologists' recall decisions reached AUC 0.942 and 92.0% specificity at the same sensitivity. The study is retrospective, uses challenge data and does not report recall rates.
Technology: Ensemble of crowdsourced deep-learning mammography algorithms combined with radiologist recall
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A crowdsourced challenge of 126 teams was tested on 144,231 US and 166,578 Swedish screening examinations, with an ensemble of top algorithms combined with US radiologists' recall decisions compared on AUC and specificity.
- Still unknown: The study is retrospective, no single algorithm beat radiologists, the ensemble was evaluated only against US radiologists, and recall rates are not reported.
- AI role: Algorithms produced cancer risk scores; an ensemble of top algorithms was combined with radiologist recall decisions.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1001/jamanetworkopen.2020.0265&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 438 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A model trained on about 2,500 molecules screened the roughly 6,000 compounds in the Broad Institute’s Drug Repurposing Hub and identified halicin, which killed many resistant bacteria in the lab and cleared A. baumannii infections in mice within 24 hours. Cell-culture and mouse results, not human studies; the mechanism remains preliminary.
Technology: Graph neural network for predicting antibacterial activity
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Bactericidal activity against a wide range of pathogens, including M. tuberculosis and carbapenem-resistant Enterobacteriaceae; halicin treated C. difficile and pan-resistant A. baumannii infections in mice. Of 23 tested predictions from over 107 million ZINC15 molecules, eight were antibacterial.
- Still unknown: Human safety and efficacy are not reported in the abstract.
- AI role: A deep neural network predicted antibacterial activity across chemical libraries; candidates were then tested experimentally.
Evidence sources: https://doi.org/10.1016/j.cell.2020.01.021
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Original institutional announcement checked for the specific results, AI contribution and limitations cited in the antibiotic dossier or mathematical follow-up pilot. Full-paper reanalysis, external replication and an exhaustive follow-up search were not performed..
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 2730 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 5/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
- same-team extension · 25 May 2023: MIT describes abaucin as a subsequent application of the antibiotic-screening program to A. baumannii. This is a different candidate and target-specific study, not replication of halicin. Source. Recorded 16 Nov 2026.
- same-team extension · 14 Aug 2025: MIT identifies halicin and abaucin as earlier screening results motivating generative design of new NG1/DN1 candidates. The later study does not establish clinical efficacy of these earlier candidates. Source. Recorded 16 Nov 2026.
Follow-up checked 16 Nov 2026 within scope: Bounded check of the original announcements cited by the events recorded here, including explicit links to later program work. This is not an exhaustive literature search or ongoing monitoring commitment..
No source-supported relationships recorded.
Deep-learning QSAR models for parasite activity and cytotoxicity prioritized commercial candidates for assay. Primary Table 3 reports LabMol-152 EC50 values of 0.049 and 0.078 µM against 3D7 and W2; LabMol-149 values were 1.450 and 0.509 µM, inconsistent with the abstract’s under-500-nM claim. The study reports in-vitro results only; the model ranked existing compounds rather than generating them.
Technology: Deep-neural-network QSAR models
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Table 3 reports strain-specific EC50 and COS-7 cytotoxicity results for tested compounds.
- Still unknown: Abstract/results inconsistency for LabMol-149 preserved; no animal or clinical evidence; earlier public version/chemical prior art unresolved.
- AI role: Activity and cytotoxicity models ranked an existing library and filters/human inspection selected compounds for assay.
Evidence sources: https://doi.org/10.1371/journal.pcbi.1007025
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: publisher primary full text. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Sumitomo Dainippon Pharma and Exscientia announced the start in Japan of a Phase I study of DSP-1181, a 5-HT1A serotonin receptor agonist created with the Centaur Chemist platform, with obsessive-compulsive disorder as the first indication. The companies said exploratory research took under 12 months versus a typical 4.5 years. The announcement gives no efficacy results. In the January 31, 2022 investor-call transcript, Sumitomo said development was discontinued because the candidate did not meet the expected Phase I criterion.
Technology: Centaur Chemist (molecule-design platform)
Publication: Announcement only · Test context: Test context unspecified in annotation. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Announcement only
- Test type: not reported
- Tested: Not reported
- Still unknown: Not reported
- AI role: Candidate created in joint research with Exscientia using its Centaur Chemist AI platform; the page does not describe what the AI did beyond design.
Evidence sources: https://www.sumitomo-pharma.com/news/20200130.html
The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 1/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In a double-blind randomised trial of 962 patients in China (484 analysed with CADe, 478 with a sham system), the deep-learning system raised adenoma detection to 34% (165/484) from 28% (132/478), OR 1.36 (95% CI 1.03-1.79). The primary analysis was per protocol, the trial was single-centre, and the abstract reports no ITT analysis.
Technology: Deep-learning computer-aided detection (CADe) system for polyps during colonoscopy
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: A double-blind randomised trial of 962 patients compared colonoscopy with a deep-learning CADe system against a sham system; the primary outcome was adenoma detection rate, analysed per protocol (CADe 34% vs sham 28%).
- Still unknown: The trial is single-centre, the primary analysis is per protocol with no ITT analysis reported, and the effect on interval colorectal cancer still needs investigation.
- AI role: A deep-learning CADe system gave real-time visual alarms for possible polyps during colonoscopy.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31981517%20AND%20SRC:MED&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 437 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The deep-learning network deepDTnet predicted retinoic-acid-receptor-related orphan receptor gamma-t (RORγt) as a previously unrecognized target of topotecan. Biochemical assays showed direct inhibition (IC50 0.43 μM), and topotecan improved outcomes in a mouse experimental autoimmune encephalomyelitis model of multiple sclerosis.
Technology: deepDTnet, heterogeneous drug–gene–disease network embedding with deep learning
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Biochemical assays showed direct inhibition (IC50 0.43 μM), and topotecan improved outcomes in a mouse experimental autoimmune encephalomyelitis model of multiple sclerosis.
- Still unknown: Evidence is preclinical: direct target and mouse-model assays do not establish safety or effectiveness in people with multiple sclerosis. Topotecan is an established anticancer drug, and its new target/indication remains a repurposing hypothesis.
- AI role: The model integrated 15 types of chemical, genomic, phenotypic and cellular network profiles to rank new drug targets. It nominated RORγt for topotecan, which the team tested using direct binding/transcriptional assays and a mouse EAE disease model.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/34123272/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 366 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
CNNs trained on over 2.5 million stimulated Raman histology images produced intraoperative brain tumour diagnoses in under 150 seconds, with 94.6% accuracy versus 93.9% for pathologists. The accuracy comparison comes from a prospective multicentre trial with 278 patients, but the abstract does not report sensitivity or specificity separately.
Technology: Deep neural networks on stimulated Raman histology images
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: Multicenter prospective clinical trial (n = 278): CNN diagnosis of stimulated Raman images was non-inferior to pathologists reading conventional histology (94.6% versus 93.9%), in under 150 seconds.
- Still unknown: Long-term patient outcomes are not reported in the abstract.
- AI role: Convolutional neural networks trained on over 2.5 million stimulated Raman histology images.
Evidence sources: https://doi.org/10.1038/s41591-019-0715-9
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 839 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 4/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Among 25,856 women in the UK and 3,097 in the US, the system reduced false positives by 5.7% (US) and 1.2% (UK), and false negatives by 9.4% and 2.7% in absolute terms compared with radiologists. Trained only on UK data, it also outperformed specialists on US data. Retrospective evaluation (Nature): prospective studies are needed, and clinical deployment is unclear.
Technology: Neural network for mammograms
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Retrospective evaluation on UK (25,856 women) and US (3,097 women) screening mammograms, compared with individual radiologists' decisions; a reader study and a simulated double-reading workflow were also run.
- Still unknown: The authors state prospective studies are required and that how to deploy the system clinically is not yet determined; the US data were enriched; the second-reader scenario was only simulated.
- AI role: Predicted from screening mammograms alone whether a biopsy would later show cancer.
Evidence sources: https://deepmind.google/blog/international-evaluation-of-an-ai-system-for-breast-cancer-screening/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-019-1799-6&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 3668 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.